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Title An Evaluation of Alternative Strategies for the Prevention of Cervical Cancer in 
Low Resource Settings 
Author Dr Lynette Denny 
Date May 2000 
Introduction: Cervical cancer is the commonest cancer cause of death among women in the 
developing world. This is in part due to the failure of these countries to establish cytologically-based 
screening programmes for the prevention of cervical cancer. This study was designed to evaluate 
alternative methods to cytology for screening to prevent cervical cancer in low-resource settings. 
Design: Cross-sectional study located in a squatter settlement outside Cape Town, South Africa 
Sample: Volunteer sample of 2944 previously unscreened women, aged 35 - 65 years, who were not 
pregnant, had not undergone hysterectomy or previous treatment for cervical disease. 
Methods: Women were screened by a trained nursing sister in the following sequence: I] A Pap smear 
was performed. 2] The tip of the cervical sampler was then placed in a collection tube for analysis of9 
different types of high-risk HPV DNA (Hybrid Capture I TM). In addition, a subset of all women with 
histological diagnosis of LSIL, HSIL or cancer and a random sample of 243 women with no 
histological evidence of disease were re-tested using the new generation Hybrid Capture II (HC II) test 
which has probes for 13 different high-risk types ofHPV and has a lO-fold lower limit for the detection 
of HPV DNA. 3] The cervix was washed with 5% acetic acid and examined for the presence of an 
aceto-white lesion using the naked-eye, followed by magnification using a hand-held 2.5x lens. 4] 
After a second application of 5% acetic acid, two 35-mm photographs were taken of the cervix using a 
Cerviscope™. The photographs were processed and evaluated at National Testing Laboratories, USA. 
Women with a cytological diagnosis ofSIL or cancer, a positive DVI examination, high levels of high­
risk HPV DNA (RLU> I Ox positive control), or a Cervigram ™ evaluation of warrants colposcopy, SIL 
or cancer were referred for anon-site colposcopic examination and histological sampling or treatment 
with LEEP (loop electrosurgical excision of the transformation zone). Women with four negative 
screening tests or no disease diagnosed by colposcopy and histological sampling were considered 
'disease free'. Women with a histological diagnosis ofLSIL, HSIL or cancer were considered 'disease 
positive'. To calculate sensitivity and specificity specifically for HSIL and cancer (Le. high-grade 
lesions), LSIL was included in the 'no disease' group. All histology and Cervigrams™ were reviewed 
masked to clinical information 
Results: Of the 2944 women screened, 3.2% (n = 95) had LSIL, 2.4% (n 74) had HSIL, 0.4% (n = 
12) had cancer, 20% (n 579) had no disease after colposcopy and histological sampling, 71% (n = 
2102) had four negative screening tests and 2.6% (n = 82) were lost to follow up. DVI identified 18.1 % 
of women as having a positive test and detected 67% (95%CI: 56 77) of the cases of HSIL and 
cancer. A positive Pap smear was diagnosed in 8% of women and identified 78% (95% CI: 68 - 86) of 
the cases of HSIL and cancer. HPV DNA testing using HC I identified 6% of women as having a 
positive test when the higher threshold of 10 x the positive control was used (i.e. I million copies of 











to 100 000 copies of HPV DNA). At the lOx cut-off, HC I identified 50% (95%CI: 39 - 61) of the 
cases of HSIL and cancer and at the 1 x cut-offHC I identified 73% (95%CI: 62 - 84) of the cases. HC 
II identified 88% of the cases of HSIL and cancer at the 1 x cut-off. By contrast CervicographyTM 
classified 11 % of women as positive and identified 58% (95%CI: 47 - 69) of the cases of HSIL and 
cancer. The specificities for HSIL and cancer of DVI and HPV DNA testing at the Ix cut-off using 
both HC I and HC II were the lowest at 84%, 89% and 82% respectively. The highest specificity for 
HSIL and cancer was found for HPV DNA testing using HCI at the lOx cut-off and for cytology at 95 
and 95% respectively. The specificity ofCervicographyTM for HSIL and cancer was 92%. 
Conclusions: The finding that DVI, a simple, cheap method of screening has a marginally lower 
sensitivity for HSIL and cancer compared to high-quality cytology, despite a lower specificity (84% 
versus 95% respectively) has important implications for low resource settings, where cytologically­
based screening programmes have not yet been established. HPV DNA testing haS. considerable 
potential as a screening test as it is an objective test, is easier to perform than cytology and it identifies 
an equivalent number of high-grade lesions as cytology. In addition, it may identity women at high risk 
for developing SIL or cancer in the future, enabling resources to be targeted towards HPV positive 
women. Shifting the cut-off to define a positive, test can a1ter the specificity of the test. 
CervicographyTM has relatively poor test characteristics and requires equipment that is more 
sophisticated than DVI. While these alternatives to cytology have the potential to replace cytology as 
screening tests in low-resource settings, their utility and cost-effectiveness in mass screening 











Oven-iew of Study 
Cervical cancer, the commonest cancer among women in the developing world, is considered a 
preventable disease. The disease is prevented by screening the cervix with cervical cytology for the 
presence of cervical cancer precursors, known as cervical intraepithelial neopiasia (CIN) or squamous 
intraepithelial lesions (SIL). Once these lesions are detected, confirmed histologically after 
colposcopic assessment, treated and followed up to detect recurrence or persistence, progression to 
cervical cancer can be prevented in the vast majority of women. In addition, cervical screening enables 
detection of early, clinically inapparent cancers which if adequately treated, have an excellent 
prognosis compared to cervical cancers treated in advanced stages. 
This model for the detection and treatment of preinvasive lesions of the cervix is considered the 'gold 
standard' for the prevention of cervical cancer. It is however, a relatively expensive process requiring 
a sophisticated health infrastructure that is rarely available in developing countries. The process 
requires high quality, well-equipped cytology and histology laboratories with ongoing training of staff 
and reliable built-in quality control. Further, the result of the Pap smear is usually delayed, 
necessitating a system of either tracking women with abnormal results or of ensuring that women 
return to the clinic for their results. Very few low resource settings have reliable methods of modem 
communication between patients and clinics, such as telephones, fax machines or even adequate postal 
services. In addition, the management of women with abnormal Pap smears may require at least 3 or 
more clinic visits, often to centres at considerable distance from where women live. As a consequence, 
instituting mass cervical screening programmes based on cytology has proved prohibitively complex 
for poor countries. Screening, if performed at all, tends to be opportunistic and hospital-based. 
Colposcopic services, if available, tend to be located in tertiary health services and are thus inaccessiple 
to the majority of women. Further, laboratory services are limited and often unable to maintain the 
high quality standards required by cytology. 
In the light of the failure of developing countries to institute cytologically-based screening 
programmes, the need to develop and evaluate alternative, more accessible methods of cervical cancer 
screening has become important. Developing a screening method that avoids the infrastructure required 
by cytology and eliminates the need for colposcopic triage may enable cervical cancer screening to be 
initiated and maintained in low-resource settings. Specifically, a screening process that uses mid-to 
low-level clinicians who are trained to perform on-site screening, diagnosis and treatment at one clinic 
visit may considerably simplify the process and reduce the costs involved. 
This thesis will present a study, performed in a periurban squatter settlement located outside Cape 
Town, South Africa, which compared the performance of three different screening methods to cervical 
cytology. The study was performed in the context of a low-resource setting where a trained nursing 
sister screened all women. In addition, women with abnormalities detected on any of the four 













daysor weeks of women being screened. This enabled the alternative screening tests to be compared in 
the context ofperforming the 'gold standard' approach to cervical cancer screening .. 
The overall objective of the study was to evaluate new and alternative methods to cytology for cervical 
cancer screening, specifically in a low resource setting. The specific objectives were: 
1. 	 To compare the sensitivity, specificity, positive predictive value and negative predictive value of 
the following three cervical screening tests with those of cervical cytology: 
• 	 Direct visual inspection (DVI) of the cervix with the naked eye and with low 
magnification after the application of 5% acetic acid. 
• 	 Detection of high-risk ofHuman Papillomavirus (HPV) infection of the cervix 
• 	 CervicographyTM (35 mm photographs of the cervix taken after the application of 5% 
acetic acid) 
2. 	 To analyse information on the performance of the four screening tests and the prevalence of 
disease in the study population to predict expected outcomes ofeach test used alone or in different 
combinations of the screening tests. 
3. 	 To determine, in a low-resource setting, the success rate, short and intermediate term complication 
rates ofLEEP as a treatment for preinvasive disease of the cervix and to evaluate LEEP when used 
in a 'see and treat' mode i.e. treatment of preinvasive lesions of the cervix with LEEP after 
colposcopic assessment but without prior histological evaluation. 
4. 	 To describe the process of setting up a cervical cancer screening study in the context of a 
community-based research project. 
The screening tests used in the study were: 
1. 	 Direct Visual Inspection of the cervix (DVI): This method of screening involves training a mid ­
level c1inician (such as a nursing sister) to wash the cervix with 5% acetic acid and to identifY 
aceto-white lesions, using the naked eye or using magnification provided by a hand-held 
magnifYing lens. The nursing sister was trained to classifY all aceto-white lesions as a positive test, 
without attempting to grade the severity of the lesion. This method of screening provides an 
immediate on-site result, uses minimal equipment, does not require the backup of laboratory 
services and can be performed in a very low technology setting. 
2. ) HPV DNA detection: Using a quantitative commercial kit, known as Hybrid Capture ITM (HC 
I)(Digene Corporation, Silver Spring, MD), which is able to detect 9 high-risk types ofHPV DNA, 
this study evaluated the role ofHPV DNA detection as a primary screening test. Women who had 
high levels of detectable HPV DNA on the cervix (equivalent to a million copies ofHPV DNA or 
10 x the positive control) were referred for colposcopic evaluation. In addition, a subset of women 
with histologically confirmed LSIL, HSIL or cancer and a random sample of women with no 
histological evidence of disease were retested using the new generation HC II test which has 












the tube-based format ofHC I). The potential advantages ofHPV DNA testing include that the test 
gives an objective result compared to the subjective nature of cytology. In addition, the 
requirements of the test are much simpler than cytology in terms of quality control and initial 
training of technicians and the test gives a more rapid tum around of results. 
3. 	 CervicographyTM: This method of screening involves taking a 35-mm photograph of the cervix 
after the application of 5% acetic acid. The slides are then developed and read off-site by specially 
trained clinicians. In the study, any Cervigram™ evaluation of 'warrants colposcopy', LSIL, 
HSIL or cancer was considered positive and women were referred for colposcopy. The advantages 
of CervicographyTM are that it provides a permanent visual record of the cervix and it is easy to 
train clinicians to use the technique. In the context of the study, it also provided a means of quality 
control for DVI and a safety net to ensure that the screening sister missed no clinical cancers. 
However, like cytology, the result is delayed and the interpretation of the slides is sUbjective. 
4. 	 Cytology: All women had a Pap smear performed and all smears were read by the University of 
Cape Town Cytopathology laboratory according to the routine protocol of the laboratory and using 
the Bethesda system for reporting. A cytological diagnosis of LSIL, HSIL or cancer was 
considered a positive test and a reason for referral for colposcopy. 
If any of the four screening tests were abnormal, women were referred for colposcopy. DVI results 
were available immediately, HPV DNA within 2 to 6 days of women being screened, cytology within 2 
weeks and CervicographyTM within 8 - 12 weeks. All women were asked to return for results or 
colposcopic examination within 2 to 6 days of being screened. 
Colposcopy was performed on-site in a specially adapted caravan, which was parked permanently at 
the study site. All colposcopies were performed by the author or under the direct supervision of the 
author. Colposcopic examination was .performed using the Reid's Colposcopic Index (RCI) to grade 
the severity of the lesions identified and colposcopy was performed blinded to the cytology result, 
unless a positive Pap smear was the only reason the woman was referred for colposcopic assessment. 
If an insignificant aceto-white lesion was noted, a biopsy was performed and if no lesion was noted, 
endocervical curettage was performed. Obvious clinical cancers were biopsied. If CIN (of any grade) 
was diagnosed at the colposcopic examination women were treated immediately, on-site, with LEEP 
(loop electrosurgical excision procedure) LEEP was performed under local anaesthetic, without prior 
histological confirmation of the lesion - the so-called 'See and Treat' approach. Women who were 
treated were followed up at 4 and 10 months post-treatment with a colposcopic examination, a Pap 
smear and either biopsy or endocervical curettage where appropriate. 
This thesis will describe the development of the screening study in the context of a low-resource setting 
and will present socio-demographic data and risk factors for preinvasive and invasive disease among 











tests are analysed and compared to one another with respect to sensitivity, specificity, positive and 
negative predictive values of the tests for the detection of LSIL, HSIL and cancer. Extrapolating from 
the performance of the screening tests, different screening strategies and their expected outcome in 
terms ofdisease detection and treatment will be discussed. Finally, the outcome of on-site treatment of 
preinvasive lesions with LEEP will be evaluated in terms of complications and eradication of disease. 
The findings of the study will be discussed in terms of a possible national screening policy and will 















1.1 The Extent of the Problem of Cervical Cancer with Particular Reference to South 
Africa 
Cervical cancer is the commonest cancer cause of death in women in Sub-Saharan Africa, South and 
South East Asia and Latin America. In 1980 there were an estimated 465 000 new cases of cancer of 
the cervix diagnosed worldwide, 80% of which occurred in developing countries l . In 1990, there were 
an estimated 360 000 new cases of cervical cancer diagnosed worldwide, with approximately 190 000 
deaths recorded 2. There is a paucity of reliable data on cervical cancer from developing countries and 
the ideal data (cancer incidence rates derived from population-based cancer registries) are in the main, 
not available 3 • 
South Africa launched a pathology-based cancer registry in 1986, relying on information reported by 
80 private and public laboratories. In 1986, the total number of cancers reported in women was 16559, 
of which 2897 (17.4%) were new cases of histologically confirmed cervical cancer (Cancer Registry of 
South Africa, 1986). In 1992, the total number of reported cancers in women had increased to 25 143, 
and the percentage of new cases of cervical cancer remained at the same proportion as was reported in 
1986 at 17.8% (n = 4467) 4. There were 1105 deaths from cervical cancer recorded in 1992. It is 
acknowledged however, that a significant number of women with cervical cancer die without the 
diagnosis of cervical cancer being made, no histological sampling is performed or the disease is not 
registered 4 • This is particularly true in the rural areas of South Africa and the former 'homelands' 
created by the Apartheid State prior to 1994 •. This suggests that the reported number of cases of 
cervical cancer is an underestimate of the true number of cases. 
According to the 1992 South African cancer registry, the overall crude incidence rate of cervical cancer 
was 231100 000 women and the Age Standardised Incidence Rate (ASIR) was 30.5/100 0004• There 
were however, marked differences in incidence of cervical cancer in the various population groups. 
Cancer of the cervix was the most common cancer among black women (33.7%), second most common 
in coloured women (24.5%), followed by Asian women (10.3%) and finally by white women (3.5%). 
The ASIR of cervical cancer in black women was 34.611 00 000 with a lifetime risk (LR) of developing 
cervical cancer of 1 in 26 compared to an ASIR of 12.3/100 000 white women with a 1 in 83 lifetime 
risk of developing cervical cancer. In 1986, the ASIR of cervical cancer for black women in SA was 
just below the 1992 figure at 31/100 000, suggesting that the incidence of cervical cancer in South 
Africa has not changed appreciably over these two time periods . 
• In 1994 South Africa underwent its first democratic election which terminated the policy of Apartheid by which 












Figure I shows the Age Specific cervical cancer rates per 100 000 women in the different ethnic groups 
in South Africa in 19924. In all groups the rate remained very low until age 30 years after which the 
rates rose steadily to peak at between 50 and 79 years. The highest age specific rate for all race and age 
groups occurred among bJack women aged 60 - 64 years with a rate of 145.6/ I 00 000 . 
The Age Specific Frequency of cervical cancer in 1992 follows a similar pattern with only 9.7% of 
cervical cancer occurring in women under 35 years of age4. The highest number of cases were 
diagnosed in the 50 - 54 year age group, 13.1 % (n = 584), followed by the 40 - 44 age group, 12.5% (n 
= 560), followed by the 60 - 64 group, 12.4% (n = 555). 
There is very little data on the incidence of cervical cancer in South Africa prior to the establishment of 
the cancer registry in 1986. However in 1960, Higginson and Oettle5 published a survey of cancer 
incidence in black and coloured people in the Transvaal (one of the largest provinces in South AtTica) 
from 1953 to 1955. Their data showed that cervical cancer was by far the commonest cancer in women, 
accounting for 41.7% of all cancers in black women and 37% of all cancers in coloured women . These 
figures corresponded to an overal.l crude incidence rate of 3 1/ 100 000 black women and 39/1 00 000 
coloured women. The data were based on all histological confirmed cases of invasive cervical cancer 
cases in the area and included rural and urban women. 
The ASIRs of cervical cancer in South AtTica are similar to those of other developing countries. Figure 
2 shows the marked difference in ASIRs in Southern Africa, South America and South East Asia 
compared to developed parts of the world such as North America and Europe, based on data published 
in 19856• These marked differences in incidence rates between developed and developing countries 
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1.1.1 Biological basis for cervical cancer screening: The Cervical Transformation 
Zone 
The cervical epithelium is derived from two embryologically distinct sources. The portio vaginalis of 
the cervix is covered by non-keratinised stratified squamous epithelium, similar to the vaginal 
epithelium. Mucus-secreting columnar cells of the same embryological derivation as the uterine 
endometrium cover the endocervical canal. At birth there is an abrupt junction between the original 
squamous epithelium and the columnar epithelium of the endocervix, known as the original squamo­
columnar junction (OSCI). In the majority of cases, this junction is on the ectocervix, but may be on 
the vagina, particularly in di-ethylstilbestrol (DES) exposed women. At about one year of age, the 
cervix begins to elongate resulting in the migration of the squamocolumnar junction towards the 
external os. At the time of menarche or during pregnancy, both the uterus and cervix enlarge. 
Enlargement ofthe cervix is accompanied by alterations in its shape, resulting in greater eversion of the 
endocervical columnar epithelium towards the vagina. 
Over time, the columnar epithelium exposed on the portio vaginalis of the cervix is remodelled and 
replaced by metaplastic squamous epitlielium. As this occurs, the original sqli3mocolumnar junction 
(OSCl) moves towards the endocervical os or endocervical canal, creating a new SCl The area 
between the original and the new SCJs is called the transformation zone (TZ) and is characterised 
histologically by metaplastic epithelium. 
The concept of the TZ is central to the understanding of the pathogenesis of squamous cell cancer of 
the cervix and its precursors, because virtually all cenrical squamous neoplasia originates at the new 
SCJ and coincides with the distribution of the TZ. In addition, in reproductive life, the TZ is located on 
the exposed portion of the cervix and is amenable to cytological and histological sampling and 
colposcopic examination. While the TZ is difficult to visualise with the naked eye, its localisation is 
greatly enhanced by the application of 5% acetic acid and the use of the colposcope. 
1.1.2 Natural history of Cervical Cancer Precursors 
It has long been recognised that cervical cancer develops from histologically well-characterised 
precursors. The first evidence suggesting the existence of precursor lesions for invasive squamous 
carcinoma of the cervix were observations made in the late 1800s tlmt non-invasive epithelial 
abnonnalities frequently existed adjacent to invasive lesions. Broders appears to be the first to propose 
the term carcinoma -in -situ (CIS) to describe tlleSe intraepithelial abnormalities7• 
Subsequently a number of case-controlled studies demonstrated that a significant proportion of women 
with CIS, who were untreated, developed cervical cancer. Petersen8 followed 127 women with biopsy­
continned high-grade preinvasive lesions oftlle cervix (called then Epithelial Hyperplasia with Nuclear 











women at the end of one year, 11% at the end of 3 years, 22% at the end of 5 years and in 33% at the 
end of 9 years of follow up. Kottmeier found that 25 of 34 women with CIS who were followed for 20 
years or more without treatment developed invasive cancer 9. 
In a study by Koss et al lO, CIS lesions were confirmed histologically by biopsy and then followed using 
cytology alone. Six percent of the women (4/67) developed invasive cancer between 16 and 54 months 
after entering the study and 5167 women developed possible invasion. Hall and Waltonll reported a 
29% progression rate of severe dysplasia to carcinoma in situ or invasive cancer over a 1 14 year 
period. 
In the 1950s it became apparent that there were another large group of cervical lesions that had some of 
the characteristics of CIS, but to a lesser degree. ReaganJ2 first introduced the term dysplasia to 
describe these lesions. DysplasIa referred to abnormalities that included a cytological and histological 
spectrum of lesions intermediate between CIS and nonnal epithelium. The WHO (World Health 
Organisation) adopted this terminology as mild, moderate, severe dysplasia and CIS for cytological and 
histopathological classification of cervical cancer precursors. 
The natural history of dysplasia was studied e"iensively in the 1950s and 1960s. Population based 
screening programmes of previously unscreened populations showed that women with mild dysplasia 
were younger than women with moderate dysplasia who in turn were younger than women with severe 
dysplasia and CIS 13. This age distribution suggested that mild dysplasia progressed over years to 
higher grades of dysplasia and finally to CIS. CIS was considered very high risk for progression to 
invasive cancer and was aggressively treated with cone biopsy or hysterectomy. 
1.1.3 Development of CIN Terminology 
In the 1960s Richart introduced the CIN classification 14. Laboratory- based studies showed that the 
differences between the different grades of dysplasia were quantitative as well as qualitative. On the 
basis of these studies, as well as long-tenn clinical follow up studies, Richart suggested that dysplasia 
and CIS constituted a histological continuum rather than a series of discrete entities and introduced the 
term 'Cervical Intraepithelial Neoplasia', known as CIN. In the original CIN terminology CINI 
corresponded to mild dysplasia, CIN 2 to moderate dysplasia and CIN3 to severe dysplasia and CIS. 
The concept of CIN was strongly influenced by the results of a long-term prospective follow up study 
of 557 women who had had three previous dysplastic smearsl). After entry, the women were 
prospectively followed for an average of 36 months using cytology and colposcopy without cervical 
biopsy. During follow up only 6% of the lesions spontaneously regressed and the remainder either 












1.1.4 The Bethesda Classification of Cervical Cytology 
As outlined above, preinvasive lesions of the cervix have been classified using a variety of different 
terminologies over time. To standardise the 'terminology chaos' that existed because ofthes~ various' 
definitions, a new classification of cytological reporting, called the Bethesda system, was devised in 
198816. The Bethesda system combines clinically similar intraepithelial diagnoses into broad 
categories, specifically low-grade Squamous Intraepithelial Lesions (LSIL), representing the changes 
of koiliocytic cytological aytpia and CINl, and high-grade SIL (HSIL), representing the changes of 
CIN 2 and 3. The new classification was designed for use in cytological screening and it remains 
technically more correct to use the more detailed CIN scale when discussing histopathology. However, 
as the behaviour of low-grade lesions differs from high-grade lesions, this study will use the terms 
LSIL and HSIL for both Cytological and histological diagnosis. 
LSIL is common and represents the usually benign cytopathological signs of HPV infection. lit 
contrast, HSIL is rare and represents a truly premalignant condition. Although LSIL can be viewed as 
an epidemiological exposure or risk factor for cervical cancer, HSIL can be viewed as more closely ·.linked to the cancer outcome. 
While this conceptual distinction is clinically useful, it is not perfect. There exists a continuum of 
changes encompassing LSIL and HSIL without a clear endpoint. At the microscopic level, for example, 
the characteristic cells of LSIL are abnormal but terminally differentiated. The atypical cells progress 
to the surface, produce keratins, die and ex-foliate as would normal cells. The gradient from LSIL to 
HSIL is characterised by increasing nuclear atypia and failure of cellular differentiation in 
progressively more superficial levels of epithelium, with CIN3 representing full-thickness replacement 












1.2 Aetiology of Cervical Cancer: The Role of Human Papillomavirus Infection 
of the Cervix 
For over 100 years it has been recognised that, the epidemiology of squamous cancer of the cervix has 
many of the characteristics of sexually transmitted diseases17, Sexual factors such as early age of first I 
intercourse, early age of first pregnancy, multiple partners or a partner who has multiple partners and a 
history of sexually transmitted diseases are known to increase a woman's risk of developing cervical 
1S 20cancer - , This strong association with sexually transmitted diseases stimulated the search for an 
infectious' agent as the cause of cervical cancer and its precursors. 
Initial attempts to identify an infectious agent as the aetiological agent for cervical cancer focussed on 
known genital pathogens as the causative agents, particularly infections by bacteria (T.pallidum, 
N.gonococcus), protozoa (T.vaginalis) and Chlamydia. None of these attempts produced conclusive 
results. ]n the late 1960s genital infection by herpes simplex virus (HSV) type-2 was considered a 
promising candidate, when sero-epidemiological studies revealed higher antibody titres against HSV-2 
antigens in cervical cancer patients compared to age-matched controls21 • Subsequent studies however, 
failed to support an involvement of HSV -2 infections in cervical cancer or preinvasive . lesions of the 
cervix22 • 
]n the J970s zur Hausen23• 24 first suggested a role for the Papillomaviruses in the pathogenesis of 
genital tract cancer, There is now a substantial body of epidemiological, clinical and molecular 
evidence that persistent infection of the cervix with certain types of Human Papillomavirus (HPV) is 
the central cause ofcervical cancer and its precursors25• 26. 
1.2.1 Human Papillomaviruses 
HPVs are non-enveloped, double stranded ieosahedral DNA viruses that are classified into various 
'types'. HPV types are defined by genomic analyses and therefore represent genotypes. The different 
types of HPVs are characterised according to DNA sequence homology. The types are numbered 
sequentially when' they are characterised. Each type has its own tissue predilection and disease 
spectrum. At present, novel HPV genomes are described as a new HPV type if the nucleotide 
sequences of the E6, E7 and Ll genes (Le. about one-third of the genome) differ by more than J0% 
from those of any previously described HPV types27• 
To date approximately 100 genotypes ofHPV have been identified, and 30 types are believed to infect 
the genital tract. HPVs infect epithelial cells and are restricted to this target popUlation of cells28 • 
Papillomaviruses are widely distributed throughout mammals and are highly species specific29• 
Different types of HPV have considerable specificity with regard to the epithelium they infect and the' 
morphology of the lesions they produce. For example, HPV types I and 4 are associated with deep 












and II cause genital warts as well as laryngeal polyps. The following HPV types typically infect the 
cervical epithelium: 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 40, 42- 45, 51 - 58, 59, 66 and 68. 
).2.2 Transmission of Genital HPV Infection 
Observational studies suggest that genital HPV infection is transmitted primarily through contact with 
infected cervical, vaginal, vulvar, penile or anal epithelium, indicating that genital HPV infection is 
sexually transmitted30• In studies of sexually inexperienced young women, HPV DNA and antibodies 
to genital types ofHPV are rarely detected3 ). 
In addition, there appears to be a positive association between increasing numbers of recent partners 
and increasing prevalence of genital HPV infection32• In a cohort study of 18 - 20 year old female 
university students with a low-risk profile for sexually transmitted diseases, the overall prevalence of 
genital HPV infection as determined by PCR-analysis was 35%32. The prevalence at enrolment among 
the 183 sexually experienced women ranged from 17% of those reporting only one partner to 83% of 
those reporting more than five partners32• 
1.2.3 Natural History of HPV Infection and Evidence that HPV Infection causes 
most Cervical Neoplasia 
There is a limited understanding of the natural history of genital HPV infections, mainly because the 
virus cannot be grown in tissue culture and is therefore particularly difficult to study. The initial site of 
HPV infection is assumed to be the germinal cells of the basal layer of the epithelium, with the virus 
gaining entry via minor epithelial injuries. The protein products of the E6 and E7 Open Reading 
Frames of the HPV genome appear to be principally responsible for the HPV neoplastic effects. The 
E6 protein binds to and inactivatesp53 tumour suppressor protein and the E7 protein binds to and 
inactivates the retinoblastoma tumour suppressor protein, disrupting cellular regulation. 
The HPV genome is maintained in the cell nucleus and is usually episomal. In invasive cancers 
however, HPV DNA integration into the host genome is found in the majority of the cases33.The 
relative expression of E6 and E7 proteins is maintained once the HPV DNA is integrated into the host 
genome. At the molecular level, human cancers result from an accumulation of genetic mutations. In 
the molecular pathogenesis of cervical cancer, persistent infection with an oncogenic HPV expressing 
E6 and E7 proteins, is the initiating event. Thereafter, somatic genetic mutations occur that may be 
involved in cervical cancer development. 
Only a small percentage of individuals infected with HPV develop cervical cancer34• 35 and the usual 
pathogenesis of HPV infections is benign. Cervical HPV DNA tends to disappear within months to a 
few years of detection, possibly due to suppression of the virus by the host and the cessation of 












Some HPV infections are however, persistent. HPV DNA persistence may be an early and important 
step in the development ofgenital lesions such as warts and neoplasia. Hildesheim et al36 observed that 
women infected with HPV types known to be associated with cervical cancer were more likely to have 
persistent infection than those infected with other HPV types. In addition, women developing CIN 
under observation were more likely than controls to have persistent rather than transient DNA 
detection. 
The role of persistent HPV infection with high-risk types of HPV in the development of progressive 
preinvasive disease is supported by a study performed by Remmink et ae 7• This group screened a total 
of 342 women with abnormal smears every 3 4 months with cytology, colposcopy and HPV DNA 
testing using PCR. Nineteen women showed progressive preinvasive disease and all were continuously 
HPV DNA positive from the beginning of the study and all had histologically confirmed CIN 3. No 
cases of progressive disease were noted in HPV DNA negative patients or those infected with low risk 
types of HPV DNA. Using life-table analysis, the cumulative rate of progressive, histologically­
verified CIN disease was 17% after 36 months. 
~.2.4 The Causal Relationship between HPV Infection and Cervical Cancer 
The epidemiological association between HPV infection and cervical cancer fulfils all the established 
epidemiological criteria for causality38. These criteria include strength and consistency of the 
epidemiological association, time sequence, specificity of the association and coherence with existing 
biological and epidemiological evidence. The association between HPV infection and cervical cancer 
isremarkably strong and consistent, with virtually no negative studies39. 
In case series worldwide, most cervical cancers have been found to contain HPV of the same 10 - 15 
types. Metastases contain the types of HPV found in the corresponding primary tumours. The most 
definitive study of invasive cervical cancer included 1050 cervical cancers from 20 countries, tested for 
all known HPV types by PCR: 93% of the cases had detectable HPV DNA, with HPV type 16 being 
the most commonly detected type40• 
Regarding a logical time sequence, HPV infection (as measured by DNA) tends to precede and predict 
incidence of cervical neoplasia. Early results from large prospective studies of cytologically normal 
women show substantially elevated relative and absolute risks of incident SIL, including HSIL, within 
a few years of viral DNA detection. Cancer-associated HPV types are associated with a higher risk of 
development of cytologically evident lesions than are other HPV types. In addition, follow up studies 
of women with LSIL have found that cancer-associated HPV types predict an elevated risk of 
progression to HSIL. 
The animal and experimental evidence for HPV carcinogenicity are strong, satisfying the causal 











has long been recognised. For instance, in the rare genetic disorder epidennodysplasia verrucifonnis, 
patients develop multiple HPV -induced cutaneous warts that are prone to squamous cell carcinomas, 
especially on sun-exposed areas of the skin41. 
1.2.5 HPV Infection of the Cervix over Time and Among Women with Normal 
and Abnormal Cervical Smears 
From a variety of studies the following factors emerge. Most individuals with genital HPV infection 
do not develop signs or symptoms that are brought to the attention of a clinician. It is however likely 
that many infections cause microscopic intraepithelial lesions that are never detected 32 .In addition, 
within a few years of the initial infection, most individuals have no molecular, microscopic or clinical 
evidence of the initial infection 42. 
Polymerase chain reaction (PCR)-based methods of HPV DNA detection have revealed that the 
prevalence of HPV infection in cytologically nonnal women ranges from 3.5 53%. However, 
Evander et al42 showed that over a 2-year period the prevalence of HPV DNA decreased significantly 
in their cohort of 276 mostly university female students. The steepest drop in prevalence was in the 
women who were 25 years old at enrolment. In Holland, HPV DNA was analysed by PCR in a cohort 
of women participating in the screening programme. A gradual decrease in HPV prevalence with age 
was found, from 14% in women up to 30 years, to 5% of women over 30 years43 . 
Koutsky et al44 studied a cohort of 241 cytologically normal women who had no past history of CIN 
and had been recruited from a sexually transmitted diseases clinic in Seattle, USA. The population was 
followed every four months by repeated HPV testing and cytological and colposcopic examinations for 
an average of 25 months. Based on survival analysis, the cumulative incidence of biopsy-confirmed 
high-grade CIN among HPV positive women was 28% at two years, compared with 3% among HPV 
negative women. Most of the incident high-grade CIN occurred within the first two years of follow up. 
Nobbenhuis et al45 monitored 353 women referred to gynaecologists with CIN ], 2 and 3 with cytology, 
colposcopy and testing for high-risk HPV DNA with PCR. The median follow-up time was 33 months. 
Thirty-three women reached clinical progression and all 33 had persistent infection with high-risk 
HPV. The cumulative 6-year incidence of clinical progression among these women was 40% (95% CI 
21 - 59). In women with end histology ofCIN 3, 95% of 103 women had persistent infection with 
high-risk HPV from baseline. Clinical progression of CIN was not seen in the absence of high-risk 
HPV infection of the cervix. In addition, among women with CIN 1 or 2 at baseline, a second test for 
HPV at 6 months predicted end histology of CIN 3 better than a second cervical smear. They 
concluded from their data that persistent infection with high-risk types of HPV is necessary for the 












1.2.6 Summary of the Role of HPV Infection of the Cervix in the Pathogenesis of 
Cervical Cancer 
The earliest known step in cervical cancer is the transmission of HPV infection. Although sexual 
transmission is the most important route of transmission of HPV, fomite transmission of HPV to the 
cervix appears theoretically possible based on findings ofHPV DNA on underclothes and gynaecologic 
equipment46• Vertical transmission of genital types of HPV is certainly possible, although the 
frequency is unknown41, 48. The cumulative lifetime probability of acquiring a cervical infection with at 
least one type of HPV is extremely high for sexually active individuals. The HPV prevalence of a 
given population depends most strongly on the age and sexual practices of the population. Young, 
sexually active women have the highest HPV prevalence49, 50. 
The current model of cervical cancer pathogenesis can be summarised in the following way. The 
central event is infection of the cervix with HPV. Infection of the cervix in most women is transient, 
but in some women infection is persistent. Persistent infection of the cervix with high-risk types of 
HPV results in morphological alteration of the epithelium beginning with koiliocytosis, followed by 
dysplastic change, representing precursors of cervical cancer, and ultimately the development of 












1.3 Do Mass Cervical Cancer Screening Programmes Prevent Cervical Cancer? 
1.3.1 Cervical Screening Programmes in Developed Countries 
There have been no randomised trials to evaluate the impact of cervical cancer screening on cervical 
cancer incidence and mortality and all data on the effect of screening has come from cohort and case­
controlled studies. However, the marked reduction in the incidence of and mortality from cervical 
cancer before and after the introduction of screening programmes in a variety of developed countries, 
has been interpreted as strong non-experimental support for organised cervical cancer screening 
programmes. 
The International Agency for Research on Cancer (IARe) conducted a comprehensive analysis of data 
from several of the largest screening programmes in the world in 1986 and sho\ved that well-organised 
screening programmes were effective in reducing the incidence of and mortality from cervical cancerS!. , 
In the Nordic countries, following the introduction of nationwide screening in the 1960s, cumulative 
mortality rates of cervical cancer have shown a falling trend. The greatest fall was in Iceland (84% 
from 1965 to 1982) where the screening interval was the shortest and the target age range the widest. 
The smallest reduction in cumulative mortality (11%) was in Norway where only 5% ofthe population 
had been part of organised screening programmesS2 • The falls in Finland, Sweden and Denmark were 
50%, 34% and 27% respectively. The highest reduction in cervical cancer incidence was in the 30 - 49 
age groups where the focus of screening was the most intense. 
In addition, the association between mortality trends and the extent of coverage of the population by 
organised screening was 1110st pronounced when the proportional reductions in the age-specific rates 
were related to the target ages of the screening programmes. The age-specific trends indicated that the 
target age range of a screening programme was a more important determinant of risk-reduction than 
the frequency of screening within the defined age range. This finding was in agreement with the 
estimates of the IARC working group, that for inter-screen intervals of up to 5 years, the protective 
effect of organised screening was high throughout the targeted age group (over 80%) 53. It is apparent 
therefore that the extent to which screening programmes have succeeded or failed to decrease incidence 
of and mortality from cervical cancer is largely reflected in 1] the extent of coverage of the population 
at risk by screening, 2] the target age of women screened and 3] the reliability of cytology services. 
The contrast between Finland, which had an organised screening programme and Norway, where an 
equivalent number of smears were performed opportunistically, indicated another important aspect of 
/ 
screening. Even though the difference in the total number of smears taken in the two countries was not 
great, the reduction in mortality was substantial for all ages in Finland, whereas in Norway, only 
women aged 30 - 49 years showed a fall in mortality rates: even for that age group, the fall was only 
half that in Finland. These data suggest that spontaneous or opportunistic screening fail to reach the 
most at risk women in the population, that is, middle-aged and older women of high relative risk and 












reasons for the failure of opportunistic screening to reduce cervical cancer mortality include sub­
optimal follow-up and management of women with abnormal smears and the lack of a co-ordinated 
campaign of informing and educating women about cervical cancer prevention. This results in women 
at high risk of disease being excluded from screening54. 
Further evidence of the impact of screening is found in the Canadian experience where the incidence of 
cervical cancer dropped from 28.4 to 6.9 and mortality from 11.4 to 33 per 100000 women during a 
20 year screening pr~gramme in British Columbia55. 
Mortality from cervical cancer in the United Kingdom fell by 30% after the introduction of screening 
in the 1960s, however some of this decrease in mortality was attributed to falling rates in older women 
and could have been a cohort effect unrelated to screening56. The need for an effectively managed 
national programme in the UK was realised by the mid 1980s, which led to the introduction of a 
computerised call and recall system for women aged between 20 and 64 years. The invitation- based 
system, together with target payments for general practitioners, improved population coverage from 40 
60% in 1989, to 80% in 1992 and to 83% in 1993. In an audit of this programme in 24 self-selected 
districts in the UK by Sasieni et al56, it was estimated that the number of cases of cervical cancer in the 
participating districts would have been 57% (95% CI: 28 85%) greater had there had been no 
screening. Further they estimated that screening prevented between 1100 and 3900 cases of invasive 
cervical cancer in the UK 
1.3.2 Cervical Cancer Screening Programmes in Developing Countries 
In many developing countries screening is either opportunistic, sporadic or does not occur at alL In 
1986 the WHO estimated that while approximately 40 50% of women in developed countries h~ (...A"';' ''1''1, 
been screened in the past 5 years, only 5% of women in developing countries had been screened5~In 
addition, most screening activity in developing countries was limited to women attending primary 
health care, antenatal and family planning clinics in urban areas, with no organised efforts to ensure 
that high-risk women attended for screening, treatment and follow Up57. While there is a paucity of data 
on screening programmes and incidence of and mortality from cervical cancer in many developing 
countries, there have been a number of attempts to establish screening programmes. Some of these 
programmes have met with marginal success, many however, have failed to either become established 
or to make an impact on cervical cancer incidence and mortality. 
1.3.3 Screening in South Africa, with Particular Reference to Khayelitsha 
There has never been a national, organised cervical cancer screening policy in South Mrica and 
cervical screening has been performed opportunistically, largely in family planning and antenatal 
clinics58. An example of the typical screening activity encountered in South Mrica is illustrated in a 











analysed by the University of Cape Town Cytology laboratory over a five year period and showed that 
the highest proportion of smears were performed in maternity obstetric units on pregnant women under 
the age of 30 years. However, the highest proportion of smears showing CIN 3 was found .. among 
women aged 30 39 years who were screened in local clinics, and the highest proportion of smears 
showing malignancy were found among women over the age of 50 years, who were screened 
opportunistically in day hospitals. The peak incidence of screening overall occurred in the 20 - 29 year 
age groups, and the screening incidence for women over 40 years or more was one third to one tenth of 
the peak screening incidence. 
The screening activity in Khayelitsha (the area in which this study was performed), follows a similar 
pattern to that reported by Baillie59 • Since 1987, cervical smears in Khayelitsha have been obtained 
from women presenting for health care at three primary health care clinics, three family planning 
clinics and one Maternity Obstetric Unit (MOU). All cervical smears taken in Khayelitsha were 
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Figure 3: Total number of smears taken per year in the Khayelitsha area from 1988 - 1995 
evaluated at the UCT Cytopathology laboratory. The total number of smears taken per year in 
Khayelitsha from 1988 - 1995 are illustrated in Figure 3 (data extracted by the author from the 
laboratory computerised database established in 1987). 
From 1988 to 1993 over 5 000 cervical smears per year were taken in Khayelitsha, with a population 
estimated at between 350 and 500 000 people. After 1994, the number of smears recorded in the 
laboratory declined to 2743 and in 1995, to 1 332. This was due to the adoption of a new policy by the 
Provincial Administration of the Western Cape 1994. This policy, designed in principle to focus 












every decade beginning at age 30. This policy resulted in a marked reduction in the total number of 
smears performed in Khayelitsha, largely because screening of pregnant women and women under the 
age of 30 years virtually ceased. 
The age distribution of the smears taken in Khayelitsha from 1988 - 1995 is shown in Figure 4. The 
majority of smears were performed in young women: 11.1 % were aged 15 19 years, 61.1 % were 
aged 20 29 years, 16.8% were aged 30 - 34 years and 11.0% were over the age of 35 years. After the 
change in policy in 1994, while the total number of smears taken decreased substantially, the 
proportion of smears taken in women over the age of 35 increased marginally from 11 to 14%. 
There are no reliable data on the extent of coverage of women in Khayelitsha, or on the impact of 
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Figure 4: Age Distribution of Cervical Smears taken in Khayelitsha 1988 - 1995 
screening on the incidence of cervical cancer in the area. This is partly due to very mobile nature of the 
population of Khayelitsha, where many women move between their rural homes and the city. However, 
Megevand et al60, recruited 5045 women living in Khayelitsha to their study and overall, 5.9% of the 
women reported that they had previously been screened. In a study by Cooper et a161 , which was a 
population-based survey of the health status of women in Khayelitsha performed in 1989, 44% of 
women had had a Pap smear but less than 50% of the women screened knew the results of their Pap 














62Cronje et al reported a similar pattern of screening in the Orange Free State (OFS), another province 
in South Africa. Just over 36% of all smears performed in the province were in women aged 25 - 34 
years and 29% of smears were performed in women aged 15 - 24 years. By contrast 19% of smears 
were in women aged 35 - 44 years and only 16% were in women 45 years and older. While white 
women constituted 21 % of the population of the OFS, (a group considered a relatively low-risk for 
cervical cancer due to their higher socio-economic status and greater access to screening), 53% of the 
women screened were white. In comparison, 76% of the population of the OFS were black women and 
only 43% of smears were performed in this group of women. Further, the vast majority of the smears 
(60%) were performed in the Bloemfontein, the capital of the OFS, with less than 10% of smears 
performed in rural areas where the majority of black women lived. 
In another study conducted in outside Pretoria, South Africa, Heystek et al63 offered cervical smears to 
and assessed knowledge of screening among 1095 attending a local clinic for non-gynaecological 
complaints. Only 2% of the women interviewed had any knowledge about Pap smears and the 
incidence of preinvasive disease of the cervix was 54/1000 women, which is relatively high. 
1.3.4 An Experience in South Africa: 'Project Screen Soweto' 
Another example of screening activity in South Africa is illustrated by a study in Soweto, South Africa, 
called 'Project Screen Soweto,64. In 1980, at Baragwanath Hospital, a large tertiary institution serving 
the inhabitants of Soweto (an African township outside Johannesburg, South Africa), an approximately 
50% increase in the admissions for cervical cancer, from 150 cases in 1970 to 236 cases in 1980 was 
documented. In addition, in excess of 70% of women with abnormal cervical smears had not been 
followed up. In recognition of the poor quality of the existing opportunistic screening programme and 
the apparently rising incidence of cervical cancer, Project Screen Soweto (PSS) was initiated in 198664• 
Prior to the establishment of Project Screen Soweto, a few basic goals were accomplished. Firstly, 
laboratory capacity for screening had been increased from 30 000 to 90 000 smears per annum. Pilot 
studies had identified the prime screening target as an existing and available pool of patients through 
the ,network of primary health care clinics. Laboratory-based follow-up services had been established 
and streamlined, and channels for communication between patients, clinicians and the laboratory had 
been created. The only unresolved problem at the time was the development of an accessible public 
education programme. This problem arose because of lack of resources but also due to fears that too 
vigorous and too early a public education programme would flood an untested screening network, 
swamping primary health care clinics, the laboratory, colposcopy clinics and the hospital wards. A 
decision was thus made to launch Project Screen Soweto prior to instituting any public health 
educational programme. 
During the planning phase of the project in 1982, 32 365 smears were taken. After the launch of the 











addition, there was a rapid decline in the diagnosis of both invasive and preinvasive cervical cancer, the 
opposite of what should occur in a screening programme conducted on a previously unscreened 
population. Unfortunately the project failed, despite following the published suggestions of Boyes et al 
based on their experience of the very successful British Columbia cervical cancer screening 
programme. The failure of the PSS was acknowledged 5 years after the commencement of the project. 
It was calculated however, that had available laboratory facilities been utilised to full capacity during 
that 5-year period, in excess of 300 000 women in Soweto would have received at least one smear, 
which should have yielded 6000 preinvasive or invasive cancers. 
The reasons for the failure of PSS are complex. An important cause of the failure of the programme 
appeared to be at the level of the administration of primary health care services, where the cervical 
smears should have been taken, but where the taking of smears was given a very low priority. Although 
not documented in the report of the PSS, it is likely that competing health needs of the largely poor 
community contributed to cervical cancer prevention efforts receiving low priority status. In addition, 
the failure to establish an effective public health educational programme resulted in women remaining 
ignorant about cervical cancer prevention and no consumer demand for screening was created. 
Allocation of financial resources may also have played an important role and the long-term savings 
created by preventing cervical cancer may not have been appreciated. For instance, with the cervical 
cancer incidence rates prevailing in 1984 in South Africa, it was estimated that a saving of R204 000 
would be obtained for every 1000 women screened, with a very favourable cost-benefit ratio of0.7265• 
1.3.5 Preliminary Results from a South African Study Designed to Formulate an 
Affordable Population Screening Programme 
In a more recent attempt to develop a national screening programme, a nationwide study in South 
Africa was started in nine provinces in 1997, funded by the Independent Development Trust. The 
intention was to screen 100 000 women in different regions of South Africa in order to determine the 
prevalence of cytological abnormalities in the population of South African women. Further aims of the 
study were to collect information about the capacity of the health services to provide screening services 
and whether women received results and appropriate action was taken where an abnormality was 
detected. 
Despite best efforts, only 20 277 Pap smears were taken throughout the country, far lower than the 
intended 100000 smears. Overall, 80% of women had never been screened and 92% had not had a Pap 
smear in the last 5 years. Of particular concern, was that only 14.9% of women with HSIL Paps and 
13.4% of the women with invasive Paps were recalled for further assessment, although just over 90% 
of the women screened received their results. This suggests that the interpretation of the smear results 











particularly poor (Personal communication, Professor Basil Bloch, Principal Investigator of the study 
and National President of the Cancer Association of South Africa). 
1.3.6 Screening Programmes in Other Developing Countries 
In India, some attempts to establish screening programmes through hospital or clinic outpatient 
services and the use of mobile cancer detection clinics, have shown a reduction in cervical cancer 
incidence. Luthra et al66 reported on a study in which 38 707 women were initially screened over a 
three-year period from 1960 to 1963 and repeat screening was performed on 26 110 women from the 
same population between 1966 and 1970. The incidence rates of cervical cancer were reduced in the 
two time periods from 1.7% to 0.63% and the corresponding rates for dysplasia increased from 2.4% to 
6.28%. 
In Costa Rica, nationwide cytology services have been available since 1970 for women aged 15 years 
and above receiving obstetric and gynaecological care. In 1987 a total of 242219 smears had been 
taken (equivalent to 287.3/]000 women above ]5 years of age). However, most of the women over 55 
years of age had never been screened. The overall crude and age-adjusted mortality rates from cervical 
cancer had not decreased in the last two decades despite the large number of smears performed61. 
In Cuba, a cervical cancer screening programme was initiated in 1967 for women aged 20 years and 
older with a screening interval of 2 years. Approximately 60% of women aged 20 - 60 years have been 
screened at least once. Coverage has been reported as 74% among women aged 20 - 25, but only 20% 
for women aged 50 years and older. Although no reduction in the incidence and mortality from 
cervical cancer in Cuba has been observed in the last three decades, the proportion of stage I cancer has 
steadily increased from 26% in 1982 to 50% in 1988 with a proportional decrease in stages 2 and 3 
cervical cancers68. 
In Cali, Colombia, cytological screening has been offered to all sexually active women through 
antenatal clinics since the late 1960s and a decrease in the incidence of cervical cancer has been 
observed 69. The age-adjusted rates of cervical cancer were 52.9, 48.2 and 42.2 (per 100 000 women) 
during 1972 1976, 1977- 1981 and 1982 -1986 respectively .. The same group showed in a case­
controlled study that the relative risk for invasive cervical cancer was 9.9 among women with no 
history of screening, compared to apparently healthy women with a history of screening. 
There has been a marked decline in cervical cancer incidence in all age groups in Shanghai, China and 
Hong Kong and this has been attributed to cervical cytology programmes initiated in the early' 1970s 70. 
In Jingan, in a rural community in China, 95% ofthe eligible population attended for screening at least 
once over a 12-year period between 1974 and 198571 • In a case-controlled study reported from this 
region, the relative risk of cervical cancer was found to be 0.33 in women who had three or more 












1974 and 1984, through some 700 gynaecological clinics throughout the country, managed to screen 
only 5.3% of the eligible women with no impact on cervical cancer incidence72. In another case­
·controlled study conducted among Thai women in Bangkok, a consistently decreasing risk of invasive 
cancer was observed with increasing frequency of Pap smears. Compared to unscreened women, risk of 
cervical cancer was reduced by approximately 75% when one Pap smear per year was performed73 • 
In Mexico, where nationwide cervical cancer screening was implemented in 1974, the mortality rate of 
cervical cancer has remained unchanged. In a study by Lazcano-Ponce et af4, it was found that 
coverage of women age 35 -64 years was between IO - 15%, the age group at highest risk for cervical 
cancer. Low utilisation of the screening programme by women at high risk was one of the main reasons 
that the screening programme had been ineffective. In another Mexican study, the quality of cervical 
smears was found poor. For example, in a random sample study of the quality of cytological smears at 
the Hospital General de Mexico, 64.1 % of samples were of low quality and the correlation between 
diagnostic error and low quality of the smear was very high at 0.87 (p<0.005) 75. 
These data on screening programmes in developing countries indicate, that establishing screening 
programmes is complex and often not possible despite best efforts. Clearly, besides considerable 
human, technical and financial resources, a series of parallel processes need to be instituted for 
screening programmes to have the desired effect of reducing incidence of and mortality from cervical 
cancer. Most developing country programmes described in the literature tend to be low-volume, based 
in laboratories with little in-built quality control measures, isolated and opportunistic without any 
systematic recruitment, follow-up and treatment of women at risk. Coverage tends to be poor, 
targeting young women who are often screened too frequently. 
1.3.7 Criteria for Successful Sc eening Programmes 
Experience from countries that have successfully maintained cervical cancer screening programmes 
indicate that instituting mass cervical screening requires a complex network of parallel factors76, n 
The following factors are considered important to ensure the success of cytologically-based screening 
programmes: 
• 	 Adequate field facilities with appropriately trained health personnel to perform quality cervical 
smears 
• 	 Wide coverage of the target population (at least 70%) at regular intervals: a minimum of 3 years 
between smears and mechanisms for contacting women on an individual basis e.g. through 
personally addressed letters 
• 	 An efficient health infrastructure with functioning management and information systems 
• 	 A cytology service with built-in quality assurance, ongoing training of cytotechnicians and regular 












• 	 An accessible and functional referral system for colposcopic assessment of women with abnormal 
smears 
• 	 Adequate diagnosis, treatment and follow up of women with abnormal smears and follow up of 
women who have been treated for preinvasive disease of the cervix 
• 	 Community understanding and acceptability 
• 	 Screening programmes should be planned at national level, they should be organised to encompass 
a call and recall system. 
• 	 A cancer registry to monitor the impact of the screening programmes 
These factors require a relatively sophisticated health infrastructure. With respect to these 
requirements, what is the situation in developing countries? The next section will explore some of the 












1.3.8 Barriers to Cervical Cancer Screening in Developing Countries, with 
Particular Reference to Sub-Saharan Africa. 
There is not a single developing country that has successfully implemented mass, organised cervical 
cancer screening, yet the greatest burden of cervical cancer is found in developing countries78• There 
are many explanations for the failure to institute mass cervical screening programmes in developing 
countries and these wiII be discussed in the following sections. 
1.3.8.1 Competing Health Needs 
The burden of diseases other than cancers is overwhelming in developing countries. In sub-Saharan 
Africa in 1995, it was estimated that communicable diseases and maternal or perinatal complications 
caused approximately 70 % of all deaths in women: the equivalent figure in developed countries was 
4.9%. The overall maternal mortality ratio for sub-Saharan Africa was calculated at 650 maternal 
deaths per 100 000 live births in 1985, which is the highest of all the world's regions (WHO 1985) 79. 
By comparison, the MMR in the USA was 101 100 000 live births. 
An additional health burden that is expected to consume significant resources is that of HI V infection. 
In 1994, the World Health Organisation80 estimated that globally more than 16 million adults and 1 
million children had been infected with Human Immundeficiency Virus (HI V). By mid 1994, 40% of 
the estimated cases of disease had occurred in women and this percentage is expected to increase 
significantly by the year 2000. In Africa it is estimated that among over 10 million cumulative 
infections, more than 50% have occurred in women. 
1.3.8.2 Limited Human and Financial Resources: 
J 
In March 1997 a conference on Cervical Cancer Prevention and Control in East and Southern Africa 
was held in Kenya and reports on the facilities for cervical cancer prevention and treatment were 
presented by representatives of 14 health ministries81 • Most countries reported high incidences of 
cervical cancer coupled with extremely limited facilities for screening or treatment. In Malawi, which 
established a population based cancer registry in 1988, the incidence of cervical cancer was reported as 
471100 000 women. Yet, the country has one pathologist, one colposcope, no cytotechnicians, no 
facilities for cervical cancer screening and no facilities for the treatment ofcervical cancer. 
In Kenya, where there is no cancer registry but the incidence of cervical cancer is believed to be 
equivalent to Malawi, only 2000 cervical smears per year were recorded in the state health service. 
There was only one laboratory in the whole country that had facilities to screen cervical smears, but a 
severe shortage of trained cytotechnicians had made screening virtually impossible. Mozambique had 
one pathologist, no cytotechnicians and the only facility for cervical screening was located at a large 











opportunistic screening existed in 40 primary health care clinics, but there were no facilities for the 
training of cytotechnicians and there was no colposcopic service in the state health sector. 
By comparison, in South Africa, with a population of 40 million people, there are 217 trained 
cytotechnicians and 781 specialist gynaecologists and all major centres have adequate facilities for the 
treatment of cervical cancer and its precursors. Despite these relatively good facilities, there has been 
no national screening programme and as indicated previously, cervical cancer remains the commonest 
cancer in women, particularly black women. A national screening programme has only recently been 
formally adopted (October 1999), which aims to provide three free cervical smears to all asymptomatic 
women over the age of 30 years. The gap however between policy and implementation remains and 
the intention is to aim to screen 80% of the population at least once in the next 10 years (Personal 
communication, Mrs Christelle Kotzenberg, Director Cancer Control Programme, Ministry of Health, 
South Africa). 
The gap between policy and implementation is well illustrated in the Western Cape, South Africa, 
where the policy of three free smears in a lifetime was introduced in 1994. As shown above the impact 
of this policy was a dramatic reduction in the number of smears performed without an appreciable 
increase in smears performed in women over the age of 30 years. 
1.3.8.3 Poorly Developed Health Care Services 
Primary health care facilities where preventative health care such as cervical screening should most 
likely be located are limited, under -resourced and over-burdened in most developing countries. Only 
60% of the population of sub-Saharan Africa have access to modern health care services82• 
In terms of access to health care, the physician: population ratio for the region in 1990 as a whole was 
1 :23 540, with a range of 1 :750 in South African urban areas to 1:72 990 in Rwanda. The regional 
nursing person: population ratio was 1:3460 ranging from 1:600 in Zimbabwe to 1:5470 in Tanzania. 
However, there was a relatively high ratio of nursing persons to physicians (5:1) for the region as a 
whole which is a favourable ratio for achieving health worker coverage of the population, compared to 
having an under-supply of physicians82 • A contributing factor to limited access to health care is the 
urban-rural bias, which is extreme in sub-Saharan Africa82 • While 87% of the region's urban popUlation 
has access to health services, more than 50% of people in most of its countries live more than 10 
kilometres from the nearest primary care centre82• 
1.3.8.4 Focus on Curative rather than Preventative Health Care: 
It has been estimated that the per capita yearly budget for health care expenditure in most African 












than being invested in large preventative health programmes. One exception to this is the HIV 
. . U d 83campaign In gan a . 
1.3.8.5 Women are Uninformed and Disempowered 
The World Development Report has cited education as an essential component to human health, stating 
that' Households with more education enjoy better health, both for adults and for children, [a result 
that] is strikingly consistent in a great number of studies, despite differences in research methods, time 
periods, and population samples,84. Women in developing countries tend to be poorly educated which 
has profound ramifications on the total quality of their lives, ranging from health care access, to health 
seeking behaviour, to the ability to generate income. The poor education of women in developing 
countries is reflected in the illiteracy rates. 
The basic literacy rate for women aged 15 and over has increased over the past few decades to at least 
75% in most countries of Latin America, the Caribbean and South Eastern Asia. High rates of 
illiteracy however, still prevail among women in most of Sub-Saharan and northern Africa, with 
illiteracy rates of up to 70% reported85. In addition, it is estimated that illiteracy rates for rural women 
are 2 to 3 times higher than those of urban women, and for older women (over the age of 45 years), 
illiteracy rates are at least twice those of women younger than 25 years85• 
In South Africa, which is one of the most developed countries in Sub-Saharan Africa, large sections of 
the population also lack adequate education. For instance, 20% of the population over the age of 20 
years have had no schooling at all, 7.5% have completed primary school and 33.9% have had some 
secondary level education. The majority ofpeople with little or no education are black women86• 
Not only are women in developing countries poorly educated but in most societies they have a status 
subservient to men with less control over family resources, minimal access to money and in general, 
inferior social power82. This combined, with poor education, has resulted in very low awareness about 
diseases such as cervical cancer and the fact that the disease can be prevented. Thus there is no 
consumer demand for services such cervical screening. 
1.3.8.6 War and Civil Strife 
In many countries in Africa, to name a few, Angola, Ethiopia, Eritrea, Rwanda, Liberia, Mozambique, 
Somalia, South Africa and more recently, the Democratic Republic ,of Congo, civil upheaval and 
general violence have been the status quo for decades. Some of the important consequences of war 
include displacement of people, the creation of refugees, disruption of health care services with loss of 
infrastructure and personnel and the diversion of state money to defence. F or instance, it has been 
estimated that 30% of the trained health personnel in Rwanda were murdered in the 1994 genocide. 











1.3.8.7 Widespread Poverty 
As an indication of the widespread poverty in Sub-Saharan countries, 41 % of the total population of the 
region has access to safe water and 26%, access to sanitation; these are the lowest percentages of all the 
developing country regions82 • The difference between urban and rural areas is marked: 79% of the 
region's urban population has access to safe water as opposed to 28% of the rural population. 
In South Africa, 33% of the black population have running tap water inside their dwellings (compared 
to 97% of the white population) and 22% have flush toilets inside their homes (compared to 98% ofthe 
white population). In the Western Cape, 18.6% of the economically active people are unemployed 
with the highest unemployment rate among Africans being 31% compared to 7.7% among the white 
population87• 
1.3.8.8 The Nature of the Screening Test 
While the factors described above are probably the most important reasons that cervical screening 
programmes have not been established in developing countries, the nature of the current screening 
process is also a contributing factor. For many developing countries, setting up quality national 
cytologically-based screening programmes.is beyond their capacity and resources. 
The first barrier to cytologically-based screening programmes is to develop the necessary infrastructure 
to perform Pap smears, transport the smears to laboratories where the appropriate processing and 
interpretation of slides can be performed. Thereafter the results need to be communicated to the 
referring clinic, and to the women who have been screened. This delay in itself is known to be a 
significant barrier to screening, with large numbers ofwomen not returning for results60• 
Secondly, for cytologically-based screening programmes to be effective, high quality cytology 
laboratories need to be established. Interpreting cervical smears is considered by many pathologists to 
be one of the most difficult tasks in pathology and obtaining a high level of proficiency requires several 
years of training. Maintaining skills requires ongoing continuing medical education, close supervision 
by trained laboratory managers and an established built-in quality control programme. 
Once a woman with an abnormal smear has been identified, she requires referral for colposcopic 
assessment. Colposcopy, where available, tends to be located in tertiary, urban-based institutions and 
provided by specialists. This requirement creates problems of access for poor women, both urban and 
rural, and contributes to the high default rate identified in a number of studies. For example, Megevand 
et a160, reported a 67% default rate for the first phase of their study, when women were referred to a 
tertiary institution for colposcopic assessment of abnormal Pap smears. A default rate of 40% was 












The modem management ofpreinvasive lesions has been considerably simplified by the introduction of 
LEEP (Loop Excision Electrosurgical Procedure), also known as LLETZ (Large Loop Excision of the 
Transformation Zone). This procedure can be performed in an outpatient setting, using local 
anaesthetic and relatively unsophisticated equipment. The complication rate of LEEP is low and the 
reported cure rate ranges from 80 - 95%90. The introduction of LEEP has made the treatment of 
preinvasive lesions more accessible to health care workers, potentially removing this procedure from 
the domain of the super-specialist. However, the correct use of LEEP is dependent on quality 
colposcopy, to prevent its unnecessary or inappropriate use91 • 
For most countries with limited or no screening, there is a concomitant lack ofcolposcopic services and 
outpatient methods of treating preinvasive disease. Hence in those countries with limited screening, 
e.g. Kenya and Tanzania, most women with abnormal smears are subjected to cone biopsy or 
hysterectomy; both radical and expensive treatments, which would be unsustainable, were a 
population-screening programme to exist. 
1.3.9 Screening in Low-Resource Settings 
The failure of cytologically-based screening programmes to be developed and sustained in low 
resource countries has stimulated the search for methods of screening that would overcome the many 
barriers identified. To screen successfully in low resource settings the following criteria would be 
optimal: 
• 	 Screening, diagnosis and treatment provided on-site, in clinics accessible to the majority of at fisk 
women 
• 	 Low costilow technology screening test 
• 	 Screening test that can lead to immediate treatment of abnormalities with the elimination of 
colposcopic triage 
• 	 Wide coverage of at risk women 
• 	 Appropriate educational programme directed towards health workers and women in the population 
to ensure correct implementation of the screening programme and attendance and compliance with 
screening programme 
• 	 Built-in mechanism for audit of the impact of the screening programme 
The next section will explore possible alternatives to cytologically-based screening programmes with 
these criteria as the basis for developing alternative methods of screening and treating preinvasive 











1.4 What are the Alternatives to Cytology? 
1.4.1 Visual Inspection Methods of Screening the Cervix 
1.4.2 Unaided Visual Inspection of the Cervix as a Screening test: 'Downstaging' 
The first attempts to develop alternative methods to cytology for screening in poor countries originated 
in India, with the introduction of Unaided Visual Inspection (UVI) of the cervix, also known as 
'Downstaging'. This involved the naked-eye speculum examination oftheappearance of the cervix by 
health workers trained in the technique. Women with an abnormal cervix were then referred for a 
second level investigation, which was either cytology (if available) or for gynaecological assessment if 
97no cytology was available92- . 
The published studies of 'down staging' indicate a very wide range (6 - 70%) of women examined by 
visual inspection were found to have an abnormal-looking cervix, depending on the criteria used to 
define a positive visual inspection. If any abnormal finding (ranging from excessive discharge up to 
growth/ulcer) was used to define an abnormal cervix, 41 - 70% were women called abnormal. If more 
limited criteria were used (bleeding on contact with the cervix, bleeding erosions, hypertrophied 
elongated oedematous cervix, growth or ulcer) 6 - 11 % of women had a positive test. All reported 
studies used cytology and/or biopsy as a reference test to study the performance of unaided visual 
inspection. 
The reported sensitivities and specificities of unaided visual inspection of the cervix for carcinoma-in­
situ and/or invasive cervical cancer are shown in Table I. The sensitivity to detect high-grade disease 
and cancer varied from 39 to 94% in different populations, using different providers and different 
criteria to define a positive test. Attempts to increase the specificity by using a high threshold to define 
a positive test resulted in unacc ptably low sensitivity. 
The results from the study by Nene et al97, which was population rather than clinic based, indicate that 
downstaging, as a screening tool is unlikely to be useful in cervical cancer control. Even with adequate 
sensitivity large numbers of women would be identified as positive and would require follow up, off ­
setting the financial savings of avoiding cytological examinations. When the sensitivity was high, the 
positive predictive value of the test was less than I %. Many early or microscopic cancers were missed 
by unaided visual inspection, as early cancers are often not clinically apparent to the naked-eye 
examination of the cervix. This explains the poor performance of unaided visual inspection for the 
detection of cancer and even worse performance for the detection of preinvasive lesions. 
Wesley et al96, who evaluated UVI in 2843 married women in Kerala, India, discussed the cost 
impJications of using low technology methods of screening. If UVI was used to preselect women for 
cytology, the costs saved would be related to not offering Pap smears to women with normal cervices 
Gust over 50% of the screened population). If 45% of women were referred for further evaluation, 











In addition, the low sensitivity would result in at least one third of the women with high-grade lesions 
being missed. They suggest that cost-savings with UVI would not be substantial. 
Jt may be that health education and awareness programmes to motivate symptomatic women to seek 
medical advice, and professional education to sensitise health professionals to the diagnosis of early 
cancer, may be as helpful (and less costly) as unaided visual inspection. In a study by Jayant et al98 on 
the impact of a health education programme on the stage of diagnosis of cervical cancer, a significant 
shift in the percentage of cervical cancers diagnosed in early stages (FlOD stages I and II) was found. 
A group of rural women were subjected to an intensive awareness campaign of symptoms of cervical 
cancer; 38% of identified cancers were early stage in 1988 - 1989 compared to 51 % in 1990 - 1992. 
The study group was compared to a control group who were not part of the awareness campaign and in 
whom the diagnosis of early stage cancers did not change over the same time period (38% in ] 988 - 89 
and 34% in 1990 - 1992). The authors suggest that an active awareness programme may achieve a 
stage-shift in the diagnosis of early cervical cancer relatively quickly and cheaply. 
Author (yr.) Visual Cytologylbiopsy findings Sensitivity (%) Specificity (%) 
inspection 
findings Positive Negative 
Singh et al Positive 149 4986 63 89 
1992 Negative 89 38746 
Bhargava et al Positive 50 125 85 96 
(1993) Negative 9 3424 
Sujathan et al Positive 68 2199 89 38 
(1995) Negative 5 1330 
Positive 60 2207 94 38 
Negative 4 1331 
Rao et al Positive 2 811 50 59 
(1995) Negative 2 1170 
Nene et al Positive 9 1111 90 43 
(1997) Negative 1 833 
Positive 6* 112 60 94 
Negative 4* 1832 
Wesley et al Positive 17 1262 74 55 
(1997) Negative 6 1558 
Positive 9* 170 39 94 
Negative ]4* 2650 
Table] : Performance of visual inspection in detecting carcinoma-in-situ and/or invasive cervical 
cancer [* A high threshold was used to define a positive test] 99 
1.4.3 Direct Visual Inspection of the Cervix after application of5% acetic acid 
Direct Visual Inspection of the cervix after the application of 5% acetic acid (DVI) was originally 
investigated as a tool to improve the sensitivity of the Pap smear. DVI involves visualising the cervix 
with the naked eye after the application of 5% acetic acid and the identification of aceto-white lesions. 
One of the earliest published studies on DVJ tOO showed DVI was an effective tool at identifYing 












detected 'atypical transformation zones', which contained either preinvasive or invasive lesions of the 
cervix. The authors suggested that DVI was as good as colposcopy in identitying potentially abnormal 
areas of the cervix, although DVI lacked the ability to discriminate between significant and 
insignificant lesions. They suggested however, that DVI could be a useful adjunct to cytology for 
cervical screening. 
Van Le et al 101 performed Pap smears on women attending family planning clinics and applied acetic 
acid to the cervix in order to identify aceto-white lesions. 85 women with normal Pap smears but 
positive aceto-white lesions were referred for colposcopic assessment. Of these women with normal 
Pap smears there were 13 cases of CIN detected by the positive acetic acid reaction; 9 women had 
CINI and 4 women had CIN 2. 
Frisch et al102 showed a decrease in the false negative rate of cytological screening by the addition of 
DVI; 3 cases of HSIL were identified by DVI that were missed by cytology. The positive predictive 
value of screening was decreased by combining cytology with DVI (compared to using cytology alone) 
however the negative predictive value increased from 67 (95% CI: 57 - 77) for cytology used alone to 
91 (95% CI: 80 -100) when cytology was used with DVI. 
1.4.4 DVI as a primary screening test 
It is however the potential of using DVI as a primary screening test that has received considerable 
attention in the past 5 years. There are many potential benefits of DVI as a screening test in low 
resource settings. DVI can be performed on-site by low-level clinicians or paramedical personnel, is 
relatively low cost, and because the result is immediately available, a recall system for women with 
abnormal results is not necessary. Another potential benefit of DVI is that of providing immediate 
treatment to women with a positive DVI examination. 
The equipment required for DVI includes a bed for examination in the lithotomy position, a good light 
source, a speculum for visualisation of the cervix, a sponge holding forceps, cotton wool for 
application of acetic acid and a supply of 5% acetic acid. After application of acetic acid, the cervix is 
inspected for the presence of an aceto-white lesion. No standardised criteria have been developed for 
defining an aceto-white lesion. Some investigators have attempted to train health workers to grade the 
intensity and extent of the aceto-white lesion and to introduce low and high thresholds for identitying a 
significant aceto-white lesion99 . Others have trained health workers to identity all aceto-white lesions, 
without attempting to differentiate between low and high-grade lesions103• While training health 
workers in the technique ofDVI, training to detect obvious clinical cancers is included. 
At the time of designing the study being presented in this thesis, there were few published studies of 
DVI as a screening test in low resource settings. Megevand et al 103 published data in 1996 on 2426 












South Africa. In their study DVI detected 64% of high-grade SIL lesions that were con finned 
histologically and missed II HSIL lesions in women who had a negative DVI test. 
More recently, Sanakarayanana et al 104 published data on 3000 women who were screened by 
paramedical personnel using DVI and cytology. The screeners were trained to grade the aceto-white 
lesions: the test was considered positive if any distinct aceto-white area was detected. I f the 
acetowhitening was doubtful or faint, the test was scored as negative. DVI was considered positive in 
9.8% of women compared to 10.2% with positive cytology (defined as atypia or worse). 
DVI detected 90.1 % of the true positive cases (defined as histologically con finned CIN 2 or worse) 
compared to cytology which identified 86.2% of the true positives. The approximate specificities of 
DVI and cytology Gust over 90%) were similar as were the positive predictive values (around 17%). In 
their study, cytology and DVI perfonned more or less equivalently as screening tests. 
The same group 105 reported on a similar study of 1 35] women, aged 22 - 70 years, who were screened, 
between 1995 and 1997. Of the women screened, 37.7% were considered DVI positive compared to 
15.2% of women with positive cytology. Of the 71 women with CIN 2 or worse, 95.8% were detected 
by a positive DVI test compared to 62.0% that were detected by cytology. Further, DV1 detected 25 
lesions missed by cytology and cytology detected one lesion missed by DVL The approximate 
specificity ofDVI was 68% compared to 89.5% for cytology. 
The University of Zimbabwe/JHPIEGO Cervical Cancer Project'06 screened 10 934 women in two 
phases (8731 in phase I and 2203 in phase II) using DVI and cytology. In phase one of the study, 
]8. ] % of women had colposcopy based on a positive DVI or Pap smear. In the second phase of the 
study, 2]47 (97.5%) of the 2203 women underwent colposcopy irrespective of the findings on DVI or 
cytology. The detection rate of CIN by DVI was similar to cytology and in phase 2 of the study, the 
sensitivity ofDVI for HSIL or greater at 77% was higher than the sensitivity of cytology at 44%. The 
specificity ofDVI for HSIL or greater however, was 64% compared to 91 % for cytology. 
These studies indicate that DV1 may have a role in screening for high-grade disease, although the 
consistently low specificity reported in a variety of studies may limit its effectiveness as a screening 
test. The impact ofreferring large numbers of women for treatment who do not have disease has yet to 
be evaluated. This thesis will present a detailed analysis of the performance ofDVI as a screening test 
in a low resource setting and will evaluate the outcome of a 'test and treat' policy using DVI as the 













AdolfStafl107 developed CervicographyTM in 1981. This method of screening involves taking a 35-mm 
photograph of the cervix (called a Cervigram™), using a specially-adapted camera, known as a 
Cerviscope™. The cervix is washed with 5% acetic acid and two Cervigrams™ are taken in 
succession. CervicographyTM was initially developed as an adjunct to cytology, and was not designed 
to replace cytological evaluation of the cervix. The advantages of the technique are the complementary 
nature of the test to cytology, and the fact that a permanent visual record of the cervix is obtained. 
A number of studies have shown that cytological detection rates of disease are markedly improved by 
the addition of a second or third test, including CervicographyTM 108. CervicographyTM has been 
consistently shown to increase the sensitivity of the screening process when used as im adjunct to 
cytology, largely because it identifies more low-grade lesions than cytOlogy109. 
Schneider et al llO screened 8460 women with CervicographyTM as a primary screening test and 
compared the results of CervicographyTM with diagnosis determined by histological analysis and 3 
cytological tests. CervicographyTM identified all I] cancers and cytology missed one. The sensitivity 
of CervicographyTM for HSIL or cancer was 49.3% overall (specificity 95.0%), 54.6% in women 
younger than 50 years of age, and 26.9% in women 50 years and older. Cytology had an overall 
sensitivity for HSIL and cancer of 77.2% (specificity 94.2%), 75.5% in women younger than 50 years 
of age and 84.6% in women 50 years of age and older. They concluded that CervicographyTM 
performed marginally better than cytology for the detection ofcancer, but worse than cytology for the 
detection of high-grade precursors. 
Nuovo et alii) conducted an extensive review of all published studies from 1966 - 1996 on the use of 
cervicography. Twenty-three reports on cervicography were reviewed. After excluding studies in which 
the reference standard (colposcopy) was not performed on all participants, 7 studies were available for 
analysis. These are summarised in Table 2. While there is a wide range of test results reported, 
reflecting different populations of women studied and different referral criteria for colposcopy, all 
seven studies find that cervicography has a high false-positive rate, with a range of 9.8 ~ 63.4 % for 
high-grade lesions reported. In contrast though, cervicography appears to have a high sensitivity for 
high-grade lesions with sensitivities of over 89% reported in five of these studies. Specificity however 
was low in all studies. The high negative predictive value (NPV) may indicate some utility of 
cervicography as a primary screening test. Only one study evaluated cervicography as a primary 
screening test1J7, and found that cervicography had a higher sensitivity than cytology (89 versus 52%, 
respectively) with similar specificities (92% an<} 94%, respectively). 
Autier et al 119 performed· a randomised study o{ cytology alone versus cytology plus cervicography 
among 5 550 women aged 18 - 91 years. One year later, women were re-called for repeat screening 











histological sampling. The principal endpoint of the study was the rate of histologically confirmed CIN 
lesions one year after initial screening. At the initial screening round, CrN (of any grade) was 
histologically confirmed in 0.14% of the group of women who only underwent cytological screening, 
compared to 0.90% of the women who were screened with both cytology and cervicography. 
High-grade 100 49.4 50.6 8.5 100.0 
Any grade 90.4 60.4 39.6 44.3 94.7 
High-grade 18.2 81.6 18.4 38.6 63.8 
Any grade 19.4 82.3 17.7 38.9 63.8 
High-grade 100.0 36.6 63.4 10.9 tDO.O 
Any grade 93.3 39.0 61.0 21.9 96.9 
Patients referred to Colposcopy clinic with abnormal Pap smears 
High-grade 95.5 48.1 51.9 6.9 99.6 
Any grade 81.8 57.7 42.3 43.9 88.5 
Any grade 73.0 64.0 36.0 45.5 84.8 
Screening Population 
High-grade 89.5 90.2 9.8 31.5 99.4 
Any grade 88.9 81.8 10.6 44.4 99.1 
Patients with condyloma 
High-grade 100.0 53.1 48.9 13.2 100.0 
Any grade 89.5 58.1 41.9 32.1 96.2 
Table 2: Summary of Cervicography Test Characteristics from Seven Eligible Studies (Reproduced 
from Nuovo et al III) [* Refers to colposcopic grade of dysplasia1 
These findings suggested that cervicography substantially increased the detection rate of histologically 
confirmed CIN in the screening process. However at the second round of screening, the prevalence of 
CrN in women screened with both cytology and cervicography was reduced (to 0.53%). This may be 
due to the regression of transient CIN 1 lesions detected initially by cervicography. On the other hand, 
it is possible that cytology detects different lesions from those detected by cervicography, and that 
cervicography- detected lesions do not express the cellular abnormalities necessary for detection by 
cytology and vice versa. Hence, cervicography and C)1010gy are complementary to one another. 
In the study presented in this thesis, CervicographyTM was evaluated as a primary screening test. In 
addition, CervicographyTM it was used as a form of quality control for DVI as it provided us with a 












1.4.6 HPV DNA testing 
The role of HPV DNA in the aetiology of cervical cancer has been discussed, as has the role of the 
persistence of oncogenic type of HPV DNA infection of the cervix in developing progressive SIL and 
cancer. The powerful association of certain types of HPV infection of the cervix with SIL and cancer 
has prompted an investigation into the role of HPV DNA detection in primary and adjunctive cervical 
screening. 
Two methods are used for the detection of HPV DNA: those that identify nucleic acids directly and 
those that amplify nucleic acids first and then detect the amplified product. The latter method, know as 
polymerase chain reaction or PCR-based techniques is considered the 'gold-standard' for HPV DNA 
detection. Direct identification of nucleic acids can be perfonned using Southern Blot, filter-in-situ 
hybridisation (FISH), in-situ hybridisation, Dot Blot and a more recent method, known as Hybrid 
Capture™. 
For HPV DNA testing to be used in a mass screening programme, Cuzick et al120 have suggested that 
the method used for HPV testing should fulfil the following criteria: 
l. 	 The test must be readily available 
2. 	 Highly sensitive and specific for a broad spectrum of high-risk types of genital HPV 
3. 	 Capable of using minimally invasive sample types (e.g. cervical brushes as opposed to tissue 
samples) 
4. 	 Possess high level of intra-and inter-laboratory reproducibility 
5. 	 Suitable for high-volume testing (e.g. 96-well microtitre plate) 
6. 	 Potential for full or semi-automated execution of the tests 
7. 	 Cost-effective execution within a large-volume screening programme 
Southern blotting has been widely used for the identification and typing of HPV and in expert hands, is 
sensitive, specific and reproducible. However, the test requires relatively large amounts of DNA such 
as would be obtained by tissue samples e.g. from a cervical biopsy. It is also labour intensive, time­
consuming and not amenable to automation and is therefore not a suitable technique for screening. Dot 
Blot is simpler and quicker to execute than Southern Blotting. Two commercially available Dot Blot 
systems that have been widely reported in the literature are the Virapap and Viratype® kits (Life 
Technologies). In general, these techniques have lower sensitivity and specificity than Southern 
blotting and the requirement for large amounts of input DNA, make these techniques unsuitable for 
screening. FISH is simple to execute but is neither sensitive nor specific and has been largely 
abandoned for clinical applications. 
New in-situ hybridisation protocols are currently being developed that can be used to detect and type 
HPV DNA in standard cervical smears and automated systems are being designed which could allow 












commercially available, however, it may be an attractive option for HPV DNA detection in screening 
protocols in the future. Similarly, while the PCR-based techniques are considered the 'gold standard' 
for HPV DNA detection and typing, there are no commercially produced kits, although these are 
currently under development. In addition, the PCR process needs to be conducted in a facility designed 
to prevent the contamination of samples with previously amplified products. While this requirement 
can be easily overcome in specialised laboratories, this would pose considerable logistic problems in 
the context of using PCR techniques in a large-scale screening programme. 
The original Hybrid Capture™ (He) technique, known as HC I, was chosen as the technique for HPV 
DNA detection in this study, as at the time, the test was commercially available and was considered the 
most appropriate test in the context of a large-scale screening project. The test is easy to perform and 
initial training of technologists is relatively simple. In addition, the laboratory requirements are 
considerably simpler than those of PCR-based techniques, as the test does not rely upon amplification 
of the target material to achieve its sensitivity. 
During the course of the study, a new generation of the Hybrid Capture™ test was introduced, known 
as HC II, which has an additional 4 probes for the detection of HPV types and uses a microtitre format 
enabling large numbers of samples (up to 96) to be processed at one time. Both tests are suitable for 
large-scale screening programmes, although the analytical sensitivity ofHC I is reported to be less than 
that of HC II 12I. HPV DNA detection by HC II has been shown in one study to have near equivalent 
ability to the PCR system based on the MY091l1 primerJ22 
Hybrid Capture I, is a quantitative test, which is available in standardised kit format. The test is an in­
vitro, solution hybridisation, signal amplification test for detecting DNA or RNA targets. In this assay, 
cellular DNA is extracted, denatured in an alkaline solution and then hybridised with complementary 
RNA probes to produce DNA-RNA molecules. The hybrid DNA-RNA molecules are then removed 
from solution by antibodies that coat the walls of the tube. These antibodies only recognise the three­
dimensional structure of the hybrid DNA-RNA molecules and double-stranded DNA or single-stranded 
RNA molecules are removed. The presence of the hybrid molecules is detected by the addition of anti­
hybrid antibodies labelled with alkaline phosphatase, which binds to the immobilised target hybrid 
molecules. The alkaline phosphatase is then reacted with a dioxetane chemi-Iuminescent substrate to 
produce light, which is measured by a luminometer. Results are then expressed as relative light units 
(RLUs), which are a measure of the light produced by the individual sample reaction divided by the 
mean level of light generated by three 1.0pglml positive calibrators. As such, a reading of 1.0 RLU is 
equivalent to 1.Opglml. 
While having a generally lower analytical sensitivity than HC II, HC I has been shown in some studies 
to have a similar sensitivity to PCR for the detection of HPV DNA. Sun et al i23 assayed cervical 
samples for HPV DNA from 520 women using HC I and PCR and they found a good correlation 












type of HPV. Cope et aJ I24 compared PCR using the MY09111 primer system with HC I for the 
detection of HPV in 499 cervicovaginal lavage specimens from women with normal cytology and 97 
specimens from women with varying degrees of SIL. While the two tests detect a different range of 
HPV types, when the tests were compared on the basis of the 14 HPV types detected by both methods, 
PCR detected 108 positive samples compared to 79 detected by HC 1. Overall however, the two 
methods agreed 93% of the time on whether a specimen was positive or negative for one of the 14 
types detected by both methods, and 97.2% of the time, they agreed on whether the specimens were 
positive for cancer-associated types ofHPV. 
Schiffman et al l2S showed that inter-laboratory agreement in three laboratories that used HC I was 
good. Inter-laboratory agreement rates on HPV positivity in a study of 199 cervical specimens for 
either high risk or low risk types ranged from 87 94% and kappa values ranged from 0.61 to 0.83. 
The advantages of HPV DNA testing include the following: HPV DNA detection is an objective test, 
the laboratory procedures use standardised kits, are relatively simple and can be performed by mid- to 
low-level technicians. In addition, large numbers of tests can be performed per day compared to the 
limited number of cervical smears that can be read per day by highly trained cytotechnologists. 
Finally, with the rapid development of modem molecular technology, it may become feasible to 
develop a fully automated method of HPV DNA detection using the hybrid capture format. The 
ultimate however, would be to develop a method of HPV DNA which could be used in the clinic as a 
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2.1.1 Overall Aim of the Study 
The study was designed to evaluate alternatives to cytology for screening for cervical cancer and its 
precursors. The target population was women aged 35 65 years, who had not been screened 
previously and who lived in a low-resource setting. 
2.1.2 Objectives of the Study 
1. To compare the sensitivity, specificity, positive predictive value and negative predictive value of 
the following three cervical screening tests with those of cervical cytology: 
• 	 Direct visual inspection (DVI) of the cervix with the naked eye and with low 
magnification after the application of 5% acetic acid. 
• 	 Detection of high-risk or oncogenic types of Human Papillomavirus (HPV) 
• 	 CervicographyTM (35 mm photographs of the cervix taken after the application of 5% 
acetic acid) 
2. To analyse information on the performance of the four screening tests and the prevalence of disease 
in the study population to predict expected outcomes ofeach test used alone or in various combinations 
of tests. 
3. To determine, in a low resource setting, the success rate, short and intermediate term complication 
rates of LEEP as a treatment for preinvasive disease of the cervix and to evaluate LEEP when used in a 
'see and treat' mode i.e. treatment of preinvasive lesions of the cervix with LEEP after coJposcopic 
assessment but without prior histological evaluation 
4. To describe the process of setting up a cervical cancer screening study in the context of a 












2.1.3 Why Khayelitsha was chosen as the study site - a Political and Historical 
Perspective 
Khayelitsha was chosen as the study site as it is a low-resource area, only 20 kilometres outside of 
Cape Town, where most people live in poverty, with poor levels of health in general and relatively poor 
health care services. Consequently, we expected to find a high level of preinvasive disease and a large 
group of unscreened women. Placing the study in this area enabled us to evaluate the different 
screening tests within the context of low-resource community. In addition, the project was able to 
provide screening services to women who would not otherwise have had access to screening. This 
section provides the reader with a history of the development of Khayelitsha and describes the socio­
demographic characteristics of the community, in order to place in perspective the conditions in which 
the study was performed. 
Khayelitsha is a peri-urban settlement that was established in 1983, and is inhabited almost entirely by 
African people. The movement of African people in South Africa was controlled and restricted since 
the early 1900s. This policy was intensified after 1948 when the now infamous policy of Apartheid 
became government policy. The essence of the policy of Apartheid was to develop South Africa along 
racial lines with the intention of creating separate states for white and black South Africans. This policy 
resulted in the creation of9 areas in South Africa that were designated as 'homelands' and which were 
supposed to become independent countries, populated exclusively by black South Africans. These 9 
areas, created along tribal lines, represented approximately 13% of the land of South Africa and were 
designed to accommodate over 75% of the population l . 
The implementation of this policy began in earnest in the early 1960s and resulted in over three and a 
half million African people being forcibly displaced and moyed to the 'correct' areas by the early 
1980s2• The intention was to move African people out of 'white rural' and 'white· urban' areas and to 
force them to move to the 'homelands'. The extent to which migration to the cities by African people 
was allowed, was determined by the need for their labour. This process was governed by a complex set 
oflaws that included the 'Pass Laws'. The 'Pass Laws' decreed that Africans had to carry a 'reference 
book' at all times to indicate whether they were 'legally' or 'illegally' resident or working in a 
particular area. 
Despite the rigorous application of these laws many African people did migrate to the cities2• These 
laws coupled with the deliberate failure to provide housing for African people in the cities forced large 
numbers of African people to live in squatter camps, in and around South African cities. 
In Cape Town (capital of the Western Cape), in the early 1980s, there were 3 established 'legal' 
townships in which African people were allowed to live and work. In addition, large numbers of 
African people had managed to migrate to the city and were living in squatter camps. It was 












residence and employment of the White and Coloured' communities'. Further, it was stated that the 
'uncontrolled influx of Black people to the Cape Metropolitan Area should be countered as far as 
possible d . 
In 1983, the proposed development of KhayeJitsha was announced. The intention was to move 'legal' 
Africans living in established townships in Cape Town or in squatter camps to Khayelitsha. 'Illegal' 
Africans were to be forced to move to the 'homelands' of Transkei and Ciskei (Transkei obtained 
'independence' in 1976 and Ciskei in 1981) 4.5. In 1984 however, there was widespread political 
violence in many of the squatter camps in Cape Town. This resulted in thousands of people being 
displaced from their homes and many people were forced to settle in Khayelitsha, in far larger numbers 
than were intended by the State. By the end of 1984, 30 000 people had moved to an area of 
Khayelitsha that became known as Site C and established the first informal settlement. By September 
1986 the total population of Khayelitsha had reached approximately 120000 people. 
In 1986 the 'Pass laws' were repealed. T his, together with the widespread poverty that had been 
created by the 'homeland' system, stimulated a large migration of rural people to urban areas. By 
1996, the total population of Khayelitsha had grown to between 350 000 - 500 000 people4 . 
2.1.4 Socio-economic and Demographic Profile of Women living in Khayelitsha 
Khayelitsha is divided into various towns, where people live in brick houses and 'sites', where people 
live in 'site and service' schemes. The 'site and service' schemes provide a plot of land with an outside 
tap for running water, a flush toijet, and refuse removal. The 'houses' or 'shacks', as they are known, 
are erected by the people themselves using materials such as wood, plastic and corrugated iron. Since 
1994 when a new government was elected and the policy of Apartheid was formally terminated, many 
of the shacks have acquired electricity. A smaller but rapidly increasing part of Khayelitsha is known 
as the 'unserviced sites' where people have moved onto vacant land and erected 'shacks' without any 
infrastructure, running water or sanitation. 
The socio-economic and demographic pro fi le of the population of Khayelitsha was described in 1991 
by Cooper et a16. The study reports on interviews of respondents living in 722 households in 
Khayelitsha in 1989; 91.3% of the respondents were women. Of the female respondents interviewed, 
13.7% lived in formal housing, 54.3% lived in serviced sites and 31.7% lived in unserviced sites. 
Seven per cent of the respondents had no formal schooling, 39% had primary school education and 
54% has some secondary school education. 
The majority of the respondents (71 %) had been born in a 'homeland' and 55.3% still regarded the 
'homeland' as home. In addition, 67.3% of women had a dwelling in the 'homeland', 41.2% had 












children living in the homeland and 86.9% had relatives living in the 'homeland'. Over 80% of the 
respondents had moved to Khayelitsha from a rural area and the primary reasons for migration were to 
work and to join a spouse. 
Of the female respondents, 45% had no employment in either the formal or the informal sector; 67% 
were unemployed if employment in the informal sector was excluded. Of the women who were 
employed, 66.2% were employed as domestic workers. Among both formal and informal sector 
employees, 80% earned less than R I 00 per week, while 89% of formal sector employees earned under 
R400 per month. 
The social and environmental conditions in Khayelitsha reflect the inequities created by the Apartheid 
system in South Africa and the problems of rapid urbanisation. Poverty, overcrowding, poor quality 
housing, inadequate sanitation and water, high levels of crime and violence and pervasive ill health 
characterise the area and its population7 
For example, the incidence of Tuberculosis in Khayelitsha was estimated to be 543 per 100 000 
population in 1996 (compared to the national prevalence of 223 per lOa 000 population)7 The 
prevalence of HIV infection in women was about 10% (derived from anonymous screening of women 
attending antenatal clinics in Khayelitsha). The infant mortality rate (IMR) for the area was estimated 
as 38.3 per 1000 live births in 1996. In 1994, the national IMR was 48.9/1 000 and 54.3/1 000 for the 
African population. Due to poor record keeping in Khayelitsha the IMR is probably an underestimate 
of the true rate. 






















2.1.5 Study site: Nolungile Clinic 
Site C was chosen as the study site because of its central location in Khayelitsha and the close 
proximity of Site C to taxi ranks, bus stops and a railway station. In 1996, Site C had a population of 
approximately 70 000 people living in about 7600 serviced shacks and 640 unserviced shacks7. The 
study site was Nolungile Clinic, which had been established in 1983. Nolungile clinic is situated in the 
centre of Site C and is within walking distance of all transport facilities and most people's homes. 
2.2 Preparations for the Study 
2.2.1 Development of Community Participation 
Four months prior to establishing the project, all Community Health Forums (CHFs), primary health 
care (PHC) services and non-governmental organisations (NGOs) working in the Kbayelitsha area 
were contacted and the nature of the proposed study was explained to members of each organisation. 
The CHFs were established after the 1994 elections in South Africa and consisted of elected 
representatives from the community who were mandated to monitor the provision of health services in 
their area. Obtaining permission to begin projects in the Khayelitsha area from these community health 
forums was an essential step in ensuring community approval and participation. 
Each section of Khayelitsha has it's own CHF, and five of these were contacted, including the CHF of 
Site C. These forums first required a meeting with the project investigator during which the nature of 
the project was explained in detail. Executive members then presented this information to the wider 
community at mass meetings. At these meetings members of the community had the opportunity to ask 
questions and to discuss the nature of the project. I attended one of these mass meetings and explained 
the rationale behind the project and it's advantages to the women who would be screened. There was 
an enthusiastic approval for the project. 
Meetings with the Association for Traditional Healers in Kbayelitsha were also alTanged. Many people 
in Khayelitsha use traditional healers as their primary or supplementary health care resource, hence the 
importance of ensuring their approval and co-operation with the project. Two separate meetings were 
held with local traditional healers. The group gave their approval and agreed to co-operate with the 
project by refelTing their patients for screening where appropriate. The CHFs and Traditional Healers 
required feedback of the results of the research project and I reported to the respective executive 













The staff consisted of two female community health workers (CHW) who had previously worked on a 
cervical project, who knew the area well and were Xhosa (the predominant 
'~UI:>~'.I:>_ of the women resident in Khayelitsha). In addition, a senior sister was employed. She 
had previously been trained in direct visual inspection (DVJ) of the had worked in the area and 
A full time medical officer was employed to oversee the non-research related medical problems of the 
women recruited to the study, to manage the data and to be trained in colposcopy and the management 
of preinvasive lesions of the cervix. 
2.2.4 Training 
Training of staff began in December 1995 and was "'''''''''''''''~,,.. midway through January 1996. The 
nursing sister was re-trained in Dvr and in the exact for examination of the women over a 
period of one week immediately prior to Her training consisted of lectures on the 
natural history of preinvasive lesions of the cervix and of cervical cancer, and included an extensive 
review of slides of normal and abnormal before and after the application of acetic acid. She 
was trained to identifY all aceto-white lesions without attempting to distinguish minor from more 
significant lesions. 
Fred Kosteki from National USA visited Cape Town and trained the nursing 
sister, medical officer and author in all of CervicographyTM. The author, a senior specialist in 
the UCT and two technologists from Department of UCT were 
trained in the of HPV DNA Hybrid Capture ITM by Thomas Associate 
Division the Department of Pathology, Columbia New 
York. 
2.2.5 Study 
At Nolungile a room was provided for the examination of the women and the Cancer 
Association of South Africa provided the project with a fully equipped mobile caravan, which was 
parked in an empty plot next to the clinic. The caravan was not used as a mobile clinic, but 
since it was equipped with a colposcope, a generator and the equipment to treat women with 
preinvasive lesions of the cervix, it was decided to use the caravan as the and treatment 
'room'. This provided extra space and greater privacy. The was used as a back up to the 











The facilities at Groote Schuur (GSH), a large tertiary in Town, were made 
available for the referral of women who participated in the study and were incidentally found to have 
or other medical n .."n,p,." Women with cervical cancer were referred to GSH 
for further 'H"'tn,,,,.,t The facilities at Nolungile Clinic were utilised for women with primary health 
care 
2.3 Inclusion 
The study was a volunteer of women in Khayelitsha 
who had not been screened and were aged 35 - 65 years. This age group was 
selected in order to screen the most high-risk women in the community. A number of large cohort 
studies indicate that the of high-grade preinvasive lesions (CrN 2 or worse) is highest in 
women over the age of 35 years. Miller et als reported on 3 cohorts of women screened in the British 
Columbia which included over 300 000 women screened. Their data confirmed that the 
incidence lesions of the cervix at around age 35 years, but continues to 
occur to an extent in women in their 60s. The in the Western Cape 
confirms these data with the prevalence of CrN 2 and 3 found in the over 35 age group. 
Inclusion criteria were: 
• Women 35 65 years 
• No history of been screened previously 
Exclusion criteria: 
• Previous hv"tPl'PI'j'nl"t)\' or previous treatment for cervical disease 
• Pregnant women 
• Women unable to informed consent 
2.4 Overall JU''''~''''''' of Study 
2.4.1 of the Study Flow 
An overview of the is illustrated in Figure 6. This was a cro,ss-seCHOI community based 













Figure 6: O"rw·;thrn of Study Flow 
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of the programme, the 
and the author "Tn"n,,,,,,'; a 'health day' in in 
We invited health workers and services from different areas of to 
Women were recruited to the study from Site C and the wider Khayelitsha area, by one of the CHWs. 
Health care shopping centres, bus stops and railway stations Khayelitsha were 
visited in rotation on a daily basis. In addition, central points in residential areas were visited and 
women were informally invited to listen to the CHW explain about cervical cancer prevention. These 
'informal' in the streets were well attended by women and men 
Extensive use was made of local and national radio and local media to inform women about the project 
and the of cervical cancer For instance, the local radio station, 
Zibonele interviewed various members of the (the the sister and one of 
the CHW s) on a regular basis throughout the 19 months of the These ",t,""",P\lV<: which 
focused on the nature and rationale of cervical cancer prevention, were followed by 'nnl'n,~_ 
in' programmes where women were invited to ask questions. 
The programmes provided the project team with insight into women's fears and 
around cervical cancer and its prevention. It became clear that the concept of 
was poorly understood and enabled us to improve the we used and our methods 
of cervical cancer prevention. In addition, it gave the team the opportunity to 
provide women with information on health issues not directly related to cervical cancer prevention, 
such as vaginal infections and transmitted domestic violence and rape, 
tuberculosis and the signs and "vrnntnm of other cancers, such as breast cancer. 
The author also appeared on national specifically on a woman's programme, which is 
run by a radio The programme had an estimated audience of one million 
women nationally and took the same format as the local Zibonele radio programme. After listening to 
the many questions and concerns women expressed during the 'rmnnp'_1 
the medical officer of the 
November of 1996. 
collaborate on the project. Health information on cervical cancer prevention, AIDS, maternal and child 
tuberculosis and prevention of sexually transmitted diseases was presented using poetry, 
songs and informal lectures. A competition was which required women to answer the 
'How is cervical cancer and over 1000 women from Khayelitsha entered the 
competition. The whole was videotaped and recorded and was subsequently 
national radio programme. The video was edited and has been shown to women 
on the 
for 
screening or colposcopy on a basis. 

The author also wrote short articles on women's health and cervical cancer prevention for the local 

newspaper. These articles were in and Xhosa and at 
approximately 3 monthly intervals. The author and participated in numerous seminars and 












These were aimed at awareness about cervical cancer prevention and the 
vmlec.olo·!1Jc:al nr(\hlprt'" at the primary health care level. 
To ensure that the women attending the project understood the information being provided by the 
project a series of focus groups were organised with women who had already been screened 
in November 1996 through to March 1997. These focus groups, conducted by a trained Xhosa 
interviewer, explored women's understanding, and fears. From these 
the educational material and the method of explaining cervical cancer prevention was refined 
Although the impact of the educational material was not formally evaluated in the study, it was our 
observation that participation in the project increased as the nature of our educational material 
improved. It appeared that a clear understanding of the purpose of screening reduced and 
provided a strong incentive to women to participate in the and to return for results and follow up. 
The focus groups also gave us into the role of the extended family in Xhosa culture. Women 
take important decisions alone. Rather it is custom for women to consult with male and older 
female members of the family before accepting treatment, if the treatment 
intervention. With this information, we included men and older women in our educational initiatives 
and encouraged women to bring their significant family members to our educational talks. 
we learnt that there was great distrust of the use of surgical methods for the treatment of 
cancer, as it is believed that cancer is a 'poison' that needs to be drawn out of the bodylO. 'Cutting' 
thr.,....I<.h cancer is believed to stimulate the tumour to grow. alerted us to the need for very careful 
explanation about treatment of preinvasive lesions to fears that we were and 
cancer. 
It was also learned that most women recruited to the study consulted with traditional healers and were 
under the impression that the project team would "", ...re"t" of this. We therefore made a specific 
of explaining that we did not disapprove of the use of traditional healers and encouraged women 
to our methods of and treatment with those used by traditional healers. 
Informed ",-,vu",..'u and Enrolment 
At enrolment, the nature and purpose of the study was outlined on a one-on-one basis to the women, 
the CHW responsible for enrolment. Eligibility criteria were checked. Informed, written consent was 
taken. The consent form was translated into Xhosa a senior lecturer in Xhosa language at the 
of Cape Town. 
Thereafter the women were a unique number and their names and numbers entered into 












HPV DNA specimen collection tube were labelled with the name and patient number of each woman 
by the enrolment CHW. 
In addition, their contact details were documented and a detailed, structured questionnaire (appendix A) 
was administered. The questionnaire elicited information on socio-economic and demographic factors, 
sexual, reproductive and contraceptive history, and life-style habits such as tobacco and alcohol use. 
The questionnaire was administered by the enrolment CHW and took approximately lO minutes to 
complete. The medical officer checked the questionnaire on a daily basis to ensure completeness of the 
data. 
Each woman was given a patient card which recorded her name, patient number, date of birth, address, 
date of enrolment and date for return for follow up. At the back of the card, space was provided for 
clinical findings by the screening nursing sister, the results of the screening tests and the colposcopic 
examination. 
2.4.4 Screening 
The nursing sister checked that the forms, slide and specimen collection tube were correctly labelled 
with the woman's name and unique study number. The nature of the screening process was explained 
in detail. Women were examined in lithotomy. 
The gynaecological examination began with the visual examination of the vulva. Thereafter a bi-valve 
speculum was passed and the vagina inspected for discharge, which was graded as mild, moderate or 
severe. This was followed by naked eye inspection of the cervix and documented the presence of 
inflammation, atrophy, ulcers, polyps and obvious cancer. The cervix was illuminated by using an 
electrical headlamp. 
A cervical smear was obtained using an Accellon Combi cervical biosampler (MedScand, Hollywood, 
FL) for the first 1200 women screened. Once the slide had been prepared for the cervical smear, the tip 
of the Accellon sampler was broken into an HPV DNA specimen collection tube (Digene Corporation, 
Silver Spring, MD). 
After the first 1200 women had been screened, the cervical sampling device was changed to an 
Aylesbury spatula and an endocervical brush. The Aylesbury spatula was first used to obtain an 
ectocervical smear and immediately placed on the glass slide. The endocervical brush was then 
inserted into the endocervical canal, turned once and immediately placed over the same glass slide and 











After the cervical smear had been performed, the cervix was washed with 5% acetic acid cotton-
wool balls soaked in acetic acid. While for the acetic acid reaction the details of the vulval, 
vaginal and cervical examination were recorded on the clinical examination form. The cervix was 
me,,,,,,,,,,,,,, with the naked eye for the presence of an aceto-white lesion. Acetic acid was then applied 
for the second time and the cervix re-examined for the presence of an aceto-white lesion a 2.5x 
hand-held monocular also known as a (SeJsi, Edmund NJ, 
USA). 
Acetic acid was applied for the third time and two Cervigrams™ (i.e. 35-mm photograph of the cervix 
taken with a adapted camera called a were taken. 
At the end of the examination, the clinical examination form and the cervigram log were completed. 
The medical officer checked these forms on a daily basis to ensure completeness of the data. 
Referral for Colposcopy 
Women were referred for colposcopy if anyone of the screening tests with or without 
magnification, positive Cytology, positive HPV DNA test or CervicographyTM) were positive. Women 
who had lesions noted on naked-eye examination of the cervix (prior to the application of 5% acetic 
acid) were referred for colposcopy at the discretion of the nursing sister, as inspection of the 
cervix without the use of acetic acid, was not considered a screening test. 
Women were informed of the result of the clinical examination and were asked to return for 
results and/or colposcopy within 2 6 of being screened. 
At the end of each day, the forms, specimen collection tubes, film and Cervigram™ logs were 
placed in separate boxes, counted and entered into a checklist by one of the CHWs. These were 
delivered on a daily basis to the project located at the CANSA, and were counted and checked 
the medical officer to ensure that the and number and forms tallied correctly. 
No formal method of control of the gynaecological examination the sister was included in 
the informal quality control consisted of sessions (on a 4 monthly 
of the nursing sister, and the appropriateness of referrals at the colposcopic 
examination. 
2.4.6 HPV DNA Testing 
HPV DNA status was determined at the University of Cape Town the first generation Hybrid 










manufacturer's protocol using the tube-based format and probes for 'high oncogenic risk' HPV 
(i.e., types 16,18,31, 51,52and 
HPV determinations were quantitative, and women with samples producing readings than or 
equal to 10 times (x) the positive control (10 or 100 000 HPV genome copies per test) were 
referred for colposcopy. Women who had a HPV DNA test but less than lOx the positive 
control were not referred for colposcopy on this basis. However, women with a positive HPV DNA 
test but less than lOx the positive control and who were positive on one of the other tests did 
undergo colposcopy. The data on these women is included in the data analysis for the purpose of 
comparison. 
The HPV DNA test was run on a basis and women were their results within 2 6 of 
the test The results ofthe HPV DNA test were entered into a coded data sheet. 
One year after the study began, Digene MD) introduced the new generation 
assay for the detection of HPV DNA, known as Hybrid ]I (HC II). A sample of Accellon 
cervical samplers that had been stored at were re-tested later at Columbia University using the 
second generation HC II assay. The sample consisted of all women with a histological diagnosis of 
high-grade SIL, or invasive cervical cancer and an 10 percent random 
(n=243) of women with no positive screening test results or with a positive screening testes), 
but no SIL or cancer detected at colposcopy and biopsy. HC II uses for 13 high-risk HPV types 
(HPV J6, 18, 31, 35, 39, 45, 51, 56, 58, 59 and 68) and a microtitre plate-based assay format. 
The chosen analytic sensitivity limit ofHC II for HPV was 1 pglml. 
Cytology 
The Town (UCT) Cytopathology .,kr,r.,tr.nf evaluated cervical smears to 
the routine nrnTn{',('I1 of the ,.,"AY",U,,"" Cervical smears were classified the Bethesda 
The different categories used are shown in Table 3. 
All slides were initially evaluated by cytotechnologists. The cytotechnologists re-screened 
100% of each other's slides. Two senior cytotechnologists then individually re-screened a random 
of j 0% of the normal smears as well as all smears taken from postmenopausal women. All 
slides identified as abnormal (ASCUS, AGUS, LSIL, HSIL or malignant) were re-screened by the 
same two senior cytotechnologists. The senior cytotechnologists referred cervical smears with a 
diagnosis of HSIL or malignancy to a Cytopathologist for review. ASCUS smears were 












Diagnostic Category Abbreviation and explanation 
Satisfactory for cytological assessment 
Satisfactory but limited by SBLB (e.g.: lack of endocervical component, 
obscuring blood or debris, scanty cellular material) 
Unsatisfactory Inadequate for cytological evaluation 
Within normal limits WNL 
Benign Epithelial Changes Infection, inflammation, atrophy, reparative changes 
Atypical Squamous Cells of Unknown Significance ASCUS 
Atypical Glandular Cells of Unknown Significance AGUS 
Low grade Squamous Intraepithelial Lesions LSIL = includes lesions previously called CINI or 
cytological changes of HPV infection 
High grade Squamous Intraepithelial Lesions HSIL = previously called CIN 2 or CIN 3 
Malignant or suspicious of malignancy 
Table 3: Classification of Cervical Cytology using Bethesda system of 1992 
Cervical cytology results were entered into a coded data sheet. Women with a cytological diagnosis of 
LSIL, HSIL, suspicious of malignancy or malignant were referred for colposcopy within two weeks of 
being screened . 
2.4.8 CervicograpbyTM 
The 35-mm ro.lls of film were sent to National Testing Laboratories (NTL), USA for processing and 
evaluation. The film was developed by NTL according to their specifications and each Cervigram™ 
Slide was reviewed for quality after processing. The CervigramTM Slides were sent to a NTL evaluator. 
Cervigram™ Slides were projected onto a screen and were approximately six feet in width. Once 
projected onto the screen, the Cervigram™ Slides were evaluated from a distance of I - 3 feet. After 
the initial evaluation, 100% of the CervigramTM Slides were re-evaluated by a second evaluator, 
blinded to the results of the first evaluation. In the case of a discrepancy, the slide was reviewed in 
conference and the evaluation of the conference was accepted as the final diagnosis. 
The classification of the CervigramTM results is illustrated in Table 4 and Figures 7 - 10 show 
photographs of Cervigram™ Slides illustrating 4 different diagnostic categories. 'Atypical' refers to 
the presence of an aceto-white change on the cervix but based on its site and morphology, colposcopy 
is not considered necessary. 'Warrants colposcopy' indicates that no definitive lesion is seen but the 












defective' means that the Cervigram™ Slide is not adequate for evaluation either due to the quality of 
the slide or the cervix is obscured by the speculum, blood or mucous. 
'LSIL' refers to an aceto-white lesion with a predicted histological diagnosis of LSlL (HPV or CIN I) . 
'HSIL' predicts a histological diagnosis ofHSIL (CIN 2 or CIN 3) and 'malignant' predicts cancer. 
Women were recalled for colposcopy if the cervigram result was 'warrants colposcopy', LSIL, HSIL or 
malignant. The results of the CervigramsTM were available within 8 to 12 weeks of the test being 
performed. 
Diagnosis Cervigram™ Terminology 
Normal 
TZ visible 
TZ not visible 
Atypical (lesion inside or outside TZ) 
Warrants Colposcopy 
LSIL (with or without TZ visible) 
HSIL 
Cancer 









Table 4: Diagnostic Categories for Evaluation of Cervigram™ Slides 












Figure 7: Cervi gram evaluation - Squamous Metaplasia 












Figure 9: Cervigram evaluation - LSIL 











2.5 Diagnosis and treatment 
2.5.1 Referral for colposcopy 
Women were referred for colposcopy if any of the four screening tests were positive. Women who 
were DVI positive or HPV DNA positive to lOx the positive control were referred for colposcopy 
within 2 6 of screened. All were performed blinded to the result of the 
cervical smear, unless a was the only reason for looSCO'DiC referraL 
Women were informed about the in the cytology result and were a date to return for results 
two weeks after being screened. Due to the delay in the result (8 12 weeks), 
women were informed that would be contacted one of the CHWs if the Cervigram™ result was 
positive and had not undergone a lY,lnO'U'Onl examination on the basis of other 
screening tests. To ensure that women were Nu,t<>r·'<>,", each woman's address or the address of a 
relative or friend was double-checked at each visit. 
2.5.2 Colposcopic Examination: Reid's Colposcopic Index 
The author performed or directly supervised all examinations. The Reid's 
Index (RCl)ll was used to and classifY the colposcopic findings. The RCI was used in order to 
standardise COIPO~;COPIC and to minimise intra-observer variability. 
The RCI considers four lesion characteristic of preinvasive cervical lesions: margin of the 
colour of the aceto-whitening, vessels within the lesion and iodine The fITst three are 
evaluated following application of 5% acetic acid to the cervix. The final sign, iodine is 
evaluated after the application of iodine to the cervix. 
The classification of the different colposcopic is illustrated in Table 5. Each sign is divided into 3 
categories characteristic of various grades of disease and is assigned a numerical value from 0 2. The 
scores for each sign are combined to establish the total RCI score. A total RCI of 0 2 represents 
benign HPV, or LSIL. A total score of 3- 5 CIN I or CIN 2 (LSIL or HSIL) and 6-8 
predicts CJN 2 or CrN 3 (HSIL). 














oPoints I Point 2 Points 
Margin 
Condylomatous or micropapillary 
contour 
Indistinct borders 
Flocculated or feathered margins 
Jagged, angular lesions 
Satellite lesions, acetowhitening 
that extends beyond TZ 
Regular lesions with 
smooth outlines 
Sharp peripheral margins 
Rolled, peeling edges 
Internal borders between 
areas of differing 
appearance 
Colour 
Shiny, snow-white colour 
Indistinct aceto-whitening, 




Dull, oyster grey 
Vessels 
Uniform, fine calibre 
Randomly arranged with poorly 
formed patterns 
Non-dilated capillary loops 
111- defined areas of fine punctation 
or mosaic 
Absence of surface 
vessels, following 
application acetic acid 
Definite punctation or 
mosaicism 
Individual vessels 





Positive iodine uptake, producing a 
mahogany-brown colour 
Negative iodine uptake by an area 
that is recognisable as a low-grade 
lesion by above criteria (5.2/6) 
Partial iodine uptake 
Variegated, tortoise-shell 
appearance 
Negative staining ofa 
lesion, which is a high-
grade lesion by the 





o - 2 benign or HPV or LSIL 3 - 5 CIN I or CIN 2 
(LSIL or HSIL) 
6 - 8 CIN 2 or 3 
(HSIL) 












Histological and Treatment 
The protocol for histological of the cervix is illustrated in Figure 12. If the total RCI was s 2 
a biopsy of the aceto-white lesion was perfonned. If no lesion was seen, endocervical 
was performed. ECC was introduced into the protocol after the first 280 women had been screened to 
ensure that occult endocervical disease would not be missed. 
Women with an RCI of 3 were offered immediate treatment, on site, under local anaesthetic, 
Treatment was performed the technique called Loop Excision Procedure 
also known as Excision of the Transfonnation Zone (LLETZ), LEEP or LLETZ 
Iy excises the entire transformation zone of the cervix to a of7-IOmm a thin wire 
electrosurgical electrode. 
After colposcopic assessment and verbal consent from the the cervix was injected with 2 to 6 
mls of local anaesthetic containing a vasoconstrictive (vasopressin) 
Adcock Ingram]. Loop size was selected according to the size of the lesion. LEEP was I'IPt·tnr'mf'rl 
a Utah Finesse Unit (Utah, Medical, At the end of the the crater 
was electrocauterised. The amount of bleeding at the time ofLEEP was documented and estimated as < 
100 mis, > lOOmis or none. In addition, women were asked whether they experienced pain, ('r~ml'lm 
dizziness or faintness during the procedure and this was recorded on the colposcopy form (appendix 
B). 
Women were informed about the symptoms and of the complications of LEEP 
and pain) and were asked to return should any have occurred. In 
they were given a pre-printed letter explaining the of LEEP and the possible 
should it be necessary to consult after hours with other health care services. The author's emergency 












Figure II : Algorithm of colposcopic management 
Histological Sampling 
at colposcopy 
Aceto-white lesion Aceto-white lesion No aceto-white lesion 
RCI < or = 2 RCI> or = 3 











If the colposcopic assessment was inadequate due to the presence of infection or severe atrophy, 
women were treated with antibiotics or either orally or locally, and asked to return for a 
colposcopic examination at a specified date. 
If a significant aceto-white lesion was detected but the upper limit of the lesion was not seen or there 
was of a cone biopsy was either on site (loop excision conisation) 
or at Groote Schuur (cold-knife If an obvious cancer was found on examination, a 
and the women were referred to Groole Schuur for further 
Processing of Histological Specimens and Clinical Management 
All """,V'''']; were in 10% formalin and saline and delivered to the UCT 
of Pathology on a basis. The ;)iJ'-"""'" were processed and evaluated at the UCT 
of Pathology, to the routine protocol of the laboratOl), 
Clinical management of women was directed the histological determined by the UCT 
V£l'"'V"Vt:C""" and women with a histological of any of SIL were treated, Thus if a 
result on a woman with a RCI of:$; 2 or an ECC was called HSIL or cancer, the patient 
was recalled for a repeat colposcopic examination and treatment. 
2.5.6 Histological Review 
Dr Thomas Wright, a ~J""'''''~' of the study, blindly reviewed all histology slides at the 
of Columbia New York. For the purpose of analysis, the Ul<I}',"'V"I., 
made on blind ''''''W''V",'''''' review was used. If a woman had more than one histological the 
most severe diagnosis was used for analysis. 
The histological '~"""~'V~V were classified as follows: 
.. LSIL (CIN 1) 
.. HSIL (eIN 2 or 3) 
.. Malignant 
The two-tiered for the classification of Cy10logical popularised the Bethesda 
has not been adopted for A number of authors have however 











inter and intra-observer reproducibility in distinguishing histologically between HPV infection only 
from CIN 1, CIN 1 from CIN 2 and CIN 2 from CIN 312. In addition, low-grade lesions appear to 
represent a different clinical entity from high-grade lesions and in general, have a lower risk of 
progression to cancer. However, some low-grade lesions may progress to high-grade lesions in the 
absence of treatment. 
For these reasons it was decided to classify the histological diagnoses in the study using the two-tiered 
system of LSIL and HSIL. Women with any grade of SIL were offered treatment to ensure that all 
cases of HSIL were identified. 
2.6 Post-LEEP Follow-up 
After treatment with LEEP, women were asked to return at 4 and 10 months post treatment for 
evaluation. At the post LEEP examination, women were interviewed about complications and whether 
they had returned to a clinic or hospital after treatment, and if so, for what reason and what type of 
treatment was given. 
Thereafter a cervical smear was performed, followed by colposcopy utilising the RCI. If no lesion was 
seen an ECC was performed. All aceto-white lesions were biopsied regardless of the colposcopic 
grade and a second LEEP was performed only if the biopsy was positive for LSIL or HSIL. 
The outcome of the post LEEP examination was entered into a coded data sheet. After the second post­
LEEP examination women were asked to return to the study site for yearly cervical smears or were 
referred to the follow up cytology clinic at Groote Schuur Hospital and were no longer considered part 
ofthe study. 
2.7 Tracing of Defaulters 
The CHWs traced women who required colposcopy for any reason (positive screening test, positive 
biopsy, ECC or for a post-LEEP examination) and who did not return for examination, on a weekly 
basis. If after 4 successive visits a woman was not found or still did not return to the clinic for 
examination, she was no longer contacted 
2.8 Ethics and Research Committee Approval 
Approval for the study was obtained by the Ethics and Research Committee of the University of Cape 












2.9 Statistical Methods 
All data were entered into coded data sheets and computerised at the Medical Research Council, Cape 
Town, South Africa. The data was analysed using SPSS statistical package. 
The socio-demographic and clinical profile of the study population was described by calculating the 
proportions with specific characteristics for categorical variables (e.g. education, housing type etc.) and 
means (and/or medians) for continuous variables (e.g. age, parity etc.). All differences between 
proportions were tested using the Chi-Squared test and differences between means were tested using 
the t-test. Statistical significance was set at 0.05. 
The prevalence of cervical disease was calculated as the proportion of women with complete follow-up 
information who had histologically confirmed low-grade SIL. high-grade SIL or invasive cancer (i .e. 
women scheduled for colposcopy but who were lost to follow-up were excluded from the 
denominators) . 
Risk factors for cervical disease were first considered in univariate analysis. In other words, we tested 
whether the prevalence of disease was different in women with the risk factor compared to women 
without the risk factor using the chi-squared test. Factors found to be statistically significant on the 
univariate analysis were then entered into a multivariate logistic regression analysis. In this model, the 
prevalence of cervical disease (outcome) was modelled as a logistic function of the relevant risk factors 
(predictors) simultaneously. Adjusted odds ratios (which provide a measure of the strength of the 
association between the risk factor and cervical disease adjusted for all the other risk factors in the 
model simultaneously) were calculated, as were 95% confidence intervals. Significance of individual 
risk factors was determined using the Wald test l 3 
Table 6: 2 x 2 Table for Calculation of Test Performance 
To calculate sensitivity we defined the "gold standard" for disease to be histologically-confirmed low­
grade SIL, high-grade SIL and invasive cancer. Sensitivity for detection of each of these categories 
individually, all three categories combined, and high-grade SlL and cancer alone were calculated. 
Sensitivity was defined as the proportion of women with the' gold standard disease' who had a positive 
screening test or as a / (a+c) (definitions of positive screening tests are included in the description of 












'no disease' in two ways: (1) no positive screening tests or no disease of any gr(lde after colposcopy 
and histological sampling or (2) no positive screening tests or no high-gr(lde SIL or cancer after 
colposcopy and histological sampling (i.e. low-grade SIL was included as "no disease"). Specificity 
was defined as the proportion of women with the 'gold standard no disease' who had a negative 
screening test or as d / (b+d). We also calculated the positive predictive value (IS the proportion with 
disease among those with a positive screening test or as a / (a+b) and the negative predictive value as 
the proportion with no evidence of disease among those with a negative screening test or as d / (c+d). 
Again these calculations considered disease in combined and individual categories. 95% confidence 
intervals for sensitivity, specificity, and positive and negative predictive value were calculated using 
methods based on the binomial distribution for confidence intervals for proportionsl4 . These 
calculations were restricted to women with satisfactory results for the relevant screening test (lnd with 
complete follow-up data. 
For the analysis of the sensitivity and speCificity of HPV testing (both for the analysis of the Hybric;! 
Capture I assay which was performed on all study subjects and for the analysis of the Hybrid Capture 
II assay which was performed on a specifically selected sub-sample of subjects) two different HPV 
DNA levels to define a 'positive' screening test were used. The first cut-off level classified only 
samples with relatively high levels of high-risk HPV DNA (RLU > lOx positi\"e control) as positive. 
The second cut-off classified samples with lower levels of HPV DNA (RLU > Ix positive control) as 
being 'positive'. The second cut-off level is that defined by the manufacturers as the standard positive 
cut-off level. Since all HPV DNA measurements are quantitative, we also used Receiver Operating 
Characteristic (ROC) curves to investigate the consequences of shifting HPV DNA test cut-off values 
used to define a positive test. 
An ROC curve plots sensitivity (y-axis) against I-specificity (x-axis) obtained when cut-off v!llues 
used to define a positive result on a test are shifted from the lowest through to the highest possible 
values. These curves can be used to identify optimal cut-off values which maximise both sensitivity 
and specificity simultaneously18. For these calculations, 'gold standard disease' was defined as 
histologically-confirmed high-grade SIL or cancer and 'gold standard no disease' was defined as no 
positive screening tests or no HSIL or cancer following colposcopy. 
We also compared the quantities of HPV DNA detected using both Hybrid Capture I and Hybrid 
Capture II in women with and without disease. The mean loglo RLU values were tested using t-tests. 
Agreement between the two HPV tests was calculated using the kappa coefficient l5 (defining the 
results of each test dichotomously i.e. positive and negative) and using the Pearson correlation 
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3.1 Study group, Recruitment, Socio-demographic Characteristics and Use of 
Contraception by the Study Sample 
3.1.1 Study Group 
From the middle of January 1996 to the end of September 1997, 2957 women were recruited to the 
study. Thirteen women were excluded from the analysis for the reasons set out in Table 7. The study 
group consisted of2944 women. 









Cervix inaccessible due to displacement of cervix by fibroids 
Inability to visualise cervix due to gross obesity & vaginal wall prolapse 
Previous cone biopsy 
Fixed deformity of pelvis and patient unable to abduct her legs 
Refused to be examined 
Aged less than 35 years 
Aborted 28 week fetus during examination 
Temporarily excluded due to problems with electricity and never returned 
Table 7: Reasons for excluding 13 women 
3.1.2 Recruitment 
On average 150 women were recruited to the study per month. In June, August 1996 and February and 
March 1997, the number of women recruited dropped considerably. This was due to widespread 
violence in Site C caused by conflict between different taxi associations operating in the area. In 
September 1996, there was a delay in receiving equipment and supplies from the USA and the 
recruitment was stopped for 2 weeks. The project closed early in December 1996 as large numbers of 












3.1.3 ""',...."'-u Characteristics 
The socio reproductive and sexual histories and life-style habits of the 
study population are summarised in Table 8. The median age was 39 years. Most women (n 1407) 
were in the 35 -39 year age group, followed by the 40 - 49 year age group (n 1058), the 50 59 year 
age group (n 389) and the smallest number of women were in the over 60 age group (n In one 
woman, the age was not recorded. 
Although 93.4% of the women were born outside of Cape Town, 71.5% had been resident in 
Town for over 5 years and 18.3% had lived in Cape Town for less than one year. 
A considerable number of women had received no formal (J less than half 
had some primary level only, 38.8% had had some secondary level and 3.6% of 
women had school (matriculation). Less than half the women were married. About a 
third of the women were in formal and 70.5% of these women were in domestic 
service. 
The of the women lived in serviced sites (62.7%) with approximately numbers of 
women in 'unserviced sites' and brick houses. The majority of women (80%) in serviced 
sites had 
Most women had been with a median of 4 pregnancies (range 0 -14). Over a third of the 
women had more than 5 and 3% of women were nulliparous. Similarly, median was 
4 with over half the women given birth to between 2 and 4 children. A third of women had 
given birth to 5 or more children. The median age of first pregnancy was ]9 years 12 43 
years). While 6.0% of women had their first pregnancy before 16 years of age, 40.4% of women had 
their first pregnancy as teenagers 16 19 years). 
The median age of first sexual pv"prliPnl'p was 17 years (range ]0 - 32 years). While the first sexual 
was at less than 16 years of age in 17.2% of women, two thirds of women had their first 
sexual f>V,"If>r"f>r'l'f> as 16 19 The majority of women had between 2 and 5 
lifetime with less than 3% of women reporting more than 5 lifetime Just under a 
third of women monogamous. 
The majority of women were active in the month prior to being interviewed. 8.6% of 












Some form of contraception had ever been used by 80.1 % of women (Table 8). There were no data on 
6 women. Of those women who had ever used contraception, the majority (90.7%) had used 
acting intra-muscular (LAIP) and less than half of the ever users had used oral 
contraception Condom usage was rare, with 67 of the ever users of contraception used 
condoms. Permanent contraception was a common choice (28.6%). 'Other' of 
included intra-uterine devices, oral quinine tablets and a range of traditional herbs. 
Current use of contraception as use of within the three months to being 
interviewed) was less common. Of the women who ever used contraception, 20.6% were currently 













Variable n* % 
Age (years) 
35 ­ 39 1407 47.8 
40-49 1058 35.9 
50- 59 389 13.2 
60- 65 89 3.1 
Total 2943 
Born in Cape Town 
Yes 193 6.6 
No 2750 93.4 
Total 2943 
Resident in Cape Town (years) 
0-1 501 18.3 
1-5 279 10.2 
>5 1956 71.5 
Total 2736 
Education 
None 420 14.3 I 
Primary only 1254 42.6 
Some Secondary 1142 38.8 
Matriculation 106 3.7 
Tertiary 19 0.6 
Total 2941 
Married 
Yes 1287 43.7 
No 1655 56.2 
Total 2942 
Employed 
Yes 921 31.3 
No 2023 68.7 
Type employment 
Domestic service 638 69.3 
Factory worker 70 7.7 
Health worker 32 3.5 
Traditional Healer 5 0.5 
Other 176 19.0 
Housing 
Brick house with services 546 18.6 
Serviced site 1845 62.8 
Unserviced site 548 18.6 
Total 2939 
Gravidity 
0 88 3.0 
I 271 9.3 
2-4 1471 50.0 
5 or greater 1111 37.7 
Total I 2941 
Parity 
0 121 4.1 
I 299 10.2 
2-4 1523 51.8 
5 or greater 998 33.9 
Total 2941 
Variable n % 
Age of first pregnancy (years) 
< 16 170 6.0 
16-19 1153 40.4 
20 - 30 1504 52.7 
>30 26 0.9 
Total 2853 .. 
Age first sex (years) 
< 16 504 17.2 
16 ­ 19 1947 66.2 
20-32 487 16.6 
Total 2938 
Lifetime partners , 
Monogamous 897 30.6 
2-5 1952 66.6 
>5 80 2.7 
Total 2929 
Sexual activity in month prior 
to interview 
none 680 23.2 
Yes 2255 76.8 
Total 2935 
Alcohol Use 
Excessive (4 or more drinks on 
one occasion) 
158 5.4 
Moderate (I - 3 drinks on one 
occasion) 
95 3.2 
None 2684 91.4 
Total 2937 
Smoking 
Yes 224 7.6 
No 2715 92.4 
Total 2939 
Contraception use 
Ever users 2357 80.2 
Never users 581 19.8 
Total 2938 
Type contraception used in 
women who ever lIsed 
contraception 
LAIP 2138 90.7 
OC 1060 44.8 
Sterilisation 682 28.9 
Condoms 67 2.9 
Other methods 96 4.1 
Total 2357 
Contraception use in the last 3 
months (% ever users) 
LAIP 487 20.7 
OC 69 2.9 
Condoms 10 0.4 
Other methods 29 1.2 
Total 595 
Table 8: Socio-demographic characteristics and contraception use among 2944 women recruited to the 












3.1.4 Stratification of Socio-demographic Characteristics and Use of 
Contraception by Age 
Stratifying the socio-demographic characteristics by age revealed that a greater proportion of the 
women aged 35 - 39 years had achieved matriculation or tertiary education, had had their first sexual 
experience before the age of 16 years and had more than 2 lifetime partners than women in the older 
age categories (Table 9). A greater proportion of the women over 50 years had no schooling and had 
more than five live births than women in the 35 - 39 age category. 
More women in the 35 - 39 year age group were born in Cape Town (6 .3%) than women in the over 60 
age group (3.4%). The proportion of women in the different age groups who were employed was 
similar (between 30 and 34%) except in the over 60 group (4.5%). Just under 5% of the 35 - 39 year 
olds smoked compared to 9.0% of 40 - 49 year olds, 12.6% of 50 - 59 year olds and 13.5% of women 
over 60. The pattern of alcohol use was similar to smoking, with 7.8% of 35 - 39 year olds using 
alcohol compared to 11.6% of women over 50 years old. 
Among women aged 35 - 39 years, 33 .3 % of women had ever used OC, and 3.6% were currently 
using Oc. By comparison, 55.4% of women in this age group had ever used LAIP and 25 .9% were 
currently using LAIP. Among women in the 40 - 49 year age group 37.8% had ever used OC but only 
1.7% were current users of the Oc. In contrast, 65.0% of women in this age group had ever used LAIP 
and 11.2% were currently using LAIP. 
Variables 
Age Groups 
35 - 39 yrs 
(n = 1407) 
40 -49 yrs 
(n=1058) 
50- 59 yrs 
(n =389) 
60 - 65 yrs 
(n = 89) 
Total 










125 4.2Matric or 3° education 
Age flTSt sex <16 years 296 21.0 170 16.1 35 9.0 4 4.5 505 17.2 
>2 lifetime partners 604 42.9 407 38.3 93 23 .9 9 10.1 II J3 37.8 
Parity 2-4 881 62.6 492 46.5 125 32.1 25 28.1 1523 51.7 
Parity> or =5 213 15.1 476 45.0 250 64.3 59 66.3 998 33 .9 
Ever users of OC 468 33 .2 400 37.8 I J J 28.5 13 14 992 33.7 
Ever users of LAJP 780 55.4 688 65.0 174 44.7 17 19.1 1659 56.4 












Screening Colposcopic Examination 
and of Women in the Study Sample 
1 Clinical 
3.2.2 Visual Inspection of the Vulva and Vagina 
Vulval lesions were noted in 7.6% (n == 223) of the women screened. The lesions were described as 
warty in 6.8% of women with vulvar lesions, ulcerative in 20.5%, inflammatory in 58.6% and as 
'other' in 14.1%. A discharge was noted in 86.5% (n 2544) of the women and this was 
classified as severe in 44.2% (n of the cases. 
Visual of the without Acetic Add 
The whole cervix was visualised in all but 20 women. Lesions were noted on the cervix with 
eye examination of acetic acid) in 10.6% (n = 313) of the women. The of 
these lesions were classified as inflammatory (84.7%), the rest being defined as (11 
endoph)'1ic (I and as an ulcer in one case. 
Women with lesions on the cervix detected with naked-eye examination before the of acetic 
acid were referred for COllPOSC()PV at the discretion of the nursing sister. For example, women with 
benign polyps or an inflamed cervix but no evidence of an aceto-white lesion were not referred for 
colposcopy. Of the 313 women with lesions noted on the cervix, 95 (30.4%) were also identified as 
DVI positive (i.e. an aceto-white lesion was noted after the application of acetic acid) and were referred 
for colposcopy. 
3.2.4 Results of and Referral for Colposcopy: 
The number of women with evaluable tests and the percentage with positive screening tests 
are shown in Table 10. All 2944 women undenvent a DVl examination. one specimen for HPV DNA 
detection was for cervical smears \vere unsatisfactory for evaluation 
and 333 (II defective or unevaluable. Of the 333 
Cervigrams™ that were not 199) were unevaluabIe due to technical problems with 
the camera or with the A further 40% (n == 134) were uneva1uable due to poor 































Table 10: Number of unsatisfactory screening tests, number of evaluable screening tests and the 
number of woman who required referral for colposcopy. [No. = number. * The total number of 
evaluable tests does not add up to 2944 due to unevaluable or unsatisfactory tests] 
Of the 2944 women screened, 18.1% (n = 534) were considered DVI positive and referred for 
colposcopy. Visualisation of the cervix with the monocular lens did not detect any aceto-white lesions 
that were not detected by urunagnified examination of the cervix. 
A positive cervical smear (LSll.." HSIL or cancer) was diagnosed in 8.1 % (n = 238) of women with 
satisfactory smears. A positive Cervigram™ (warrants colposcopy, LSIL, HSll.., or cancer) was 
diagnosed in 10.6 % (n = 276) of women with evaluable Cervigrams™. HPV DNA at 10 times the 
positive control was detected in 6.1 % (n = 180) and HPV DNA at I x the positive control was detected 
in 16.2 % (n = 465) of the women screened. 
Of women with evaluable cervical smears 84 .8% (n = 2478) were normal and 87.3% (n = 2279) of 
evaluable Cervigrams™ were evaluated as normal. A diagnosis of ASCUS was made in 7 .0% (n = 
206) of cervical smears compared to 2.1 % (n = 56) of Cervigrams™ that were evaluated as ' atypical ' . 
While cytological evaluation reported HSIL in 2.7% of cases, the CervicographyTM evaluation was 
HSll.., in 1.1%. Cytology reported LSIL in 5.3% of smears compared to 7.7% of Cervigram™ 













In 28.7% (n of women were on any of the four tests and were referred 
for colposcopy. Of these, 91.0% (n = 765) were examined coJposcopically. The at colposcopy 









Lost to follow up 
n = 77 





Figure 12: Algorithm of women referred to colposcopy and the outcome of the colposcopic 
examination [* Other histology: 4 women had biopsies, one had a hysterectomy for a prolapsed fibroid, 
one had a cone biopsy and one had a polypectomy] 
Aceto-white lesions were seen in 77.3% (n 591) of the women who underwent Of these 
women, 420 had a RCI ::; 2 and a was performed in 4 1 1 cases. An ECC was ""'.,,"' ...... in 7 
women with a RCI ::; 2 because the aceto-white lesion was located in the endocervix and was 
technically difficult to biopsy. In two cases, the colposcopic assessment of the cervix was normal and 
no histological was performed. These women were called for disease. 
A RCI of;::: 3 was in 171 of the women who had aceto-white lesions at colposcopy and a 
",,,,,-tr,,·rn,>r! in 87.1 % (n = 149) of these women. a Reid score of;::: 3, the 
22 women did not have a LEEP performed for the following reasons: 
LEEP 
• 9 women had an obvious cancer and a biopsy was performed 
• 4 women were found to be nrp'un'"nt and a biopsy was nprtl)rm on one of them 












• 3 women required cone biopsies for suspected micro-invasion or upper limit of the lesion not 
seen 
• I woman required a cone biopsy but this was technically impossible and a hysterectomy was 
performed 
• I woman required treatment for severe vaginitis and did not return for a repeat colposcopy 
• In 3 cases the RCI was 2': 3 but the biopsy did not confirm the presence of a lesion (in all cases 
immediate LEEP was not performed due to technical difficulties) 
The coJposcopic assessment was inadequate in a further three women and it was impossible to assign a 
Reid Score and no histological sampling was performed. These women were treated and asked to 
return for repeat colposcopy, but all three defaulted. 
No aceto-white lesion was noted at colposcopy in 171 women. No ECC was performed in 50 women. 
Of these 50 women, ECC was not performed in 48 women as ECC was not performed at the beginning 
of the study. One woman had a large prolapsed fibroid and had a hysterectomy and no CIN was found 
in the hysterectomy specimen. One woman had an endocervical polypectomy only. These 50 women 
were coded as negative for disease for the purpose of analysis. An ECC was performed in the 
remaining 121 (67.8%) women who had no visible lesion at colposcopy. 
In addition to the 149 LEEPs performed on a 'see and treat' basis, a fmther 29 LEEPs were performed. 
These 29 women were recalled for repeat colposcopy despite a RCI < 3 on the basis of the diagnosis of 
LSIL or HSIL made by the UCT pathologists (n = 28) and a discrepancy between positive screening 
tests and colposcopy (n = I). 
In summary, there were a total of 178 LEEPS performed: 149 were performed on a 'see and treat' 
basis, 28 after repeat colposcopy and prior histological sampling, and one after repeat colposcopy 
because of a discrepancy between positive screening tests and the original negative colposcopy. 
3.2.6 Histological Diagnosis after LEEP performed on a 'See and Treat' basis 
Of the 149 women who underwent LEEP on a 'see and treat' basis, there were 45 (30.2%) cases of 
histologically-confirmed LSIL, 42 (28.2%) cases of HSIL and one case of micro-invasion. In 61 
(40.9%) of the cases there was no SIL or cancer detected in the LEEP specimen. 
3.2.7 Women with Positive Screening Tests who did not undergo Colposcopy 
Of the 842 women referred for colposcopy, 9.1 % (n = 77) did not receive a colposcopic examination. 
The majority of these women either gave incorrect addresses or did not live at the addresses they gave, 











The number of women with positive screening tests who were not examined colposcopicaJly is 
summarised in Table I I . Overall, 4.5% of the women who were DVI positive, 5% of the women who 
were HPV DNA positive (at the lOx level), 14.3 % of the women with positive cervical smears and 




No. of colposcopies 
performed 
No. Lost to Follow Up 
n % n % 
DVI 534 510 95.5 24 4.5 
Cytology 238 204 85.7 34 14.3 
CervicographyTM 276 239 86.5 37 13.4 
HPV DNA (lOx) 180 171 95.0 9 5.0 
Table II: Total number of women with positive screening tests who underwent colposcopy and who 
were lost to follow up [No. = number] 
Analysed in more detail, a trend of increasing lost to follow up over time emerges. For instance, there 
were 100 women who were DVI and HPV DNA negative but who had a positive cervical smear and 
24% of these women did not undergo a colposcopic examination. Similarly, there were 90 women who 
were DVI negative, HPV DNA negative and had a negative cervical smear but had a positive 
Cervigram™ and 29% of these women were not successfully traced for colposcopy. 
3.2.8 Final Disease Status of the Study Sample 
The fmal disease status of the 2944 women included in the study is as follows: 71.4% (n = 2102) were 
negative on all four screening tests and were considered by definition as having no SIL or cancer. 
After colposcopic examination and histological sampling, there was no disease diagnosed in a further 
19.7% (n = 579) women. A histological diagnosis of LSIL was made in 3.2% (n = 95) of women, 
HSIL in 2.5% (n = 74) and cancer in 0.4% (n = 12) of women . No diagnosis was made in 2 .8% (n = 
82) women who were lost to follow up or did not undergo histological sampling. These results are 












Final disease status of study sample n % 
Negative all four screening tests 









HSIL 74 2.4 
Cancer 12 0.4 






Table 1: Final disease status of the 2944 women recruited to the study [*includes 4 women who 
underwent colposcopy but no histological sampling was performed and one woman who had a biopsy 
that was unsatisfactory for histological sampling] 
The majority of the women with cancer (n = 7) had advanced disease (stage lIb and above) and all 
these women were symptomatic. One of the women with Stage Ib and the two women with stage Ia 
were asymptomatic. There were 2 women with FIGO stage la, 3 with stage Ib, 3 with stage II b, 3 with 
stage III b and one with stage IVa. 
3.2.9 Distribution of SIL and Cancer in 5 year age groups 
The proportion of women in five-year age categories who had histologically confl.fll1ed LSIL, HSIL or 
cancer is shown in Table 13. There was a tendency for a decreased prevalence ofLSIL in women over 
50 years compared to younger women. HSIL was diagnosed in 4.5% of women over 60 years 
compared to 3.0% of women in the 35 - 39 age group, but this difference was not statistically 
significant. There were no cancers in the 35 - 39 year age group compared to 3.4% of the over 60 age 
group and this different was highly significant. 
The prevalence of disease in the different age groups using smoothed 10-year age intervals is illustrated 
in Figure 13. The same pattern of disease prevalence is seen in this graph as is seen using 5-year age 
intervals as shown in Table 13. Of note in Figure 13, is the much higher prevalence of HPV DNA 



















Age categories in years 
45-49 50-54 
in =429) In =221) 
55-59 
(n = 156) 
60-65 




n % n % n % n % n % n % n % 
LSIL 51 3.7 27 4.5 10 2.3 2 0.9 4 2.6 I 1.1 95 3.3 0.07 
HSIL 42 3.1 14 2.3 8 1.9 3 1.4 3 1.9 4 4.5 74 2.6 0.38 
Cancer 0 0 4 0.7 3 0.7 0 0 2 1.3 3 3.4 12 0.4 <0.000 
Table 13: Proportion of women in each age category who had histologically confirmed LSIL, HSIL or 
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3.3 Socio-demographic Factors in relation to HSIL and Cancer, Women to 
Fonow-up and a Positive HPV DNA (Jx) 
3.3.1 Association of Socio-demographic Factors with HSIL and Cancer 
The results of the univariate for the risk of having HSIL or cancer are shown in Table 14. 
current use of LAIP and not married were associated with HSIL. age and 
use of alcohol were the only risk factors associated with cancer. 
Multivariate regression analysis was used to calculate the odds ratios and 95% confidence 
intervals (el) for the various risk factors. All factors that were significant on univariate analysis were 
put into the multivariate analysis. For the association with being unmarried was increased, but 
not with an OR of 1.55 (95% el: 0.95 - 2.56). The association with smoking was no 
with an OR of 1.97 el: 0.99 - 3.93). The association with use of LAIP 
remained with OR of 2.17 el: 1.29 - 3.64). The association between HSIL and the 
use of LAIP specifically controlling for age, smoking and being currently sexually active was 2.08 
el: 1.21-3.58). 
For cancer, the association with each year of increased age remained with an OR of 1.12 
(95% e[: 1.06 - 1.20) but the association with alcohol was no longer "'Q'''''lJ',"QI significant (OR 












Variable Total No. 
HSIL P value Cancer P value women 
Age n % n % 
30 - 39 1365 42 3.1 0 0 
40-49 1031 22 2.1 7 0.7 
50 -59 377 6 1.6 2 0.5 
60 -65 88 4 4.5 0.17 3 3.4 <0.000 
Education n % n % 
No school 407 13 3.2 2 0.5 
Primary 1213 29 2.4 6 0.5 
Some secondary 1116 29 2.6 4 0.4 
Matric or tertiary 123 3 2.4 0.85 0 0 0.84 
. Born in Cape Town n % I_ n % 
Yes 193 8 4.1 0 0 
No 2668 66 2.5 0.16 12 0.4 0.35 
Age first sexual n % n % 
intercourse 
I ­ I -
< 16 486 15 3.1 1 0.2 
> or = 16 2371 59 2.5 0. 12 11 0.5 0.42 
Married n % n % 
Yes 1254 24 1.9 4 0.3 
No 1606 50 3.1 0.05 8 0.5 0.46 
Parity n % n % 
Nulliparous 115 1 0.9 0 0 
One 293 7 2.4 1 0.3 
2-4 1482 43 2.9 3 0.2 
5 or> 969 23 2.4 0.54 8 0.8 0.11 
No. of sexual n % I n % 
partners - 1-
0-2 1773 45 2.5 8 0.5 
3 or more 1076 29 2.7 0.80 4 0.4 0.75 
Smoking n % n % 
Yes 216 10 4.6 2 0.9 
No 2641 63 2.3 0.04 10 0.4 0.23 
Alcohol use n % n % 
Yes 240 10 4.2 3 1.3 
No 2615 64 2.4 0.11 9 0.3 0.04 
OC n % n % 
Never 1827 55 3.0 8 0.4 
Ever 966 17 1.8 4 0.4 
Current 2 2.9 0.06 0 0 0.64 
LAIP n % n % 
Never 750 15 2.0 5 0.6 
Ever 1615 37 2.3 7 0.4 
Current 471 22 4.7 0.02 0 0 0.36 
-
-
Table 14: Univariate analysis of risk factors for HSIL and cancer [OC = Oral contraception; LAIP = 












Association of Socio-demographic Factors Women who were Lost to 
Follow-up 
A univariate of the association between factors and women who failed to 
return for their colposcopic examination was performed. Of the women who required colposcopy and 
who were born in Town, 100% (56/56) were followed up as to 90.2% (7091786) of the 
women who were not born in Cape Town (p == 0.007). In addition, women who lived in unserviced sites 
(p 0.03), who used alcohol (p = 0.03) and were nUlliparous (p less likely to 
return for follow up. Age, marital status, employment, level of age of first sexual 
smoking and use of contraception were not associated with follow up. 
Association of Socio-demographic Factors with a HPV DNA test 
(Ix) 
Table 15 shows the of HPV DNA (I x) in relation to characteristics with 
the ratios. The of HPV DNA was lowest in women 40 - 49 
years (I Prevalence of HPV DNA was higher in women who lived in unserviced were 
had more than two sexual partners during their had at least one live birth and were 
current users ofLA!P. The association between HPV DNA and current use of LAIP was reduced (OR 
1.2 95% CI: 0.85 1 after adjusting for age, education, housing type, marital status, current sexual 
lifetime number of age of first sexual intercourse, parity and smoking. The 
association between HPV DNA prevalence and current sexual activity was somewhat (OR 1.4 
95% CI: 1.07 1.84) after adjusting for the same variables. All other associations were similar in 

















Ratio (95% CI) 
Age (years) 
35 - 39 1407 17.5 
40-49 1058 13.8 0.79 (0.65 - 0.95) 
50 -59 389 17.2 0.99 (0.77 - 1.26) 
60 - 65 89 18.0 1.03 (0.65 - 1.63) 
Education 
.~ 
None 419 18.6 
Some Primary 1254 15.6 0.84 (0.66 - 1.06) 
Some Secondary 1142 16.0 0.86 (0.68 - 1.09) 












1.26 (0.99 ­ 1.60) 
1.43 (1 .08 ­ 1.88) 
Married 
Yes 1286 12.8 
No 1655 18.7 0.69 (0.58 - 0.82) 
Currently sexually active 
Yes 2260 16.4 
No 680 15.3 1.07 (0.88 - 1.31J 
>2 sexual partners 
1- -
Yes 1113 18.1 
No , 1816 14.9 1.21 (1.02 - 1.43) 
Age first sex < 16 years -
Yes 505 17.4 
No 2433 15.8 1.10 (0.89 -1.36l 
Parity 
Nulliparous 121 7.4 
One 298 15.4 0.48 (0.24 - 0.95) 
2-4 1523 16.8 1.09 (0.82 - 1.45) 
5 or more 998 16.4 1.06 (0.79 - 1.44) 
LAIP Use 
Never 794 15.0 
Ever 1659 15.4 1.03 (0.84 - 1.25) 
Current 487 20.3 1.36 (1.07 - 1.73) 
Smoking 
Yes 224 16.1 
No 2714 16.1 1.00 (0 .73- 1.36) 
Table 15: Prevalence of high risk HPV DNA (1 x) among 2943 women by socio-demographic and 











3.4 Performance of the Screening Tests 
3.4.1 Results of the Screening Tests among the 2944 Women Screened and the 
Histological Diagnosis in Women who underwent Colposcopy 
The results of the four screening tests among the 2944 women screened and the histological diagnosis 
in women who underwent colposcopy is shown in Table J6. The data on women who were HPV DNA 
positive at the I x cut-off are shown for purposes of comparison. 
Women who were negative on all four screening tests were not referred for colposcopy for reasons 
explained in the methods. The prevalence of disease in the individual negative screening tests is 
estimated from the colposcopic examination of women who were negative on one screening test, but 
positive on one or more of the other screening tests. This represents the number of known cases of 






















No. of women (%) with each histological diagnosis who 
underwent colposcopy 
No disease 
n == 579 
LSIL 









534 18. I 
n % 
250 lOA 














Cytology WNL 2478 84.8 505 20A 455 90.1 34 6.7 16 3.2 0 0.0 
ASCUS 206 7.0 43 20.9 34 79.1 7 16.3 2 4.7 0 0.0 
LSIL 155 5.3 128 82.6 64 50.0 43 33.6 20 15.6 I 0.8 
HSIL 80 2.7 73 91.3 21 28.8 I I 15.1 35 47.9 6 8.2 
Cancer 3 0.1 3 100 0 0.0 0 0.0 0 0.0 3 100 
HPVDNA <I 






















CGTM Negative 2279 87.3 427 18.7 346 81.0 49 11.5 30 0.7 2 0.5 
Atypical 56 2.1 28 18.7 24 85 .7 3 10.7 I 3.6 0 0.0 
WC 35 1.3 29 82.9 21 72A 2 6.9 6 20.7 0 0.0 
LSIL 203 7.8 173 85.2 124 71.7 26 15.0 23 13.3 0 0.0 
HSIL 29 1.1 28 96.6 8 28.6 10 35.7 9 32.1 I 3.6 
Cancer 9 0.3 9 100 2 22.2 0 0.0 0 0.0 7 77.8 
Table 16: Results of the four screening tests among 2944 women screened and the histological 
diagnosis among those who underwent colposcopy [* Columns do not add up to 2944 because women 
with unsatisfactory smears, one missing HPV DNA result and defective CervigramsTM are excluded. 
The difference in the number of women with positive screening tests and the number of women who 
underwent colposcopy, represents women who were lost to follow up or women who had negative 
screening test but underwent colposcopy due to one or more other positive screening tests] 
Of the 12 women with invasive cancer and 74 with histologically confirmed HSIL identified in the 
study, DVI correctly identified 75% (n = 9) of the cancers and 63.5 % (n = 47) of the HSIL lesions. 
Similarly, cytology identified 83.3% (n = 10) of the cancers and 75.3% (n = 55) of the cases of HSIL. 
HPV DNA testing at the lOx level identified 33.3% (n = 5) of the cancers and 51.3% (n = 38) of the 











the lower cut-off was used. CervicographyTM identified 66.7% (n = 8) of the cancers and 51.3% (n = 
38) of the cases ofHSIL. 
No disease was found after colposcopic assessment and histological sampling in 79.4% of women with 
a positive DVI test, compared to 41.7% of women who had a positive cervical smear, 64.8 % of women 
with a positive CervigramTM and 49.1 % of women with a positive HPV DNA test (lOx). Of the women 
with a positive HPV DNA test at the lower threshold (1 x) and who underwent colposcopy because of 
having other positive screening tests, 72.3% had no disease confirmed histologically. 
There were 22 women who had unsatisfactory smears and 8 women had a colposcopic examination on 
the basis of other positive screening tests: one woman had HSIL (12.5%), two had cancer (25%) and 5 
women had no disease (62.5%). Of the 333 women with unevaluable CervigramsTM, 66 had a 
colposcopic examination on the basis of other positive screening tests: 5 women had LSIL (7.6%), 5 
had HSIL (7.6%), 2 had cancer (3.0%) and 54 women had no disease (81.8%). 
3.4.2 Sensitivity and Specificity of the Screening Tests 
As outlined in the methods section, the sensitivity and specificity of each screening test was calculated 
assuming that women who were negative on all four screening tests and women who had colposcopy 
but negative histology, were negative for SIL or cancer. Disease positive women were those who 
underwent colposcopy and after histological sampling had a diagnosis of LSIL, HSIL or cancer or 
HSIL or cancer. Women who were lost to follow up or who had unevaluable screening tests were 
excluded from the calculations for test performance. 
The estimated sensitivities, specificities, and 95% confidence intervals of the different screening tests 





























(50.5 - 65.2) 
66.9 
(59.4 - 73.6) 
50.3 
(42.6 - 58.1) 
48.1 




(54.2 - 76.6) 
75.3 
(63.6 - 84.4) 
50.8 
(38.0 - 63 .5) 
51.4 
(39.5 - 63 .0) 
71.6 
(59.8 - 81 .2) 
67.4 
(56.4 - 76.9) 
78.3 




(39.1 - 60.9) 
73.3 
(62.4 - 82.0) 
84.9 
(83 .5 - 86.2) 
96.8 
(96 .1 - 97.4) 
93.5 
(92.4 - 94.4) 
96.9 
(96 .1 - 97.5) 
87 .8 
(86.5 - 89 .Q) 
83.7 
(82.3 - 85. I ) 
95.0 
(94.0 - 96.0) 
92.2 
(9l.l - 93.2) 
95.4 
(95 .5 - 96.1) 
89.2 
(88.0 - 90.4) 
Table 17: Sensitivities and specificities of the screening tests - 95% confidence intervals in brackets 
[any disease = LSIL, HSIL or cancer, no disease = no LSIL, HSIL or cancer, CGTM = Cervicography; 
HPV (lOx = HPV DNA positive at 10 x the positive control; HPV (Ix = HPV DNA positive at any 
level positive] 
Comparing the sensitivities of the screening tests for any disease, cytology and HPV DNA testing (Ix) 
performed equivalently and DVI performed marginally better than CervicographyTM or HPV DNA 
testing (lOx). DVI, cytology and HPV DNA testing (I x) had similar sensitivities for the detection of 
HSIL and were higher than the sensitivities of either CervicographyTM or HPV DNA testing (lOx). 
For HSIL and cancer, the sensitivity of DVI was marginally lower than the sensitivities of cytology and 
HPV DNA testing (I x). CervicographyTM and HPV DNA testing at the lOx level had lower 
sensitivities for HSIL and cancer than the other screening tests and were equivalent to one another. 
DVI had the lowest specificity for HSIL and cancer at 83.7. Cytology and HPV DNA testing at the lOx 
level had the highest specificity and the specificity of CervicographyTM was lower than the specificity 
of cytology. While lowering the threshold for HPV DNA detection to any level positive would have 
increased the sensitivity of the test, the specificity decreased to 89.2. 
3.4.3 Estimation of Sensitivity and Specificity using Cytology as the 'gold 
standard' 
In an attempt to estimate the degree of verification bias introduced into our calculations of sensitivity 
and specificity by the failure to apply the 'gold standard' (i .e. histology) to all women who were 
screened, we estimated the sensitivity and specificity of the screening tests using cytology as the' gold 
standard' (a test that was applied to all women who were screened). Specifically we estimated the 
sensitivity of the tests for HSIL and cancer where women with a normal smear, ASCUS or LSIL were 
considered 'negative for disease'. Women with a smear of HSIL or cancer were considered 'positive 














(HSIL and cancer) 
Specificity 
(HSIL and Cancer) 
DVI 
HPV DNA (Ix) HC I 
HPV DNA (Ix) HC II 
CervicographyTM 
53.0 
(41.8 - 63.9) 
77.1 
(66.3 - 85.3) 
80.7 




(81.6 - 84.4) 
85.6 
(84.2 - 86.8) 
64.8 
(59.7 - 69.7) 
90.7 
(89.5 - 91.8) 
Table 18: Sensitivity and Specificity of the Screening tests using Cytology as the 'Gold Standard' 
While the sensitivity of DVI for HSIL and cancer using cytology as the gold standard is somewhat 
lower than when histology is used as the gold standard, the specificity is unaltered. The sensitivity and 
specificity of HPV DN A testing at the I x level using HC I and of CervicographyTM remain unchanged. 
The specificity of HPV DNA testing using HC II is significantly lower, however. 
3.4.4 Positive and Negative Predictive Values of the Screening Tests 
The PPVs of each screening test and the 95% confidence intervals are shown in Table 19. DVI and 
HPV DNA testing (Ix) had the lowest PPVs compared to the other screening tests. Cytology and HPV 
DNA testing (lOx) had the highest PPVs and were equivalent to one another. CervicographyTM had a 
PPV intermediate between DVI and cytology. Using the lower threshold for HPV DNA detection 
reduced the PPV of HPV DN A testing for HSIL and cancer by nearly 50%. 











(29 .2 - 41.6) 
50.8 




(8.8 - 14.5) 
31.9 
(25.6 - 38.8) 
19.2 
(14.6 - 24.9) 
25.0 
(19.0 - 32.5) 
14.0 
(11.0 - 17.6) 
Table 19: PPVs of the screening tests for any disease (LSIL, HSIL and cancer and HSIL and cancer 











The NPVs of the screening tests are shown in Table 20. Cytology and HPV DNA testing (Ix) had the 




NPV - no disease 
96.8 
(96.0 - 97.4) 
NPV - HSIL and cancer 
98.8 
(98.5 - 99.4) 
Cytology 
97.8 
(97.1 - 98.3) 
99.3 
(97.8 - 98.8) 
Cervicography 
96.3 
(95.7 - 97.2) 
98.6 




(95.7 - 97.2) 
98.4 
(98 .9 - 99.6) 
HPY (Ix) 
97.7 
(97.0 - 98.2) 
99.0 
(98.3 - 99.2) 
Table 20: NPVs of the screening tests for no disease and for HSlL and cancer with the 95% Confidence 













3.5 Factors Influencing the Performance of the Screening Tests 
3.5.1 Sensitivity, Specificity, PPV and NPV of the Screening Tests in Three Age 
Categories 
The sensitivities and specificities of the screening tests for HSIL and cancer in three age groups are 
shown in Table 21. While the sensitivity of DVI in the 40 - 49 year age groups appears higher than the 
other age groups this difference is not statistically significant (p = 0.22). Similarly, CervicographyTM 
appeared to perform better in the 40 - 49 year age group (p = 0.34). Cytology had the highest 
sensitivity in the over 50 age group (p = 0.79). In contrast, HPV DNA testing at both the lOx and I x 
levels appeared to perform slightly worse in the 40 - 49 year age group compared to younger and older 
age groups (p = 0.27 and 0.17 respectively). 
The specificity of DVI in the older age group (> 50 years) was significantly greater than in younger age 
groups, as was the specificity of cervicography, both visual screening techniques. The specificities of 
the other screening tests did not vary in the three age groups. 
Screening test + 
Age in years 
Sensitivity P value Specificity P value 
DVI I 
35 - 39 59.5 83 .1 
40-49 79.3 82.1 
50 - 65 66.7 0.22 88.9 0.004 
Cytology 
35 -39 78.6 95.0 
40-49 75.0 94.0 
50 - 65 84.6 0.79 95 .6 . 0.56 
,. CGTM 
35 - 39 53 .8 90.4 
40-49 70.4 93 .2 
50 - 65 46.2 0.34 95 .0 0.005 
,.,HPV (lOx) 
35 - 39 57 .1 94.7 
40-49 37.9 96.2 
50 - 65 53.3 0.27 95.6 0.31 
HPV (Ix) 
35 - 39 81.0 
7 
85 .0 
40-49 58.6 87.9 
50 - 65 80.0 0.17 84.9 0.10 
Table 21 : Sensitivities, specificities and P values for HSIL and cancer of the different screening tests in 











The PPVs of the screening tests for HSIL and cancer in the three age groups are shown in Table 22. 
The PPVs of all the screening tests appear to increase with age, but the numbers of women with HSIL 
or cancer in the older age groups are small and the observed differences are not statistically significant. 
Screening test II PPV P Value NPV P Value 
DVI 
35 - 39 
1-
10.1 98.5 
40-49 11.4 99.3 
50 -65 16.4 0.35 98.8 0.28 
Cytology . 
35 - 39 34.4 99.3 
40 -49 32.5 99.3 
50 -65 35.5 0.94 99.5 0.84 
CGTM 
35 - 39 15.4 98.4 
40 -49 24.0 99.0 
50 - 65 24.0 0.23 98.1 0.36 
HPV (lOx) 
35 - 39 25.5 98.6 
40-49 22.4 98.2 
50 - 65 28.6 0.83 98.4 0.74 
HPV (Ix) 
35 - 39 14.7 99.3 
40-49 12.3 98.7 
50 - 65 15.0 0.79 99.2 0.32 
Table 22: PPVs, NPVs and P values of the screening tests for HSIL and cancer in the three age 
categories 
Sensitivities and specificities of the different screening tests for HSIL and cancer using smoothed 10­










Figure 14: Sensitivity and specificity of cytology for HSIL 
and cancer by age 
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Figure 16: Sensitivity and specifity of DYI for HSIL and 
cancer by age 
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Figure 15: Sensitivity and specificity of CervicographyTM 
for HSIL and cancer by age 
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Figure 17 : Sensitivity and specificity of HPY DNA testing 
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3.5.2 Other Factors Influencing Performance of the Different Screening Tests 
The sensitivity of DVI was much higher among women with cervices that were described as inflamed 
by the nursing sister, compared to women whose cervices were not described as inflamed (92.3 % 
compared to 63.0%; p = 0.04) but there was corresponding decrease in specificity (74.9 versus 84.5% 
respectively; p = 0.000). 
There was no statistical difference in sensitivity and specificity of the screening tests among women 
who used LAIP, nor was there a difference in relation to parity. Due to very small numbers of women 
who were current users ofOC, it was not possible to meaningfully calculate the influence ofOC use on 
the performance of the screening tests 
3.6 Number of cases of LSIL, HSIL and Cancer Detected with One, Two, Three 
or Four Positive Screening Tests 
Table 23 shows the number of cases of LSIL, HSIL and cancer that were detected in women with one, 
two, three or four positive screening tests and who underwent colposcopy. 
Of the 29 women who were positive on all four screening tests and who underwent colposcopy, 55.2% 
had HSIL and 6.9% had cancer compared to 30.9% HSIL and 10.9% cancer in the 55 women who were 
positive on three screening tests and underwent colposcopy. Of the 169 women who were positive on 
two screening tests and who underwent colposcopy, 14.2 % had HSIL and 1.2% had cancer compared 
to 3.3 % HSIL and 0.4% cancer in women with one screening test positive. 
Of the 318 women who had a positive DVI and who underwent colposcopy but were negative on the 
three other screening tests, 3.4 % had HSIL or cancer compared to II % of women who were DVI 
positive in combination with other positive screening tests. Of the women who were negative on all 
screening tests except cytology, 7.7% had HSIL (there were no cancers) compared to 32% of women 
overall who were positive on cytology and other combinations of screening tests. 
Similarly, of women who had a positive Cervigram™ only, 1.5% had HSIL (there were no cancers) 
compared to 23% of women who had a positive Cervigram and other screening tests. Of women who 
were positive on HPV DNA testing (lOx) only, 3.4% had HSIL compared 25% of women with a 
positive HPV DNA test (lOx) in combination with other screening tests. 
Of the women who had only two screening tests positive, the greatest proportion ofHSIL or cancer was 
detected by the combinations of positive cytology and a positive HPV DNA test (lOx) and positive 
cytology and a positive Cervigram™ (30.8 and 30.0% respectively). Of the women with the 












compared to 8.3% of women who were DYI positive and HPY DNA positive (lOx) or 6.7% of women 
who were DYI positive and CervigramTM positive. 
Screening tests 
I 
DYI HPY Pap CG To,"' I No. (% of women with disease who underwent 
colposcopy 
- - - - 2102 
One screening test positive 





Pap CG Test Pos 
colps* 
n % n % n % 
- - - + 90 65 3 4.6 I 1.5 0 0 
- - + - 86 65 13 20.0 5 7.7 0 0 
- + - - 60 59 10 16.9 2 3.4 0 0 
+ - - - 337 318 13 4.1 9 2.8 2 0.6 
Total 573 507 39 7.7 17 3.3 2 0.4 
Two screening tests positive 
DYI 
HPY 




n n n 
+ + - - 12 12 3 25.0 1 8.3 0 0 
+ - + - 15 15 0 0 3 20.0 0 0 
- - + + 14 10 5 50.0 3 30.0 0 0 
- + - + 4 3 I 33.3 0 0 0 0 
- + + - 44 39 12 30.8 II 2.6 2 5.1 
+ - - + 93 90 II 12.2 6 6.7 0 0 
Total 182 169 32 18.9 24 14.2 2 1.2 
Three screening tests positive 
DYI 
HPY 






n n n 
+ + + - 12 12 6 50.0 5 41.7 0 0 
- + + + 10 9 4 44.4 3 33.3 1 I 1.1 
+ - + + 27 25 6 24.0 9 36.0 5 20.0 
+ + - + 8 8 0 0 0 0 0 0 
Total 57 55 16 29.0 17 30.9 6 10.9 
Four screening tests positive 
DYI HPY (lOx) Pap 
I 





n n n 
+ + + + 30 29 8 27.6 16 55.2 2 6.9 
Total 842 760 95 12.5 74 9.7 12 1.6 
Table 23: Number of cases of LSIL, HSIL and cancer detected with one, two, three or four positive 
screening tests [* The difference between the number of positive cases and the number of colposcopies 
performed, represents the number of women lost to follow up; + = screening test positive; - = 
screening test negative; Test pos. = total number of cases that were screening test positive; No. coJps = 












3.7 Evaluation of the Performance of Colposcopy in the Triage of Women with 
Positive Screening Tests 
Colposcopy is traditionally accepted to be an essential step towards a definitive diagnosis of positive 
screening tests, such as an abnormal cervical smear. Colposcopy is used to direct appropriate 
histological sampling of the cervix, to exclude occult micro-invasive disease and to determine which 
aceto-white lesions represent significant pathology and require treatment. 
Colposcopic assessment identified 170 of the women who underwent colposcopy as having SIL or 
cancer (i.e. RCI ~ 3). Of these women, 6.5% had cancer, 25.9% had HSIL, 26.5% had LSIL and 41.2% 
had no disease confirmed histologically (Table 23). Of the 417 women classified as having no 
clinically significant disease at colposcopy (i.e. RCI = I - 2), 6.2% had HSIL and 11.3% had LSIL 
confirmed histologically (there were no cancers). When expressed in terms of what proportion of 
women with SIL or cancer were miss-classified as lacking significant disease by a colposcopic 
assessment of RCI of I - 2, colposcopy miss-classified 49.5% (47/95 of the cases of LSIL) and 35.1% 
(26/74 of the cases ofHSIL). 
In contrast, of the 173 women with no aceto-white lesion identified at colposcopy, one woman with 




Histological diagnosis after colposcopic evaluation 





















RCI ~ 3 
(n = 170) 





(n = 760) 
Table 24: Number of women with no disease, LSIL, HSIL or cancer who had a colposcopic evaluation 
of RCI ~ 3, RCI < 1 -2 and no aceto-white lesion seen at colposcopy 
The type of positive screening test influenced the sensitivity and specificity of colposcopy for HSIL 
and cancer (Table 25). For instance, the sensitivity of a colposcopic diagnosis of RCI ~ 3 for HSIL and 
cancer in women who were DVI positive was 58.6% compared to a sensitivity of 79% when the 
referring screening test was a positive cervical smear, 75 .6% for a positive HPV DNA test (lOx) and 
70% for a positive Cervigram™. Of note however, the specificity of DVI for HSIL and cancer was 
increased by the combination of DVI and a colposcopic assessment of RCI ~ 3 whereas it was 























3.8 HPV DNA testing 
3.8.1 Comparison of HPV DNA Testing using Hybrid Capture I and Hybrid 
Capture II in relation to Disease Detection 
As mentioned in the methods section a sample of stored HPY DNA specimen collection tubes were 
retested at Columbia University using the newer generation Hybrid Capture Assay, known as HC II 
(Digene Diagnostics, Sliver Spring, MD). The sample consisted of all women with histologically 
confirmed LSIL, HSIL or cancer and a 10% random sample (n = 243) of women with no evidence of 
disease (either all screening tests negative or no evidence of disease after colposcopy and histological 
sampling). This section presents the results of the HC II test and compares them to the HCI (tube­
based assay) that was used to screen women in the study. 
The difference in the prevalence of HPY DNA positivity in the different grades of disease, using HC I 
(tube-based test) and HC II (micro-titre plate test), is illustrated in Figure 18. 
Figure 18: Graphic illustration in the prevalence of no disease. SIL and cancer using the two different 
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HPV DNA testing (Ix) using HC I was positive in 12.2% of women with no disease, 65.3% (62/95) of 
cases of LSIL, 71.6% (53174) of HSIL, 83.3% (10/12) of cancers. Compared to women who were 
negative on all four screening tests or who had no disease confirmed histologically, the prevalence of 
HPV DNA was 6.8-fold higher (95% CJ: 5.20 - 8.97) in women with cancer, 5.9-fold higher (95% Cl: 
4.93 - 7.00) in women with HSIL, and 5A-fold higher (95% CI : 4048 - 6040) in women with LSIL. 
Using HC II, HPV DNA prevalence in all disease categories was higher than HC I. HPV DNA using 
HC II was positive in 18.2% (44/243) of women with no disease, 70.5% (67/95) of women with LSIL, 
86.5% (64174) of HSIL and 100% (12/12) of women with cancer. The prevalence of HPV DNA in 
women with histologically confirmed disease was roughly equivalent between HC II using a lOx cut­
off and HC I using a I x cut-off. 
Overall, among women with HSIL, 10.8% were missed by both HC I and HC 11,2.7% were detected 
by HC I but not HC II, and 17.6% were detected by HC II and not HC I. Among women with no 
evidence of disease, 9.5% were classified as positive by both tests, 4.5% were classified as positive by 
HC I and not HC II , and 8.6% were classified as positive by HC II and not HC I. Kappa coefficients 
indicated good agreement stratified by disease category: 0041 among women with HSIL, 0.54 among 
women with LSIL and 0.51 among with no disease or negative screening tests. 
The sensitivities and specificities of HPV DNA testing using Hybrid Capture I and II at different cut­
offs for a positive test are shown in Table 26. The sensitivity of the HC II test for HSIL and for cancer 
is considerably higher than the sensitivity of HC I. However the high sensitivity of the test is at the 
expense of a lower specificity. 
Sensitivity Specificity 'I 
Type of HPV test Cancer No disease 
(n = 951 
LSIL HSIL 
(n = 2681) (n=74) (n = 12) 
HCI 
72 83 8865
HPV > I x pos control 
HPV > lOx pos control 46 42 9751 
Random sample 
(n = 243) 
HCII 
Microtitre plate test 
HPV > I x pos control 82 
HPV > IOx pos control 
70 86 100 
74 100 9059 
Table 26: Sensitivity and specificity of HC I and HC II for SIL and cancer 
Quantities of HPV DNA measured using HC I and HC II were significantly correlated (r = 0.81) 
although mean levels of HPV DNA were approximately IO-fold higher using HC 11 (Figure 21). 
Agreement between the two tests was good (kappa = 0.67) if both tests were classified as positive to 1 
x the positive control. Agreement was marginally better (kappa = 0.77) if HC I was classified as 












Although HPV DNA prevalence in both tests increased with the of the quantity of HPV 
DNA detected in samples did not vary between the different grades of disease. 
Using He I and the analysis to women with detectable HPV DNA, the geometric mean 
levels standard deviation) of HPV DNA were 11.4 ± 6.61 in women with cancer, 21.& ± 3.&& in 
women with and 21.7 ± 4.&6 in women with LSIL. He """',,,,;>tru' mean levels were 
113.& ± 6.92 in women with cancer, ]49.3 ± 7.90 in women with HSIL and 50.0 ± 8.78 in women 
with LSIL 
3.8.2 Estimated ROC 
Roe curves the relative performance of He I and He II are shown in 20. The area 
under the ROe curve was 0.8& for He II and 0.&3 for He I, indicating better performance of 
He II. However, when the cut off values of the two tests were set such the of HPV DNA 
was below &%, the abilities of the two tests to confirmed cases of HSIL or 
cancer were almost identical. He II had improved detection of cases of HSIL and cancer to 
He I only once lower cut-off values) was allowed 
3.8.3 Proportion of Cancer Classified as HPV DNA using HC 
I and HC II with Different Cut-off Values to Define a Positive 
Table 27 shows the proportion of all cases of histologically confirmed HSIL and cancer that were HPV 
DNA positive using He I and He 1I different cut-off values to define a positive HPV DNA test, 
such that the prevalence of HPV DNA in women without disease varies between 2.5 and 15%. Women 
with LSIL or with at least one screening test who did not receive ..."I"n',"''','''' are excluded 
from the table. 
He II identified 88% of all cases of HSIL and cancer if the prevalence of HPV DNA detection in 
women without disease was allowed to increase to I which occurred when I x the positive control 
was used as the cut-off for a test. He I reached a plateau of 73% detection of all cases of 
HSIL and cancer when the of HPV DNA in women without disease was 12%. At an HPV 
DNA prevalence of around 5% in women without either test was able to identifY over half 












Type of HPV test 
Proportion HPV 
positive among women 
without disease 
Proportion HPV 
positive with HSIL or 
cancer 
Cut-off value used to 
define HPV test as 
positive 
0.025 0.430 14.9 
0.050 0.570 4.8 
I 0.075 0.640 2.7 
HCI 0.100 0.709 1.4 
0.122 0.733 1.0 
0.125 0.733 0.9 
0.150 0.756 0.7 
0.025 0.453 257.5 
0.050 0.57 119.2 
0.075 0.605 52.7 
HCII 0.100 0.791 8.3 
0.122 0.814 4.32 
0.125 0.837 2.34 
0.150 0.884 1.00 
Table 27 : Estimated proportions of all cases of HSIL and cancer classified as HPV positive and 
estimated HPV prevalence in women without disease (all screening tests negative or no disease after 
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3.9 Follow-up Post-LEEP 
3.9.1 Immediate Complications Post-LEEP 
Bleeding at the time of LEEP was considered excessive (> I 00 m1s) in 4.5% (n 8), moderate 100 
mls) in 49.4 % (n = 88) and no bleeding at all was documented 46.1 % (n 82) of the 178 women 
treated with LEEP. While 27.5% (n 49) women complained of pain or during the 
procedure, 5.1 % (n 9) of the women complained of dizziness or faint. There were no serious 
complications. 
3.9.2 Post-LEEP Follow-up 
All women treated with LEEP were asked to return for follow up at 4- and lO-months post treatment. 
This group consisted of a total of 178 women: 149 women who had a LEEP at the first co\poscopic 
examination, 28 women who had LEEP performed on the basis of a biopsy or one 
woman who had colposcopy and LEEP on the basis of between tests and 
the original colposcopy. In total, 141 (79.2 of these women returned for their follow up visit at 4 
months and 64 (35.9%) returned for the second post-LEEP check up at 10 months. 
3.9.3 Post-LEEP Follow-up at and to-months: Prevalence of SIL and Cervical 
Stenosis 
Of the 141 women who returned for UV'>L-J..JLJ.~l follow up at 4-months, 8 (5.7%) cases of cervical 
stenosis were diagnosed and no histological sampling was possible in these women. SIL was 
diagnosed in 9 (6.4%) women who returned for their 4-month check up. Of the 64 
women who returned for their lO-month follow up, there were a further 4 (6.3%) cases of 
cervical one case of HSrL and 3 cases of LSIL 
Tables 28 and 29 show the number of cases of SIL and cervical stenosis diagnosed at the 4- and 10­
month check ups respectively in relation to the LEEP Of the 51 women who had 
HSIL in the original LEEP and who returned for the 4-month follow up visit, one woman had 
persistent HSrL (2.0%), 3 women had LSrL 2 (3.9%) women had cervical stenosis 
and 45 women had no disease confirmed histologically. Of the 40 women who had LSIL in the 
LEEP and who returned for the 4-monlh check up, 3 had LSIL 
there were no cases of HSIL and 3 (7.5%) women had cervical stenosis. Of the 49 women who had no 
SIL in the LEEP 2 had LSIL histologically confirmed at the 4~month 












Histological Diagnosis In Histological diagnosis at 4-month follow u~ 
original LEEP specimen* No disease LSIL HSIL Cervical Stenosis 
No disease 
(n = 50) 
LSIL 
(n = 40) 
HSIL 



















Table 28: Histological diagnosis and cervical stenosis at 4 months post LEEP follow up [* includes 
only women who returned for post LEEP follow up] 
Sixty-four women returned for the 10-month follow up and overall, 4 (6.3%) women had cervical 
stenosis, 3 (4 .6%) had LSIL and one woman (1.2%) had HSIL. Of the 23 women who no disease in the 
original LEEP specimen, one woman (4.3%) had HSIL at the lO-month follow up and a further 3 
(13.0%) women had developed cervical stenosis. Of the women with HSIL in the original LEEP 
specimen, 2 (8.7%) women had LSIL diagnosed at the 10-month follow up, no women had HSIL and 
there was one case of cervical stenosis (4.3%). 
Histological Diagnosis in Histological diagnosis at 10-month follow up 
original LEEP specimen* No disease LSlL HSIL Cervical Stenosis 
No disease 
(n = 23) 
LSIL 
(n = 18) 
HSIL 
(n = 23) 
Total 

















Table 29 : Histological diagnosis and cervical stenosis at 10 months post-LEEP follow up [* includes 
only women who returned for post LEEP follow up] 
3.9.4 Intermediate Complications of LEEP as Assessed at 4 month Follow-up 
Visit 
Of the 141 women who came for post-LEEP assessment at 4 months, 24 (17%) reported that they had 
required medical treatment after the LEEP procedure. Of these women, 14 (58.3%) complained of pain 
and 7 (29.2%) complained of excessive bleeding and 3 women had unspecified complaints. Only one 













3.10 of the Different Screening Protocols 
3.10.1 Introduction 
One of the criteria that may enable successful screening in low resource settings, would be the 
elimination of colposcopic and histological sampling before treatment in the of 
women with abnormal tests. Colposcopy and services are not 
available in low resource and elimination of this step in the management of preinvasive disease 
may streamline the process, reduce the high default rate and enable on-site treatment. A particularly 
and attractive screening would be to screen and treat women at the first using a 
low technology screening test such as DVI. 
This next section considers the outcomes of three different screening in which 
women would be treated, based on the screening test without the use 
Three possible approaches to include women treated based on: 
Positive screening tests used alone, in other words, a 'Test and Treat' protocol. 
2 Selecting a subgroup of women who are positive on one screening test and then to perform a 
second screening test if the first test is If both tests were positive the women would 
be referred for treatment, so-called 'Two-Stage 
3 Combining two tests, such that if either one or the other were the women would 
be referred for treatment. 
3.10.2 'Test and treat' Screening Protocol 
Table 30 shows the ¥V'''",',V of women screened who would be correctly treated and over-treated by 
each screening test if women were treated on the basis of a positive screening test in the absence of 
colposcopy or histological sampling. HSIL and cancer would be correctly identified and treated in a 
similar proportion (approximately 2% of all women screened when any of the four screening tests 
were used). However, over-treatment of women without cervical disease would be more likely with a 
positive DVI and a positive HPV DNA test at the lower threshold for a positive test. For example, if 
women with positive DVI results were treated in the absence of colposcopy, 18% of the population 
would be treated and 14.4% of the screened population would be treated the fact that they are 
disease free. This rpr'I'P"pn:t" 79% of the women with a positive DVI test 
In contrast, if a positive cervical smear was used to determine who to treat in the absence of 
colposcopy, 8% of the screened population would be treated and 3.4 % of the total screened population 
would be treated being disease which represents less than half (42%) of the women with a 











HPV DNA positive (I x positive control) women have no disease, but at the higher cut-off (lOx) the 
test would perform similarly to cytology with 49% of women with a positive test having no disease. 
Screening test 
Percentage ofall women screened* 
Total treated 
Correctly treated 






HPV DNA (lOx) 





















Table 30: Percentage of all women screened who would be correctly treated and over-treated by each 

screening test in the absence of colposcopy (adjusted for lost to follow up) [* Percentage with LSIL, 

HSIL or cancer among those with a positive test result who underwent colposcopy multiplied by the 

percentage of women who were test positive on the screening test. 

+Percentage with no histological evidence of SIL of any grade or cancer among those with a positive 





Women called negative by the different screening tests would not be referred for treatment. From our 
data the number of known cases of SIL or cancer that would not be treated in a 'test and treat' 
screening protocol using DVI would be 1.2% of the women with a negative DVI test, 0.7 % of women 
with a negative cervical smear, 1.3 % of women with negative Cervigrams™, 1.8 % of women with a 
negative HPV DNA test (lOx) and 1.0 % of women with a negative HPV DNA test at the I x level. 
(These data are calculated from the overall disease prevalence, 3.3 % adjusted for lost to follow up 
minus those with disease who had positive screening tests). 
3.10.3 Sequential or Two-Stage Screening 
The six possible sequential pairs for 'Two-stage screening' include DVI and cytology, DVI and 
CervicographyTM, DVI and HPV DNA testing, HPV DNA testing and CervicographyTM, HPV DNA 
testing and cytology and CervicographyTM and cytology. 
3.10.3.1 Sensitivities, Specificities, PPVs and NPVs for HSIL and Cancer of the 
Different Sequences in Two Stage Screening 
The sensitivities and specificities of the different screening sequences for HSIL and cancer are shown 
in Table 3 I. Sequential testing would result in considerable loss of sensitivity compared to the four 











tests in sequence would have resulted in over half the cases of HSIL and cancer being missed. HPV 
DNA testing (Ix) and cytology had a sensitivity of67.5 (similar to DVI, cytology or HPV DNA testing 
(I x) when used alone) but had a far better specificity than DVI used alone (97 versus 83% 
respectively). Specificity was high for all six sequences. The order in which the tests were performed 
did not alter the results as calculated here. However, in a real situation, prior application of acetic acid 
would be expected to reduce the performance of cytology in women so screened. 
While the sensitivities of the different sequences were markedly reduced compared to using the tests 
alone, the PPVs of the tests were significantly higher. A positive DVI and cervical smear had a PPV of 
nearly 50% compared to II % when DVI was used alone. A positive DVI and positive CervigramTM 
(both visual inspection methods) had the lowest PPV at 25% compared to 40% when CervicographyTM 
was combined sequentially with HPV DNA testing (I x) and 53% when CervicographyTM was 
combined sequentially with cytology. 
Screening tests -
both positive 





































Table 3 J: Sensitivities, Specificities, PPVs and NPVs of the six different sequences for HSIL and 
cancer using the two-stage screening model [+ = positive; Pap = cytology; CG = CervicographyTM, 
HPV + = HPV DNA testing (I x)] 
3.10.3.2 The Percentage of Women Screened who would be Referred for 
Treatment and the Percentage of Women who would be Correctly Treated and 
Over-treated using the Six Different Screening Sequences in the Absence of 
Colposcopy 
Table 32 shows the percentage of the women screened who would be referred for treatment and the 
percentage of women with positive screening tests who would be correctly treated or over-treated if the 












women screened who would be referred for treatment is significantly lower for all the six sequences 
compared to using the screening tests alone. However, the percentage of cases of SIL or cancer 
correctly treated would also be decreased compared to using the screening tests alone, except for the 
sequence ofHPV DNA testing and cytology. 
In contrast to screening and treating women on the basis of positive screening tests alone, sequential 
screening reduces the number of women who are over-treated, particularly with the visual inspection 
methods of DVI and CervicographyTM. For example, the sequence of a positive DVI test and a positive 
Pap will refer 3% of the population screened for treatment and 0.8% of all women screened would have 
no cervical disease and would be over-treated (representing 28 % of women with positive screening 
tests). By contrast, 79% of women with a positive DVI test used alone would be over-treated in the 
absence of colposcopy and histological sampling. A similar reduction in over-treatment is noted with 
the other five sequences. 
Screening 
sequences 
Percentage of all women screened * 
Total treated Correctly treated 







































Table 32: Percentage of women screened using the six different sequences who would be correctly 

treated and who would be over-treated in the absence of colposcopy.(+ = positive; Pap = cytology; 

HPV = HPV DNA testing at the Ix level; CG = CervicographyTM). 

[*Percentage of women with LSIL, HSIL or cancer among those with a positive test result who 

underwent colposcopy multiplied by the percentage of women who were test positive on the screening 

test. +Percentage of women with no histological evidence ofSIL of any grade or cancer among those 

with a positive test result who underwent colposcopy multiplied by the percentage of women who test 
















3.10.4 Combination of Screening Tests 
Combining two screening tests such that if either one or the other test were positive women would be 
referred for treatment, is another possible screening strategy. The six combinations of tests include; a 
positive DVI or cervical smear, DVI or CervicographyTM, DVI or HPV DNA (Ix), HPV DNA (Ix) or 
cervical smear, HPV DNA (I x) or CervicographyTM and a positive cervical smear or CervicographyTM. 
3.10.4.1 Sensitivities, Specificities, PPVs and NPVs for HSIL and Cancer of the 
Different Combinations of Screening Tests 
The sensitivities, specificities, PPVs and NPVs of the different combinations of tests for HSIL and 
cancer are shown in Table 33. All the various combinations show significantly greater sensitivities 
compared to using the tests alone, but there is a corresponding decrease in specificity. The combination 
of a positive DVI or a positive cervical smear and a positive DVI r HPV DNA test (I x have 
equivalent sensitivity, although the specificity of the latter is lower. 
A positive DVI or CervicographyTM test, both visual inspection methods of screening, has the lowest 
sensitivity and PPVs of the various combinations. Compared to sequential screening, the PPVs of the 
different combinations are much lower and are more or less equivalent to the PPVs of the screening 
tests used alone. The NPVs are nearly 100% for all the combinations. 
Screening 
combinations 





































Table 33 : Sensitivities, specificities, PPVs and NPVs of the different screening combinations for HSIL 










3.10.4.2 The Percentage of Women Screened who would be Referred for 
Treatment and the Percentage of Women who would be Correctly Treated 
Over-treated the Different Screening Combinations in the Absence of 
Colposcopy 
Table 33 shows the nprrpnt<l of the women screened who would be referred for treatment and the 
percentage of women with positive screening tests who would be correctly treated or over-treated if the 
six screening combinations were used without colposcopy. The percentage of women referred for 
treatment is significantly higher for all the six combinations to using the tests 
alone or sequentially. While the percentage of cases of SIL or cancer correctly treated would be 
increased compared to the other screening strategies, the per'cerlta~~e of women who would be over­
treated is dramatically greater than using screening tests in sequence and similar to the "('r,~pnll'lo" 
tests alone. 
For while the combination of a DVI test or a positive cervical smear would refer 23% 
of women for treatment, 17.3% of the screened would have no evidence of disease 
(representing 74% of women with positive tests, almost equivalent to women on the 
basis of a DVI test alone. Similar pel·celtlta.ges of women over-treated without disease are 
















I Total treated 
23.3 
Percentage of all women screened* 
Correctly treated 







23.0 2.6 2.5 17.9 
HPV+ or 
Pap+ 
18.0 2.5 2.6 12.9 
HPV+ or 
CG+ 
21.0 2.6 2.9 15.5 
Pap+ or 
CG+ 
14.0 2.6 2.6 8.7 
Table 34: Percentage of women screened using the six different combinations who would be correctly 

treated and who would be over-treated in the absence of colposcopy (+ = positive; Pap = cytology; 

HPV = HPV DNA testing at the Ix level; CG = CervicographyTM) 

[*Percentage with HSIL or cancer or LSIL those with a positive test result who underwent colposcopy 

multiplied by the percentage of women who were test positive on the screening test 

+Percentage with no histological evidence of SIL or any grade or cancer among those with a positive 




















This cross sectional study was performed on a volunteer sample of women living in a peri-urban 
settlement outside Cape Town. The main aim of the study was to define the comparative effectiveness 
of alternatives to cytological screening for the detection of cervical cancer and its precursors in a low­
resource setting. Despite the relatively good performance characteristics of cervical cytology as a 
screening test for invasive and preinvasive disease, alternatives are being actively sought because it has 
proven difficult to introduce and maintain cytologically-based cervical cancer screening programmes in 
many resource-poor settings. 
4.2 Study Sample 
Since the study was designed to evaluate alternative methods for the detection of cervical cancer and its 
precursors in low-resource settings, it was important to locate the study among women of low socio­
economic status living in a low-resource setting. 
The characteristics of the study sample closely resembled the socio-economic and demographic profile 
of women living in Khayelitsha as described in the population-based survey by Cooper et al in 19911. 
Of the women interviewed in this survey, 54% lived in serviced sites (compared to 67% of the women 
in this study). The same numbers of women were employed as in this study (31 %) and in both studies 
the majority of the employed women were domestic workers. The number of women with no formal 
schooling was higher in this study (14% compared to 7% in the study by Cooper et al) but the number 
who had had some primary and some secondary level education were similar in the two studies. The 
similarity of the demographic profile of the women in the two studies suggests that our study sample 
was representative of the women of the Khayelitsha community and of women of low socio-economic 
status in general. 
Selection bias in the study sample cannot be ruled out. While not formally evaluated, we conducted 
focus groups with women who had participated in the study in order to refine and develop educational 
material. During discussion in the focus groups, it became apparent that 'word of mouth' was a 
common source of referral to the study, in addition to our more formal recruitment strategy. One of the 
main reasons for this was that besides offering a screening service, the project personnel paid particular 
attention to the non-research related health needs of the women and provided a level of care not 
commonly encountered in the State-funded primary health care service. 
For example, approximately 10% of the women who were enrolled in the study were referred to tertiary 











gynaecology clinics. Tn the focus groups, women repeatedly expressed their satisfaction at having their 
'other' health problems attended to. It is possible therefore that the study sample were relatively self­
selected once knowledge became widespread that a fairly comprehensive health service was being 
offered by the project. This bias however, would not have affected the performance of the screening 
tests nor would it have prevented comparison of the performance of the screening tests in the context of 
a low-resource setting. 
Women who had previously been screened were specifically excluded from the study in order to 
perform the study in a 'screen naive' population, such as would be encountered in many African 
countries. We restricted participation to women aged 35 to 65 years in order to capture the most high­
risk women in the population. The fact that only 3% of the women recruited were over 60 years of age, 
may reflect the reluctance of this age-group of women to undergo gynaecological examination and a 
lower utilisation of health services in general. 
The study population had many of the characteristics associated with populations at high risk for 
preinvasive and invasive cervical cancer. Over 50% of women had between 2 and 4 pregnancies, 66% 
had their first sexual encounter as teenagers and 67% had between 2 and 5 lifetime partners. Munoz et 
al2 evaluated risk factors for CIN3 and carcinoma in situ in two case-controlled populations in Spain 
and Columbia In both Spain and Colombia, early age at first intercourse was associated with a 
significantly elevated risk of CIN 3. In addition, there was a significant increasing trend in risk of CIN 
3 with increasing number of pregnancies, but this was only observed in Colombia. In both Spain and 
Colombia, the risk of CIN 3 increased with the number of lifetime sexual partners. The similarity in 
lifestyle characteristics of the women in our study and in those with established cervical disease in 
Spain and Colombia, indicates that our study sample were at particularly high risk for cervical disease. 
Finally, the location of the project in an area within walking distance of most women's homes, meant 
that women without access to transport, those employed in the informal sector and unemployed women 
living in Khayelitsha had relatively easy access to the study site. Colposcopy was specifically 
performed on a Thursday afternoon as it is well known that many domestic workers have Thursday 












4.3 Strengths and Limitations of the """"'£'1'<1 
The of this were that the majority of the women (90%) with positive tests 
underwent colposcopy and histological all colposcopies were performed by the same 
colposcopist, which limits inter-observer and all was reviewed, blinded to any 
clinical information, at a centre of excellence. the screening tests were evaluated in the context 
of a population in a low resource Evaluation of screening test in other than 
the population can produce considerable and unmeasurable bias, such as when screening tests are 
evaluated in a highly selected population as occurs in colposcopy clinics. 
In addition, a trained nursing rather than medical officers or all 
Throughout Sub-Saharan the ratio of nurses to patients is than the 
ratio of doctors to patients, particularly in rural areas. It is therefore that sisters would 
be at the forefront of any established programmes in low-resource settings. The 
of DVI in this study is an indication that sisters can be trained to 
examinations, to evaluate the cervix and to interpret their findings 
appropriately. 
The use of community health workers (CHWs) who had lived in and understood the community to 
perform the recruitment, education and of women is another strength of the study. 
None of the CHWs had completed high school and two had previously worked as domestic \Au,>:r"P1"<: 
yet they were able to understand the nature and purpose of and to this to 
women in a manner that was accessible and understandable. Their closeness to the community 
,,,.,,,,,,,,,......,,,.. trust and possibly enhanced compliance with the of the study. The on-site 
medical officer and the author constantly monitored the of the education provided by the CHWs 
to the women recruited to the study. The level of shown the women was considered 
remarkably however this was not evaluated. It did however, confirm the value of 
training relatively uneducated women to become CHWs and to fairly tasks. This 
is important information and indicates that CHWs can and should be incorporated into the design of 
or any newly established cervical cancer programmes. 
The main limitation of the was that the standard' for detection of cervical disease, that 
colposcopy followed histological was not applied to all study The failure to 
the to on screen ing tests, particularly if the procedure 
is invasive such as colposcopy and has been a limitation of many 
studies. Some have even claimed that it is 'unethical to biopsy healthy women in order to 
establish the prevalence ofdisease in normal (control) populations,J· 4. 
The failure to nl-"r',nnm colposcopy in women with four negative tests results in a form of 















6. Verification bias refers to a distortion in the estimates of accuracy of the test when only 
selected undergo disease verification with the 'gold standard' e.g. when only women with 
tests undergo and histological sampling. In a meta-analysis of Pap test 
accuracy et only 18% of reviewed studies verified disease status in all subjects. Pap test 
were verified in a much lower nrrmn.-flrm than those who were positive and were often 
selected for disease verification on the basis of other positive test such as occurred in this study, 
or risk factors for cervical disease. In these it is likely that verification bias will result in 
an over-estimation of sensitivity and an under-estimation of specificity7. 
In this the overall disease is low and we used four independent screening 
tests to screen this population of women. We expect therefore, that the number of cases of disease 
missed in the screen negative women to be so low, that our estimates of sensitivity and specificity, 
while not accurate, are a reasonable reflection oftest np,·t:m·mlOl 
In an to quantify the of verification bias, we considered the sensitivity and of 
DVI and HPV DNA testing using "urn,r",,, as the 'gold standard'. We found the performance of the 
tests to be similar to that observed when judged against our combination of four negative 
tests or negative histology after colposcopic examination. Thus it appears that the extent of 
the verification bias was small. 
A further limitation of this in terms of the results into clinical 
is that the findings were made in the context of a closely monitored research study, with dedicated 
training and audit. Whether the performance of the tests would be replicated in 
a clinical setting, without the quality control built into a research study, remains to be 
evaluated. 
In addition, the study n1'r>V1l1pl'1 a 'vertical' service to the women being screened, in that the study 
were dedicated to education, treatment and of women 
follow-up. There is an intense debate in South Africa and other developing 
countries on the sustainability of 'vertical' health care programmes as opposed to 'horizontal' health 
care programmes. The latter programmes employ mUlti-purpose health workers from health 
centres and clinics, rather than personnel dedicated to health problems. The level of 
compliance achieved in this study is a reflection of what can be achieved with dedicated staff. Whether 
this could be sustained in a poorly-resourced health care infrastructure is untested, another factor that 












4.4 Association of Socio-demographic Characteristics with HSIL and Cancer 
Epidemiological studies have identified a number of risk factors for the development of both cervical 
cancer and its precursors. These include early age of first age of first pregnancy, number 
of sexual partners, use, socio-economic interval since the 
last Pap smear, a of abnormal immunosuppression and infection with 
Herpes simplex virus 2 or specific ofHPY 16 and 18)8.17. 
Although the risk factors for cervical cancer and its precursors are similar, the strength of the 
association between these risk factors and cervical cancer is generally stronger than between the risk 
factors and SIL. The two major independent risk factors identified for cervical cancer precursors have 
been lifetime number of sexual partners and smoking IS. 19. Some studies have also identified 
onset of sexual activity to be an important risk factor2o• Harris et a1 21 , in an to 
correlated risk factors for preinvasive found that the number of sexual as a risk factor 
exerted effects of age at first whereas the reverse was not true. They 
concluded that the role of adolescent sexual activity as a risk factor for preinvasive lesions was 
unsupported their data. 
In this the only risk factor that achieved statistical significance after multivariate logistic 
regression analysis was the association between ever use of long acting injectable progestogen 
contraception use (LAIP) and HSIL (OR 2.17, 95%CI: 1.29 3.64). This association was 
when ever use of LAIP was specifically controlling for age, and being 
active (OR 2.08; 95%CI: 1.21 3.58). 
Published data on the relationship between LAIP use and cervical cancer and its precursors is 
inconclusive. Herrero et al22 in a case-controlled found that the RR of invasive cancer in women 
who had used "m,tr"f"P:nti'liP" for 5 years or longer was 2.4 (95%CJ: 1.0 The effect of 
prolonged use of LAIPs was stronger for women use for 10 or more years (adjusted RR 
95%CI: 1.1 24.9) and among women who reported never having had a Pap smear or having had a Pap 
2 or more years before the interview (adjusted RR 6.3, 95%CI: 2.1-1 However, women reporting 
use of LAIP for less than 5 years had an adjusted RR of 0.5 0.3 0.9). The reduced cervical 
cancer risk associated with short-term use of LAIPs may have related to more intensive screening when 
this method was initiated. 
In contrast, a WHO Collaborative Study of and Steroid Contraceptives, which conducted a 
case-control in Mexico and Kenya, found no increased risk in 













However, in the same WHO the relationship of LA!P use to the risk of carcinoma-in-situ 
showed an elevated risk in women who had ever used LA!P and the risk increased with duration of use 
trends in relative risk with times since first and last use of LAIPsof . In addition, 
users. Their findings suggested that if LAIP increase the risk of carcinoma-were observed in 
then either this was a reversible or the cervical lesions induced by LA!P tended not to 
progress to invasive disease. 
Similar to the WHO collaborative study, a case-control study in Costa Rica in 1988 showed no 
increased risk of invasive cancer or of carcinoma-in-situ in women who used LAIPs. very 
few women in the had used ICs for longer than 2 years25. 
The association between LA!P and HSIL noted in this may be explained by the relatively strong 
relationship between HPV infection of the cervix and use of LAIP. In our study, this was 
statistically on univariate but not multivariate analysis controlling for age, education, 
type, marital starus, current sexual activity, lifetime number of age of first sexual 
intercourse, parity and smoking. The relationship however between current sexual and 
HPV infection of the cervix was after controlling for the same variables (OR 1.4: 9S%CI: 
1.07 - I It is that the increased risk of HSIL in ever uses of LAIPs observed in this study, 
represents greater sexual activity among users, rather than a direct effect of LAIP on the 
n<>!"n"o",y",c.c of HSIL. This would need to be tested on a much sample of women to 
be validated. 
Of the women who failed to return for colposcopy, the majority were women who lived in unserviced 
sites, women who used alcohol and nulliparous women. Women living in unserviced sites the 
poorest and most marginalised women in the community, a group for whom health care, particularly 
preventative health care, is unlikely to be a priority. Use of alcohol among women in the Khayelitsha 
is uncommon and women who do use alcohol, most likely ""''''''0<"''''''' women who are 
significantly socially dislocated. It is likely that both groups of women are at for cervical 
disease. A number of studies have that women at highest risk for cervical disease are least 
likely to attend screening programmes 26 28. Efforts to improve compliance among this group of 
women need to be developed for each health care Providing on-site and treatment for 
these women enabled these women to come for but did not overcome their resistance to 












4.4 Summary of Main Findings with to Test Performance 
This study has found that none of the non-cytological methods of cervical screening, when used alone 
provide the same combination of high sensitivity and as the cervical smear. However, the 
high and specificity of cytology in this study may nol be reproducible outside the research 
context. A recent comprehensive meta-analysis of all published cervical screening studies from January 
1984 to March 1992, which consisted of 62 studies, estimated the of cytology in screening 
studies to be between 49 - 67%, with specificities ranging from 62 77%. Further, from ROC 
sensitivities as low as 20 35% were recorded if specificities of90 95% were achieved7• 
In this cytology performed better than reported in this meta-analysis with a sensitivity of 78% 
and a specificity of 95% for HSIL and cancer. However, the cervical smears were taken by a well­
trained nursing sister under ideal conditions i.e. women were examined in the lithotomy position with 
good quality lighting and quality sampling devices. In addition, the smears were read by highly trained 
cytotechnologists, who were aware that the smears were part of a research study, and the smears were 
read in a laboratory attached to an academic institution with stringent built-in quality control. 
Although both DVI and HPV DNA testing (at I x positive control) had an acceptable level of estimated 
sensitivity for HSIL and cancer (67 and 73% respectively) and statistically equivalent to that of 
cytology at 78%, both tests had a considerably lower specificity than cytology at 84 and 89% 
respectively. The relatively low specificity of these two tests would have resulted in many women 
without cervical disease being classified as disease positive. This would overburden the colposcopic 
services if colposcopy were used to triage women with abnormal screening tests or would result in 
considerable over-treatment of women lacking cervical disease if a 'Test and Treat' policy were 
followed. Although HPV DNA testing lOx the positive control) had an estimated 
equivalent to that of cytology (both 95%), the test would identify only half the cases of HSIL or cancer 
in the population screened. HPV DNA testing HC II had the highest sensitivity for HSIL and 
cancer of all the tests, but with the expected 'trade-off' of a lower 
CervicographyTM .."",-+",-,.,.".,-1 only better than HPV DNA testing lOx positive control) 
with sensitivity of 58% for HSIL and cancer, and a lower specificity than cytology at 92%. 
In contrast to sensitivity and specificity, which cannot be estimated with unless the 'gold 
standard' is applied to all women the predictive value of the tests is not 
influenced by this limitation. The PPV of a test indicates the likelihood of disease a 
positive test. 
While DVI and HPV DNA testing I x the positive control) identified the number of women 
as having a positive test (18 and 16% respectively), both tests had a low PPV for biopsy-confirmed 
HSIL and cancer at II and 14% In contrast, HPV DNA testing but only 










identified as having a positive test at 6% and double the number, 25%, of women had biopsy 
HSIL or cancer. CervicographyTM on the other hand performed better than DVI, but 
identifying 11 % of women as a test, of whom 19% had HSIL or cancer. 
In contrast, cytology identified 8% of all women screened as having a positive test and HSIL and 
cancer were histologically confirmed in 32% of the cases. 
The which is a measure of the likelihood of having no disease given a negative screening 
was high for all the screening tests. A NPV is an important characteristic of a 
test as it that women with negative tests are very unlikely to harbour undetected 
disease. 
The n"'r~Ar'm",,,{'p of the screening tests in terms of PPV and NPV was not influenced by 
age. The however of both visual that is DVI and CervicographyTM tl"'LlIIVU'''. 
increased in the 50 - 65 year age group. This is most due to the absence of active 
in older women, to fewer false calls. Similar findings with regard to the 
of , were reported in a of 8460 Costa Rican women who were 
screened with cytology, HPV DNA testing and 26. Their data showed a significant 
decrease in of CervicographyTM with age, but an increase in The decrease in 
was most likely due to lesions being 'hidden' in the endocervical canal and was strongly 
related to status. In our study however, of did not decrease 
appreciably with age. 
In summary, HPV DNA testing (at I x positive control) and had similar sensitivities for 
HSIL or cancer, but the specificity of cytology was much than either DVI or HPV DNA testing 
(at thelx In terms of sensitivity, and HPV DNA (at lOx positive 
np,·tA,'ITI'·/'I the worst, although both tests had than either DVI or HPV DNA 
(at 1 x the No test had a PPV above 50% for HSIL or cancer, although 
had a PPV of under 60% if all cases of SIL (including were included in the 
calculation. HPV DNA using HC II had the highest sensitivity of all the tests. 
4.5 Visual Inspection of the Cervix after Application of Acetic Acid 
Visual methods as alternatives to cytology in low-resource have received 
considerable as they are perceived to require a lower level of infrastructure and to be less 
than They do not require laboratories with their attendant and 
control costs. In addition, provide an immediate result, an in where women 
live considerable distances from health clinics or where it is difficult to track women who have 










Many studies of DVI that have incorporated the use of acetic acid washing of the cervix have 
found the sensitivity of DVI to be equivalent to that of cytology for detecting HSIL or 
cancer. These studies have enrolled women from diverse clinical including Italy, India, 
South Africa and the United States. The results obtained with DVI have been remarkably 
consistent the diverse clinical ""'""Ut;" 
• 31 
This study confirms these results and extends them by demonstrating that the use of low magnification 
(2.5x) does not enhance the sensitivity of visual inspection. Not a single case of disease was identified 
using magnification that was not also identified by the nursing sister using her alone. 
While the sensitivity of DVI for HSIL and cancer is acceptable at 67%, the specificity and PPV of the 
test are both low. These have important implications for a programme, particularly 
ifDVI were to be used in a 'Test and Treat' protocol, because numbers of women would undergo 
treatment to prevent cervical cancer in a small proportion of women in the screened population. The 
of such a protocol cannot be assessed until a comprehensive cost-benefit analysis is performed 
and the consequences of numbers of women are defined in terms of side 
effects, outcome of treatment and acceptability to the popUlation. 
One important question is whether the specificity of DVI can be improved? 
4.5.1 Methods of Increasing the Specificity of DVI 
1] Develol)ment of standardised training and interpretation of aceto-white lesions 
Possible methods of increasing the specificity of DVI include the development of standardised and 
reproducible criteria to define a positive test, such as is done with colposcopy, namely the Reid 
Colposcopic In our the sister was trained to identify all aceto-white lesions 
without attempting to the of the lesions. In India, Sankaranarayanan et ae9 trained 
paramedical staff to differentiate significant from insignificant aceto-white lesions, The scrccners, who 
were cytotechnicians, were trained to grade the aceto-white lesions in the following way: the test was 
considered positive only if a distinct aceto-white area was detected. If the was 
doubtful or faint, the test was scored as DVl was considered in just under 10% of the 
women screened compared to 18% in the Khayelitsha where the nurse was not trained to 
differentiate 'mild' aceto-white from more distinct aceto-white lesions. In addition, in the Indian study, 
DVI detected 90.1 % of the tme positive lesions, with an estimated specificity of over 90% rrnnn"r"rI to 
83% in this study. In the Zimbabwe cervical project, screeners were also not taught to 
the severity of the aceto-white lesions3l . Twenty per cent of the women screened were called DVI 













Sankaranarayanan et al29, 30 suggest that improved techniques for performing DVI of the cervix could 
reduce the false positive rate of DVI and improve specificity without compromising sensitivity. For 
instance, they recommend training staff to recognise artefacts due to glare from the light source, to 
wipe away mucus and cervical secretions and only to refer those women with dull aceto-white areas 
that cannot be wiped away. Larger studies are needed to prove that this approach is reproducible and 
sustainable. 
2] Pre-treatment of cen'ico-vaginitis 
This study found that visible inflammation of the cervix was associated with a significantly higher 
sensitivity for HSIL and cancer but there was a concomitant decrease in specificity of DVI. Lower 
genital infections, which cause cervical inflammation, may be the cause of the high false positive rate 
of DVI or low specificity. In our study, over 80% of women were noted to have a significant vaginal 
discharge and in just under half of these women the discharge was characterised as severe. 
In phase two of this study, which is an extension of the study presented in this thesis and in which a 
similar population of women were screened, women were tested for T. vaginalis infection, as well as 
endocervical infection with either C. trachomatis or N. gonorrhoea [Hybrid Capture GC/CT DNA 
Assay, Digene Diagnostics, Silver Spring, MD]. Of the women screened. 20% had culture proven 
Trichomonas infection and 8% had C. trachomatis or N. gonorrhoea infection of the cervix, indicating a 
high prevalence of cervi co-vaginal infection in this population of women35 
Whether it is possible to decrease the false positive rate of DVI by pre-treating women with clinical 
cervicitis with antibiotics is unclear and there are no published data to support this approach. The only 
available data on this approach is Pteliminary data from an ongoing study in Kenya, based in a family 
planning clinic. DVI was falsely positive in 17/30 women pre-treated with antibiotics compared to 
23/35 women who were not pre-treated with antibiotics (p = 0.5) suggesting that pre-treatment with 
antibiotics did not influence the outcome of DVI [Personal communication, Dr Hugo De Yuyst, 
Kenyan Screening Study]. Clearly pre-treating all women before screening would greatly increase the 
costs and complexity of the screening process. 
3J Use of DVI in Sequential or Two Stage Screening 
The Two-Stage Screening approach incorporating two sequential screening tests (the second performed 
only if the first is positive), followed by immediate treatment of women positive on the two tests 
performed in sequence, could reduce many of the obstacles to cervical cancer screening experienced in 
low resource settings and improve the specificity of DVI testing. 
For example, using data from the Khayelitsha study, DVI followed by either an HPY DNA test or a 












than 5 % of the screened population. In addition, specificity is greatly from 84% if DVI is 
used alone to over 97 99 % for DVI followed by either HPV DNA cytology or rp<:nP('t. 
The 'pay-off for the increased specificity is a reduction in from 67% to 48% for the 
detection of HSI L and cancer. In a true low-resource where facilities for do not 
this low sensitivity may be considered acceptable. The specificity means that far fewer women 
without disease will be treated, while just under half of the disease in the screened 
population would be detected, 
Although will reduce the number of more 
tests by the screened popUlation, the infrastructure to perform the more sophisticated 
tests will still be required. With this infrastructure could be centralised to save 
costs, but will introduce the same problems associated with delayed results and recall of women with 
abnormal tests. since only women with a positive DVI test will be selected for a second test, 
resources could be focussed on these women for further and surveillance rather than the entire 
screened population. 
4.5.2 Service Implications of DVI 
While DVI is a low technology test, it trained and committed 
Gynaecological examination of women with a speculum and performing DVI a high 
degree of commitment and of nursing staff. In primary health care clinics, which typically 
in low-resource are under-staffed, it may be difficult to motivate statT to perform this 
apparently 
This also raises the question as to whether screening can be performed in an at 
primary care level or whether a DVI-based service would need dedicated staff and facilities. 
The study was delivered as a classical 'vertical' with all staff dedicated to 
recruitment, screening and tracking of women with abnormal results when required. In the context of a 
busy clinic with limited staff it may not be possible to provide such a service. In future studies, we 
will be evaluating the service delivery implications of DVI, specifically looking at the advantages and 
of DVJ into primary care compared to establishing a vertical 
process, with and dedicated staff. 
4.5.3 Quality Control of DVI 
Another important limitation of DVI is the lack of standardised and reliable quality control. In this 
study, quality control of DVI was through assessment of the appropriateness of referrals at colposcopy. 
In a setting where DVI would be used without colposcopy, the only form of quality control would be 
reduction in the incidence of cervical cancer in the screened population, data that would take years to 












and evaluation of trainers would introduce a further method of quality control and this in itself will 
require additional resources. 
Repeated DVI Testing 
One of the debates about revolves around intervals. The false negative rate of 
cytology has been shown to decrease if the test is at regular intervals
34 
- 38. ln a study 
conducted by WHO and IARC in 1985 and reported by Eddi8, it was estimated using mathematical 
modelling, that screening 100% of the female population aged 35 64 years every year with cervical 
cytology, would reduce the cumulative incidence of cervical cancer by 93%. women every 3 
years would reduce the incidence by 91 every 5 years by 85% and every 10 years by 64%. The 
Khayelitsha evaluated DVI as a once off test and we cannot comment on the 
cumulative impact of repeated DVI testing. For countries such as South women 
every 10 years, that is, all women 30 60 years with 3 free cervical smears in a lifetime 
has been estimated to be 
being an ...hp"""'r and more implementable test than cytology, may enable more 
frequent than even yearly if resources permitted. We can only "IJI;;,,",UI'''''' on the 
of yearly or three yearly DVI on the incidence of cervical cancer, but if the false rate of 
the process decreases with repeated and the high found in many DVI 
studies is reproducible, the may be considerable. Only a detailed cost-benefit study and 
implementation ofDVI in the field would enable this question to be answered. 
In addition, DVI was not evaluated as a test treatment for preinvasive lesions and there 
is no published data on the utility of DVI in this context. In a programme based solely on 
DVI for both and follow up, this aspect will need to be carefully 
evaluated. 
Conclusions: DVI as a Primary Screening Test 
This study has shown that DVI performs equivalently to cytology in terms of sensitivity and will detect 
the majority of high-grade preinvasive and invasive lesions in the screened population. We have also 
shown that a trained nursing sister in a primary health care clinic can perform the test 
adequately. There remain however, many unanswered questions about the utility of DVl as a screening 
test for a national population screening programme, particularly if DVI were to be performed in the 
context of 'Test and Treat' protocol, without the use of colposcopy and histological For 
H • .>''' .. ..,,",, what are the implications of (\\Jf'r_tlrp"t numbers of women? Would it be acceptable, 
in order to cervical cancer, that nearly 80% of all women undergoing treatment do not have 












strategy? What is the cost-benefit ratio? Can DVI be introduced into an integrated primary 
health care or does it a vertical structure? 
The answers to these \.jU""U'UI may lie in the level of health care infrastructure available to different 
health care a screening test that subjected numbers of women to a treatment 
intervention that had side effects and complications, and was UniiCCepl:aO.le to the women 
screened, would not be ",.,'prlmn under any circumstances. In the future, we will be evaluating 
the consequences of DVI in a 'Test and Treat' protocol, in a randomised study, in 
which nursing sisters will be trained to perform cryosurgery on women with positive DVI tests, The 
main outcome measures will be reduction in the incidence of complications and acceptability of 












4.6 HPV DNA as a Primary Screening 
4.6.1 Introduction 
Despite the evidence that specific of high-risk HPV are -"-'~-"J associated with the development 
of cervical cancer, limited data are available on the use of HPV DNA testing as an alternative 
method. There are a number of reasons why HPV DNA testing has not been widely adopted 
for cervical cancer Foremost among these is the natural history of HPV infections. 
Anogenital HPV infections are common in young, sexually active populations40• 41. For Ho et 
al40 followed 608 women (mean age 20 years) and found that the cumulative incidence of HPV 
DNA infection, as measured by PCR and included for all known high-risk of was 
43% (95% CI: 36 49). The median duration of infections was only 8 months CI: 7 
10). 
Further, 1l''',,",UVll, even with types ofHPV, such as HPV 16 or 18, does not always lead to the 
development of SIL. The majority of HPV infections in young women are transient and a 
minority of HPV-infected women develop persistent . Even women who are rll'r'"i"lrpnt 
infected with HPV DNA can manifest variable shedding of the virus over time. Hildesheim et a143 , 
followed a population of 393 middle class women with normal smears, mean age 26 years, and 
tested for multiple HPV DNA types using PCR. Of those women infected with HPV 50% had 
persistent infection over a 14-month period. 
Nobbenhuis et al44 showed in their study of 353 women with abnormal Pap smears (mean age 32 years, 
range 18 - 55), that the overall median clearance time of HPV was 25 months. After 5 years 
of follow up, 67% of women had cleared their infections. Further the median time of clearance of 
newly acquired HPV was 6 months. This relatively long overall clearance time may be due to the fact 
that large numbers of women had HSIL, a group of women who seldom clear HPV infection. 
Another reason HPV DNA has not been ,,1'I1",,-,t",1'1 for routine cervical cancer is 
that the earlier cornm,erci available HPV DNA molecular tests lacked the 
sensitive HPV DNA tests have become commercially available 
such as Hybrid I and II. These tests have sensitivities that have been shown equivalent or 
46,47. Theto that of cytology in high-grade SIL and cervical of 
these highly sensitive tests offers the potential for replacing conventional cytological in 
where cytological programmes have not been successful. 
4.6.2 Advantages of DNA Testing 
HPV DNA testing offers a number of theoretical advantages over cytological screening in selected 












objective and provide a quantitative determination of the amount of HPY DNA present in a sample. A 
mid-level technician can test numbers of samples for HPY DNA per day, whereas cytological 
screening trained cy10lechnicians who can evaluate 55 80 specimens per dal8. 
In addition, cervical inflammation and cervico-vaginitis are not known adversely affect the results of an 
HPV DNA test, which are common in women in low-resource However the ultimate clinical 
acceptability of a test de{:lencls on the and of the test in the 
population. 
4.6.3 Sensitivity and Specificity of HPV DNA 
The of HPY DNA testing (at Ix the control) was equivalent to or better than 
Cj1ology in this cytology performed well in this study and better than 
in the by Fahey et ae. The estimated specificity of HPY DNA testing at the 
standard cut-off value for a test (Ix) was lower than that of cyiO!Ogy in this 
Comparable to cytology could only be achieved if the sensitivity of HPV DNA was 
allowed to decrease to around 57% by using more stringent, cut-offyalues for a test. 
Of the two HPV DNA assays evaluated in this study, the second generation HC II assay was ,,,,,,pr,,,r 
in some to the first generation HC 1 assay. HPV DNA was detected in 88% of 
,vomen with HSIL and 100% of the women with cancer the He II assay, compared to 72% of the 
cases of HSIL and 83% of the cancers using the HC I assay. When the cut-off value of HC II was 
shifted to a at which its sensitivity was to that of He 1, the specificity of HC II was 
better than that of HC I. In addition, the better performance of HC II compared to He I is 
reflected in the associations between HPY and cervical disease obsen-'ed He 
II although HC I was not able to achieve the same as 
HC to be practical for a scr,eenme: test in a low-resource "'AUB,5, He I 
to HC II. 
In the context of good sensitivity the ability of the test to detect all women with the 
condition of has to be balanced against the of the test. Specificity is particularly 
important in cervical cancer screening because by its nature, requires numbers of 
otherwise healthy women to be tested, and positive tests result in a follow up colposcopic 
examination that is both uncomfortable for women and costly. Specificity lakes on added importance in 
low-resource settings where colposcopy is nol available and \-"here all women who are classified as 
positive by a test may treatment. One of the advantages of HPY DNA in 
these is that the specificity of the test can be altered adjusting the cut-off level used to 
define a result. For example, ROC if over-treatment of 10% of women with no 
evidence of cervical disease were acceptable, then He II could detect 79% of the cases of HSIL and 
cancer. If over-treatment of only 5% of women with no evidence of disease were then both 










4.6.4 Other Studies ofHPV DNA ",,, ..,.n... as a Primary Screening Test 
There have been very few studies on the use of HPV DNA as a primary screening test. Cuzick 
et al49 PCR assay and cytological testing on 
1985 women who presented for routine cervical screening between 1992 and 1994, median age 29 
years. HPV testing was for types 16, 31 and 33. HPV DNA testing had a sensitivity for HSIL of 
75% and a PPV of 42% compared to a cprlcnn,,'rv of 56% for cytology (any grade of SIL used for 
colposcopic referral), with a PPV of 35%. 
performed HPV DNA a 
In a later study, 2988 women, 34 years and underwent cytology and HPV DNA for 
forthe consensus PCR/SHARP . The sensitivity of10 high-risk types of 
HSIL in this older population of women was with a PPV of 63%. 6% of the 
were positive for high-risk HPV the PCR/SHARP assay. The ofHPV DNA 
for high-grade disease was with a PPV of 17.4%. In addition to with PCR/SHARP 
assay, women who were on the PCR assay or cytologically positive and a of controls 
negative on both tests were retested HC I and the newer generation HC II test. The HC I test had 
a slightly better than the PCR assay, but a very poor specificity to an 18% false 
positive rate. the HC II which was used in 60% of the study had a 
sensitivity of greater tl13n 95% and a false positive rate of 4.9% when used at the recommended cut-off 
level of 1 pglml. All the HPV DNA positive high-grade lesions had a value in excess of 4 pglml, and if 
a 2 pglml cut-off were used, tllese was no loss of sensitivity and the false positive rate was reduced to 
2.3%. 
Schiffman et on a much study of tile screening performance ofHPV DNA as 
a scr;eenmg test on a cohort of 8554 Costa Rican women, Using the HC II assay and the low 
cut-off for a nn<:il,,!p test control), 88.4% of the 138 high-grade lesions and cancers were 
detected 12 cancers were HPV nr.,,,t,,,,1'\ with a COlpO!;COPIC referral rate 
of 12.3%, comparison, Pap smear ASCUS as a cut-off 
for referral resulted in a of 77.7% and a specificity of 94.2% with a referral rate for 
colposcopy of 6.9%. In addition, by analysing ROC curves by age HPV was shown to 
be optimal at older ages, where sensitivity was maintained with increased and reduced rates 
of referral for colposcopy (21, 11,2 and 7.1 % in each advancing tertile of age reslpectiv(~ly) 
The finding that tlle performance ofHPV DNA testing in a high-risk, unscreened population 
is equivalent to that of expert cytology has important implications for countries that have not yet 
developed national cervical cancer screening programmes. In many it may prove easier to 
establish clinical laboratories for large-scale HPV DNA testing than to establish high quality cytology 
laboratories. HPV DNA requires less skilled technicians and is easier to perform than cervical 
In HPV DNA testing not only identifies women who have high-grade 












future, HPV DNA would thus allow follow up efforts to be to women at greatest risk 
for developing cervical disease in the future. Cost effective analysis of HPV DNA testing is 
needed in order to evaluate its impact on cervical cancer prevention in various health care c",,.tI",~C 
4.6.5 Two-Stage Screening 
Similar to DVI the specificity of HPV DNA testing is significantly enhanced by or 
sequential for all possible sequences HPV testing. HPV DNA followed by 
cytology only for those with a positive test (at I x the positive control) had a sensitivity for HSIL and 
cancer almost equivalent to cytology at 68% with a higher (97%) than when cytology was 
used alone. In addition, the PPV was also higher at 41 with a NPV of 99%. Further, based on our 
data, this sequence of tests would refer only 5% of the women to 16% if HPV 
DNA were used alone. 
The sequence of a positive HPV DNA test followed a Pap smear, would services 
for 16%, as to 100% of the population were to be used as the only 
test. If this quality of test were to be replicated in a clinical setting, it would 
offer a very high quality ]n order though, to institute national 
with HPV, the of implementing widespread HPV would have to be evaluated on a 
scale. If however, with the rapid development of modem molecular technology, a type 
of HPV DNA test could be and it was this method of could 
revolutionise in poor countries. low resource countries may still not be able to establish 
quality "V.flIfHJV and in those Two-Stage DVI may be an option. 
HPV DNA testing in sequence with DVI also achieves a very specificity and an improved 
PPV, but at the cost of a significantly lower However, the very high NPV of 98%, would 
enable women with HPV DNA tests, followed by a DVI to be safely excluded from 
the screening programme, probably for as long as 10 years. 
4.6.6 Prevalence of by 
The prevalence of high-risk HPV DNA was very high in this population of older African women. 
HPV DNA was detected in 16% of women with HC I assay and 22% of women with the HC 
II assay the standard cut-off (RLU > 1 x control) to derme a positive test, and relatively 
levels of high-risk HPV DNA were in many of these women. Furthermore, the prevalence 
of HPV DNA did not decrease significantly with age, although the prevalence followed au-shaped 
curve with the lowest found in the 40 - 49 year age group. In women with no evidence of 












(using He I) and 18% (using He II) were HPV DNA positive. These prevalence rates are much higher 
than those reported from studies on women in developed countries. 
Melkert et al52 investigated the prevalence of HPV DNA in four groups of women with cytologically 
normal smears. The first group consisted of young women aged 15 - 34 years visiting their doctors for 
check-ups, the second, were women aged 35 - 55 years participating in a triennial screening 
programme. The third and fourth groups were women attending a gynaecological outpatients 
department and were aged 15 - 34 and 35 - 55 years, respectively. The prevalence of high-risk types of 
HPV was 3.8 and 3.3% in the younger age groups and 0.9% and 1.5% in the two older age groups 
respectively (p< 0.00 I). The highest prevalence of HPV types 16 and 18 was in the 20 - 24 year age 
group at 8 - 10 %. In the older women, the prevalence of HPV DNA was much lower. However, 
similar to the prevalence of HPV DNA across the age groups in our study, HPV DNA prevalence 
followed a u-shaped curve in women between 35 and 55 years. 
Meijer et al53 reported on HPV DNA testing by peR of women engaged in a population-based 
screening programme, aged 35 - 55 years. The prevalence of high-risk types of HPV DNA (HPV types 
16 & ] 8) was 0.9%, compared to a group of women attending gynaecological outpatients in whom the 
prevalence of high-risk HPV DNA was 7%. The higher prevalence of HPV DNA in this group 
however, was strongly associated with a history of cervical pathology: 78% of women with HPV 16 
and 18 had a history of eIN 1 - 3. 
Reithmuller D et al54 evaluated the use of He II among 466 women attending their hospital for routine 
screening (mean age 36.2 years; range 16 - 76) and 130 with abnormal cytology referred to their 
colposcopy clinic (mean age 35.1; range J6 - 66). Using the I x cut-off for a positive test, 17.8% ofthe 
women presenting for routine screening had a positive He 11 test for high-risk types of HPV DNA. 
However, there was a statistically significant decrease in the prevalence of high-risk HPV DNA with 
age. For instance, in women aged 16 - 24 years, the prevalence of high-risk types of HPV DNA was 
20.4% compared to 17.6% in women aged 35 - 44 years, 8.9% in the 45 - 54 age group and 5.8% in 
women older than 55 years (p = 0.023). Interestingly, the prevalence of high-risk HPV DNA in the 35 
- 44 year age group was similar to the prevalence of HPV DNA in women aged 35 - 39 years old in 
the Khayelitsha study, but the prevalence in older women was very much lower. 
There is little data on the prevalence of HPV DNA in healthy women in Africa. In Kenya, an HPV 
DNA prevalence of 20% (types 6, 11, 16, 18, 31 and 33 tested using peR) was found among 77 
women, attending a family planning clinic, with cytologically normal smears (mean age 25 years). On 
testing specifically for HPV 16, J8 and 33 using peR, 10% were positive, which is considerably lower 
than found in our study, but the study sample is small and restricted to young women attending a 










In a study conducted in among 140 HIV commercial sex workers (CSWs), mean age 
30 years, and 619 HIV negative mean age 29 years, both risk groups for sexually 
transmitted 56% of the HJV women and 40% of the HIV had positive HPV 
DNA tests PCR and Southern transfer hybridisation). the of HPV DNA 
detected are not described in the article, and it is that these were low-risk and were 
a highly selected population at risk for sexually transmitted diseases. 
In in a study of 262 women presenting for opportunistic screening and who had 
cytologically normal smears, the overall incidence of HPV DNA positivity was 13% using Southern 
blot hybridisation and 9% were for of women aged 20 39 
years, 16% were positive for HPV DNA t'C\,mn»rF'ti to 6% of women over the age of 39 
Southern blot hybridisation however is known to underestimate and the authors commented 
that the true prevalence of HPV in normal cervical smears in Town women was probably much 
higher than in the study. 
In a systematic review ofHPV DNA in cervical screening programmes by Cuzick et al58 studies 
of HPV DNA prevalence in 'normal' populations of women were reviewed. Only studies that used 
methods with some form of amplification of HPV DNA, either amplification with PCR) or 
signal amplification (as with Hybrid Capture™), were incorporated in the review. In almost all studies 
prevalence of HPV DNA in 'normal' women decreased with age. In large studies that looked 
specifically at high-risk types of the prevalence was typically 10 30% at 20 - 30 years of age, 
to 3 10% over the age of 30 years. The authors comment that there is still controversy as to 
whether falls still further over age 40 years or to rise again, and they indicate that 
more data is required for a fuller understand ng ofHPV in women over 40. 
They further point out that other than disease status, the of HPV in a population is strongly 
influenced by lifestyle factors, particularly because it is well known that HPV is a transmitted 
disease. The dominant epidemiological factors associated with high prevalence ofHPV are the number 
of sexual in the last few years, and age of first intercourse. 
The prevalence of HPV DNA detected in our of women may be explained by the 
high proportion of women who began sexual intercourse as as well as the high 
of the women and the rate of other sexually transmitted diseases found in this population. 
The contribution of the 'male factor' was not evaluated in this study, but it is that male 
have multiple and act as a reservoir of infection of their female partners. Co­
nv,rh'rh1"J with other such as Tuberculosis, which has an estimated incidence of over 50011 00 
000 of the population in may contribute to low immunity and inability to clear infection. 
A further consideration is the impact of the HIV on the prevalence of detectable HPV in the 











compared to HIV negative women, as well as significantly increased HPV detection in women with 
63symptomatic HIV infection59. • HIV testing was not performed on the women reported in this study, 
but in a subsequent study (not reported in this thesis), which was conducted from January 1998 to 
November 1999, 8% of women in the same age group and from the same population were HIV 
positive. There are no data on the prevalence of HIV in older women in Khayelitsha, however, data 
from anonymous testing of women attending antenatal clinics between January 1996 and end 1997, 
indicated an HIV prevalence of approximately 10%. 
4.6.7 Issues to be considered in Assessing Cost-effectiveness of HPV DNA Testing 
as a Primary Screening Test 
A cost benefit-analysis of HPV DNA testing as a primary screening test using the data presented here 
has not yet been performed. It is of value however to consider the issues that would be involved. Very 
few cost-analyses of HPV DNA testing have been performed, and most studies concerned with cost, 
base their conclusions on assumptions about the impact of HPV testing within existing cervical 
cytology programmes. An economic assessment of the introduction of HPV testing into a cervical 
cancer programme would require data on: I] the costs of collecting specimens and the laboratory tests, 
that is, of the screening process itself, 2] the costs of following up and treating HPV positive women 
and 3] estimates of the effectiveness of HPV testing in reducing morbidity and mortality from cervical 
cancer. 
A review of the costs of the cervical cytology programme of the National Health Service in the United 
Kingdom by Havelock64 in 1994, found that the major cost is of screening itself, that is, taking and 
processing the smear. The cost of inviting the women for testing and making a diagnosis using 
colposcopy and histology was relatively small by comparison. It is likely that this will be true of HPV 
testing as well, although the costs of recalling women in developing countries has never been 
evaluated. Where modem communications such as telephones, faxes, email and postal services do not 
exist, recall of women is likely to require a more labour-intensive approach and therefore be less 
efficient. 
The most important measure of the effectiveness of HPV testing will depend on the extent to which 
HPV testing will contribute to the reduction in the incidence of and mortality from cervical cancer. The 
more effective the screening activity, the more disease is diagnosed and treated. When this results in 
prevention of invasive cervical cancer, the cost of its treatment including hospitalisation, surgery and/or 
radiotherapy, will be saved . The more efficient the screening activity, the fewer women will be treated 
unnecessarily for disease that would not progress or would even regress in the absence of treatment. 
Ultimately the balance between the rate of identifying and successfully treating preinvasive disease, 
and the appropriateness of the screening programme combined with the cost of the programme will 












In the case of HPV testing it is important to keep in mind that only a minority of women who test 
positive for HPV are likely to develop clinically significant disease, so many 'well' women will be 
labelled as having an In there is the problem that some may be attached 
to positive for HPV since the virus is known to be sexually and this may deter 
compliance with the programme. There are no studies on how women would react to the 
information that they are infected with a virus thought to be associated with a life­
threatening disease, and how this compares to the reaction to that have an abnormal 
Pap smear. 
There have been virtually no studies on the cost-benefit of HPV DNA however Jenkins et al 65 
used a stochastic model to predict resource use for HPV testing, three alternative screening 
policies. They express the results in terms of the numbers of diagnostic tests needed and the impact on 
mortality from and incidence of cervical cancer, but do not explicitly estimate costs. The screening 
strategy of interest to this is one of routine screening by HPV with cytological follow-up 
for HPV positive women to our Two-Stage This strategy was 
estimated to reduce by about 25% the numbers of Pap smears The authors concluded that the 
cost-effectiveness of HPV as a routine screening test will on the proportion 
of HPV negative cancers, as this would allow much longer intervals of up to 10 years. HPV 
testing is likely to be cost-effective (lower cost and improved control and automation) in 
comparison with where HPV negative precancers are less than 5%. The model however made 
no attempt to cost resource-use directly or to include treatment costs. The model is insufficiently 
detailed to derive estimates of cost per life-year gained or even of increased cancer detection. 
Cuzick et al58 in their constructed two models that contrasting estimates of 
the cost-effectiveness of HPV In model A chose the most favourable combination of 
parameters i.e. nrCHJrf""" HPV inf ctions have a the of the H PV lest is 
and the HPV in women without cervical is relatively low. In model the 
opposite were made. For primary considered J] adding HPV to 
cytology and 2] replacing cytology with HPV considered 3 and 5 year 
intervals. 
For both more intensive Pap smear 3 instead of 5 yearly would 
more 8.311 000 women compared to 7.0/1 000 (in a situation where the lifetime risk of 
from cervical cancer without is 10.9/1 000 women), but this was less cost-effective. 
This is caused a considerable decrease in and surveillance costs if women are screened 
less which outweighs the decrease in effects and the higher costs for invasive and advanced 
cancer. 
According to model A, which was favourable for HPV screening, the combination of and 












costs are only slightly For screening with HPV testing only, the effects of 5-yearly screening 
are lower than for smears (70 versus 76%), but the costs are reduced by 75%, resulting in 
a substantially lower cost-effectiveness ratio (£ 100 per compared with £390 pre life­
year gained). The lower costs of the HPV -only screening programme were mainly the result of lower 
screening costs and less treatment of women referred without cervical neoplasia. 
For model B, which was unfavourable for HPV screening, the use of HPV testing to supplement or 
replace cytology-based programmes, resulted in worse cost-effectiveness rates than cytology 
screening. Combined yielded a higher mortality but this was not proportional to 
the increase in costs if an HPV test were added to the Pap smear. For with HPV alone, both 
the effects were lower and the costs were higher. The higher costs were mainly the result of increased 
surveillance costs and lower in diagnosis and treatment costs. 
The authors conclude that the results of their show that for values of prevalence, 
sensitivities and HPV testing may be effective and cost-effective. There are 
uses of HPV that would benefits at a lower cost than many health care 
programmes. the wide range of results that came from and low estimates for these 
















4.7 CervicographyTlII as a Primary Screening Test 
At the outset, it is important to realise that CervicographyTM was never devised as a primary screening 
test, rather, it was designed as an adjunct to cytology, The basic concept behind CervicographyTM is 
that a person (physician, nurse, technician) without any knowledge of colposcopy can, after very brief 
training, take a picture of the entire cervix, which can then be sent to an expert for evaluation. In 
addition, it provides a permanent visual record of the cervix after the application of acetic acid66 The 
entire cervix is visible for evaluation and magnification is achieved by projecting the slide image onto a 
large screen and observing the projected picture from a short distance, giving ultimately a 
magnification of 16 x, 
While we aimed to analyse the performance of CervicographyTM as a primary screening test in our 
study, an important additional reasons for including CervicographyTM was as a safety net to detect 
cancers that may have been missed by the nursing sister and as a means of quality control of DVI., 
From the outset, it was clear that the requirements ofCervicographyTM suffer from the same drawbacks 
as cytology. The result is delayed and like cytology, the test requires subjective evaluation by experts. 
For low-resource settings without on-site trained Cervigram™ evaluators, this would require sending 
the film to other centres, or even other countries, for evaluation, greatly complicating the screening 
process, 
Further, cervigrams are prone to a number of technical mishaps, We found that 333 (11.3%) of 
Cervigrams™ were unevaluable, compared to 22 (0,7%) unsatisfactory Paps and one sample unsuitable 
for HPV DNA testing, Of the unevaluable CervigramsTM, 60% were due to technical problems with 
the camera or with the electricity supply and the rest were due to poor quality Cervigrams™ caused by 
the presence of blood, mucus or the speculum obscuring the cervix. In a low-resource setting, this 
number of unsatisfactory evaluations would be unacceptably costly and would result in many women 
having to be re-screened, a particular problem for women who have to travel long distances to local 
clinics, 
The performance characteristics of CervicographyTM have already been discussed in relation to DVI 
and HPV DNA testing and will not be repeated here, Suffice to say that we do not recommend 
CervicographyTM as a primary screening test in low-resource settings, but do recommend its inclusion 












4.8 Outcome of Treatment 
Negative histology after 
Overall 178 women were treated with LEEP in the sludy, but only 149 were treated on a 'see and treat' 
basis i.e. without histological sampling prior to treatment. Of the LEEPs performed without prior 
histological sampling, 41% had no histological evidence of either CIN or cancer, so-called, negative 
LEEPs. These women could be regarded as having been over-treated, despite having un<ier.gOIle 
colposcopic evaluation. 
histology after LEEP has been reported in a number of studies a 'see and treat' 
Murdoch et al67 reported an overall 41 % 1<:!!,.1I1\;<:; LEEP rate, in a selected group of 
women ""''''UU''I'> a colposcopy clinic because of abnormal cytology. In women who had had 
histological sampling, negative LEEP histology was found in 43% compared to 38% of those women 
treated with LEEP on a 'see and treal' basis. Of the latter women, 93% had decision of less 
than CIN 1, 53% of CrN 1, 43% of CrN 2 and 18% of CrN 3. In view of these data, the authors 
cautioned against the 'see and treat' approach in women with 
In a of LEEP performed at the colposcopy clinic at Groote Schuur Hospital 
(GSH)68, 18% ofLEEPs after histological (21 out of 1 were ".v.,~",,,,,,,~.. 
compared to 14% who were treated on a 'see and treat' basis (16 oul of 114). Of note, women 
are referred to the GSH clinic wilh LSIL (2 to 3 LSIL over 12 to 18 
months) or one Pap of HSlL or suspicious of An additional in the by 
et al was that 25% of biopsies were falsely which the point made by the 
that a biopsy is only as reliable as the colposcopist's ability to identity the most 
abnormal area for biopsy. 
A wide range of negative LEEP rates have been ..on,... ...'''.. in the literature, from 5 - 41%. All of these 
studies have been performed in colposcopy clinics where women have been referred with abnormal 
. False or false histology in the LEEP and 
possible complete excision or resolution of the lesion after prior 
explanations for false LEEP histology. In addition, some series have reported negative LEEP 
where there has been extensive thermocoagulation preventing a histological In 
one series, sectioning of the LEEP was for LEEP in 2% of 
cases • 
4.8.2 The Role of Colposcopy in Determining Histological Outcome 
In our DOS:COI)V was "",'1",',n,,£1 on women who were on any of the four 













only reason for referral for colposcopy. Colposcopy correctly identified all 12 cancers, one of these 
however, was diagnosed after a cone biopsy due to an unsatisfactory colposcopy. LSIL and' HSIL were 
correctly identified in 27 and 26% of colposcopic assessments (where RCI was j or greater), 
respectively. However, colposcopy miss-classified 50% of the cases of histologically confirmed LSIL 
and 35% of the cases of HSIL as lacking cervical disease (RCI less than 3) 
The outcome of the colposcopic assessment was strongly influenced by the nature of the positive 
screening test used for referral. For instance, among women with positive DVI examinations or 
Cervigram™ evaluations, just under 30% with a RCI ;::: 3 had HSIL confirmed histologically for both 
tests. In contrast, approximately 40% of women with positive Pap smears and positive HPV DNA tests 
had HSIL These results may have influenced the colposcopic assessment in that the colposcopist had a 
greater expectation of finding disease with the latter two tests and may hm·e interpreted aceto-white 
lesions differently. 
Colposcopy is optimally performed in the absence of infection and under ideal hormonal conditions, 
for instance, during day 8 and 12 of the menstrual cycle, when the cervical mucus is most translucent 
and abundant and the external os is most widely dilated. These conditions were not met in the context 
of our study. Although colposcopy was deferred in some women for treatment with antibiotics or local 
estrogen cream, the majority of colposcopies were performed when women presented without deferring 
assessment, regardless of the presence of atrophy or inflammation. This policy was followed in order to 
minimise defaulting and to truly evaluate the provision of an on-site screening and treatment service in 
a low-resource setting. Performing colposcopy under these circumstances may explain the high rate of 
negative histology after LEEP, or, by inference, the high false positive rate of colposcopy. 
In a meta-analysis of colposcopy for the diagn<2sis of SIL by Mitchell et a1 76, 9 out of 81 studies were 
selected for incorporation into the analysis as they distinguished histologically normal cervices from all 
other diagnoses. The individual estimations of sensitivity of diagnostic colposcopy were high (range 87 
- 99%), whereas those of specificity were lower and wider (range 23 - 87%) Similarly, among 8 
studies with fully separated disease categories, for distinguishing normal cervix, atypia and LSIL from 
HSIL and cancer, the estimations of sensitivity of diagnostic colposcopy were high (range 64 - 99%), 
whereas those of specificity were lower (range 30 - 93%). High-grade lesions appeared to have 
distinguishing characteristics that allowed them to be better separated from LSIL than was possible for 
separating LSIL from a normal cervix. 
In an overview of the literature from 1972 to 1995 on the positive predictive value of colposcopic 
examination77 colposcopy correctly identified CIN 3 in an average of 78% (range 44 - 93%) of cases 
examined among selected women in colposcopy clinics. The corresponding figures for CIN 2 and 3 













Colposcopy in the Khayelitsha study was performed in women selected on the basis of four different 
screening tests with varying sensitivities and specificities. In the majority of cases the colposcopist was 
blinded to the result of the Pap smear. However, even with the use of colposcopy, significant numbers 
of women were over-treated or miss-classified by the colposcopic diagnosis. 
4.8.3 Complications of LEEP 
Of the 178 women who underwent LEEP, excessive bleeding at the time of the procedure was recorded 
in just under 5% of the women (although none of these women required admission to hospital and the 
bleeding was controlled at the time of the procedure). A further 49% of women had moderate bleeding 
that was controlled with ease at the time of the procedure (estimated at less than 100 mls of blood) and 
in 46% of women there was no bleeding at all . While cramping and pain related to the procedure was 
recorded at the time of LEEP in 28% of the women, none of the women required medication to control 
pain and the pain was not persistent. No serious complications at the time of LEEP were recorded. 
A limitation of our data on post-LEEP complications is that these were recorded by interviewing the 
women at 4 months. All women were strongly advised to return to the project if any complications 
developed and the author's emergency telephone number was given to the patients should 
complications occur. While women did return to the project when complications occurred, this was not 
recorded in a systematic manner. Hence, our data on post-LEEP complications are limited by patient 
recall and by the fact that we only have information on women who returned for post-LEEP follow up. 
It is possible that the complication rate was higher among those who did not return for follow up, 
however this is speculative. 
Of the 141 women who returned for the post LEEP visit at four months, 17% (n = 24) reported that 
they required medical treatment after LEEP. Of these women, 14 developed infection (just under 10% 
of the women treated with LEEP who were followed up). 7 had e:-.:cessive bleeding and 3 women had 
unspecified complaints. Twenty-three of the 24 women attended primary care facilities for treatment of 
complications and one woman with excessive bleeding was referred to the emergency unit at Groote 
Schuur Hospital. 
Cervical stenosis was recorded in 5.7% (81141) of the women who returned for their 4 month post­
LEEP check-up. A further 4 (6.3%) cases of cervical stenosis were diagnosed in the 64 women who 
returned for their 10 month post LEEP check-up. 
In a randomised trial of LEEP, Cryotherapy and Laser vaporisation of the cervix, Mitchel et al78 
reported complications from LEEP in 7.6% (101130) of women treated. The majority of the 
complications related to bleeding (70%), there was one case of infection, one woman complained of 












Ferenczy et rpr,ortPI1 on 1070 women who underwent LEEP and who returned for 
follow up. were recorded in 7% (n = 71) of women; 37 had intra-or 
operative and one woman admission to hospital to control Seven women 
developed a purulent and pelvic pain within one week of treatment. A further 13 
(J .2%) women cervical stenosis and they noted that 11 of these women were over the age of 
45 and were not on hormone replacement therapy. 
The rate in the Khayelitsha study is higher than in series conducted in 
colposcopy clinics in countries, particularly of cervical stenosis. the relatively 
high rate of lower tract infection in women in our study, this is not surprising. 
HflUlP'VPT there were no serious complications noted at the time of the and only one woman, 
that we know admission to hospital for management of excessive 
of Disease Post-LEEP 
Overall, SIL was in 9 (6.4%) of the 141 women who returned for their 4-month VV."-1J~A_' 
check-up. one woman had HSIL confirmed histologically and this woman had HSIL OIa:gnose:a 
in the The other 8 women had LSIL confirmed at the 4-month 
visit, and in two cases the original LEEP diagnosis was negative. At the IO-month one case 
ofHSIL was in a woman whose original LEEP histology was (1.2% of women who 
returned for follow-up). LSIL was diagnosed in a further three women (4.6% of the women who were 
followed-up), 2 with original LEEP histology of HSIL and one with LSIL. 
These rates of compare favourably with series published from colposcopy 
clinics in countries. Ferenczy et af5 reported a 'cure rate' of 93% of women with LSIL 
treated with one LEEP (7% persisted) and 90% of women with HSIL treated with one LEEP 
procedure. The increased to 96 and 93% respectively when treatments were performed. 
Flannelly et analysis of the first 1000 women treated in their unit with 
LEEP from 1989 1991. cytology was available for 977 women, 975 who had at least one 
follow up smear, 930 had at least two, 845 had three and 686 had more than three follow up smears. 
Overall 8.2% of follow up smears were found to have CIN. Of women with initial ofCIN 3 
in the LEEP 8% compared to 4% of women with initial of CIN I. 
Hulman et al 80 rpnortf'l1 on a retrospective review of 669 women treated with LEEP and followed up for 
1.5 to 3.5 years. Persistence or recurrence of histologically confirmed CIN was 6.7% for initial 
pathology ofCIN I, 13.4% with CIN 2 and 21.7% for CJN 3. 
Our were followed up for a 10 month period post-treatment and this is probably too short a 










cytological abnormalities post-LEEP occurred within 18 months of thereafter the rate 
decreased but remained for a further 48 months. term follow up from their study is still 
awaited. 
ln summary, LEEP was found to be a safe in our hands with a cure rate of over 90% for 10 
months of follow-up. Unfortunately, significant numbers of women did not return for both the 4 and 10 
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The main conclusions from the are the following: 
I. 	 service close to where women live with a rapid tum around of results (2 
resulted in an excellent follow up rate of just over 90% of screen 
women. The the between women being screened and treated the higher the default 
rate. The of the defaulters were the poorest and most marginalised women in the 
that this group of women require special attention. The poor 
follow up rates have important implications for mass programmes in 
resource-poor where recurrence/persistence rates of disease of at least 5 10%, if not 
would be expected. 
2. 	 a mid-level clinician, such as a nursing sister, to screen women proved to be feasible. In 
Health Workers were found to be a valuable resource in the project and were 
trainable as both educators and administrators. The sustainability however of a vertical 
service in low-resource health care settings, as was delivered in this study, is questionable. 
3. 	 HPV DNA at the lower cut-off level (I x) and cytology had sensitivities for 
the detection of HSIL and cancer (range 67 - 78%). However, both DVI and HPV DNA 
(I x) had lower and PPVs than cytology. If a were to 
be based on a 'Test and Treat' protocol DVI or HPV DNA (I x) as the 
tests, not only would a relatively of the screened population be referred for 
treatment, but also numbers of women without cervical disease would undergo treatment. 
While DVI and HPV DNA may identify two-thirds or more of the high-grade lesions in the 
screened 11 % and 14% of the screen positive women would have high-grade 
DVI and HPV DNA (Ix) respectively. Increasing the threshold for a positive 
HPV DNA test to lOx the control (that to high levels of HPV DNA), 
reduces (to 50'%) with a concomitant increase in specificity and PPV. This approach 
would reduce both the number of women referred for treatment and the number of women over­
but half the cases of disease would be missed. 
4. 	 of HPV DNA testing is superior to that of expert cytology but the 
is lower. The specificity of HPV DNA testing however can be altered by altering the 
cut-off level to define a positive test. 
5. 	 CervicographyTM is unlikely to have utility as a primary screening test, because of its relatively 
poor test characteristics, the need for experts to read the slides, the technology required and the fact 











would need to be trained. CervicographyTM does however have a role as a 
method of quality control of DVI and the slides can be used to train sisters in DVI in the 
context of a research study 
strategies need to be evaluated according to 6. 	 Different health resources. Two-
offers many advantages, particularly in very low resource where facilities 
for laboratory-based tests are limited. Two-Stage any of the six sequences, 
reduces the number of women referred for treatment if DVI is used as the initial 
screen, reduces the number of more expensive tests e.g. or HPV DNA tests The 
loss of sensitivity with Two-Stage Screening may be in where Nl1e"""",, 
services are limited or do not exist at all. The higher of however, 
will prevent large numbers of women undergoing unnecessary treatment 
7. 	 On-site provision of colposcopy and LEEP used in a 'see and treat' context was safe and effective 
in our hands. The main concern was the relatively of cervical stenosis in treated 
women, which may lead to inadequate follow up or complications such as 
haematometria, in these women. LEEP may not be the ideal method of treating 
preinvasive disease in low resource settings, particularly as it the use of local anaesthetic 
and a fair amount of technical skill. Alternative ablative such as cryotherapy that do not 
require local anaesthetic and do not rely on may be more appropriate. 
5.2 Reeommendations 
This study has shown the potential utility of both DVI and HPV as alternatives to cytology in resource­
poor settings. In order to extrapolate these data into to day clinical practice, further studies on the 
performance of the tests jn the field without the close supervision of a well-controlled 
research study) need to be conducted. it is essential that standardised methods of interpreting 
aceto-whitening are as well as curricula for of health workers to perform DVI. 
While both tests will most cases of disease in the screened population, a significant 
number of women would be over-treated if treated on the basis of the screening tests. 
Considering the burden of cervical cancer, would this necessarily be a negative outcome? 
It is with this background that we recommend further studies designed to answer the following 
questions be initiated. The that need to be addressed are the following: 
I. 	 What would be the and acceptability (to women and to health care workers) of a 
'Test and Treat' in which women would be treated by nursing sisters, on-site, on the basis 
of a positive test alone DVI or HPV)? Would such a protocol reduce the incidence 
of and mortality from cervical cancer? Would women agree to be tested on a for a 












Finally ultimately of greatest concern to health policy planners, what would be 
the costs per life saved of a 'Test and Treat' protocol, compared to either no programme 
or a cytologically-based "r",ar~,mnrlp? 
2. 	 What would be the rate of treatment when performed in a low-resource setting by 
sisters without guidance? that will need to be evaluated include 
pelvic inflammatory disease, cervical stenosis, and requiring additional medical or 
surgical management. 
3. 	 Could either DVI or HPV DNA testing be used effectively for Dm;l-U'eatm follow-up of 
women? 
efforts need to be directed towards an even method of HPV DNA 
than is t"l1r't'pn,tl" available, Iy a side-room of test that can an immediate result or a 
fully automated process for In some low resource settings, such as in the emerging 
it may be possible to establish HPV laboratories although, current costs of the kits and the 
may prove to be prohibitively expensive. In very low resource such as are found in 
up HPV laboratories even with lower level technicians is unlikely to be feasible in the 
next few decades. 
Of critical importance though, is whether there is a cost-benefit in terms of lives saved 
these alternative methods compared to cytology. The acceptability of these tests to the screened 
as well as test and treat protocols need to be rigorously evaluated. 
an important component of the success of this was that from the outset, the women and 
the community were consulted. Our approach was to encourage parllClD8nQ! of the women 
screened and we viewed them as our 'teachers' In other words, it was the women themselves who 
showed us 'the way' in terms of developing educational material, the service to suit their 
needs and with non-western health care providers in the area. For screening to be 
it is essential to consult with the women and their and to design a 
programme which is not acceptable to women, but recognises and 1"P<:""rll1 to the many barriers 
that prevent, particularly poor women, from or complying with a programme. 
Final Comment 
In an era during which HPV vaccines are being it is tempting to halt 
the search for alternative methods of to prevent cervical cancer. It is important however to 
remember that the clinical utility of HPV vaccines is possibly 10 to 20 years away. In the 
infrastructure to distribute HPV vaccines will need to be developed, and some have estimated this will 
take at least another 60 years. In the we have a to continue the search to 
£1 ..'11"1"'''' methods of for women in the poorest countries of the world, that are 


















Date of interview 
I I 
Year 
Interviewer Name: _________________ ................................. 13 

1. Year of birth: __________ 
How old are you? (age in years) _____________ 
2. Were you born in Cape Town? 
Yes ........................... ............................... 1 

No ............................................................ 2 

18 
IF NO, how long have you been in Cape Town? 
0-1 year ................................................ 1 

1 year to 5 years .................................. 2 

More than 5 years......................................... 3 

19 
3. What is the highest level of schooling you have completed? 
No school.... .... ....... .... ..... ..... ................... .... 88 

std 1 or less ............................................... . 01 

std 2 ....................................................... . 02 

std 3 ....................................................... . 03 

std 4 ....................................................... . 04 

std 5 ....................................................... . 05 

std 6 ....................................................... . 06 

std 7 ....................................................... . 07 

std 8 ....................................................... . 08 

std 9 ....................................................... . 09 

std 10 ..................................................... . 10 

Any tertiary/university ........................... . 11 












Yes ............................................................ 1 





how much the year does your husband live you? 

All round (9 or more months year) 1 

Greater than 1 month but less 9 months ......... 2 





which best your situation? 

Live with boyfriend ..................................... 1 

Separated! (not remarried) ........... 2 









5. Do you have ajob? 




what is your occupation 
6. How 
 most your money? 

Own job ............................................................................. 1 

or making from home (Informal sector) ........ 2 

Husband or boyfriend's job ............................................... 3 

Help from or friends ................................................. 4 







7. 	 are you now? 

House .......................................................... 1 

Shack on a site ............................... 2 

on an unserviced site/ 







8. 	 At your quarters, do have running 

indoors ............................................... 1 

on property but not indoors.. ............. 2 
















9. At your living quarters, do you have electricity? 
Yes ............................................................ 1 

No ............................................................ 2 

31 
10. How old were you when you became pregnant for the first time? ......................... 32 
 IT 
(Write 00 in blocks if never pregnant.) 
IF EVER PREGNANT 
lOa. How many times have you been pregnant? ............................................... 34 I 
(Write 00 in blocks if never pregnant) 
IF EVER PREGNANT 
lOb. How many times have you had a live birth? .............................................. 36 I 
(Write 00 in blocks if no live birth) 
11. How old were you when you first had sexual intercourse? .................................... 38 
 IT 
(This includes sexual intercourse with a man, even if you 

were an unwilling partner.) 

12. How many different men have you had sex with in the last month? ................ 40 
(Write 00 in blocks if no sex in the last month) 
13. How many different men have you had sex with in your entire life? ............... 43 

14. 	 Have you drunk any alcohol in the last month? 
Yes, moderate or large amount (4+ drinks on a single occasion) ...... 1 
Yes, small amount (0-3 drinks on a single occasion) ...................... 2 
N one at all ..................................................................................... 3 .. 
.............. 46 

Have you EVER used any method of birth control? 
Yes ................................................. 1 

No ................................................... 2 (IF NO, SKIP TO Q 18) 

47 
15a. IF YES, have you EVER used the following? 
Birth control pills Yes .............. 1 No ................ 2 
 L 















Condom Yes .............. 1 No ..... ....... .... 2 
 D 
50 
Sterilization Yes .............. 1 No ........... ..... 2 
 D 
5J 
DOther ______ Yes .............. 1 No ........ ........ 2 

52 
ISb. IF YES TO ANY ABOVE, have you used the following IN THE LAST 
3 MONTHS? 
DBirth control pills Yes .. ... ........ . 1 No . . ... .... . ...... 2 

........... . ..... . ... . . . ... . 53 

Injection (Depo) Yes . .. ........... 1 No ........ ..... ... 2 
 D 
54 
Condom Yes .............. 1 No ................ 2 
 D 
55 
Other ______ Yes ...... ........ 1 No .... ..... ....... 2 
 D 
56 
16. Do you smoke regularly? (Regularly means at least daily on average and smoking 
includes cigarettes, pipe, rolled cigarettes) 
Yes ......... ........ ...... .......................... 1 

No ..................... ........ ...................... 2 
 D 
57 
17. For what reason did you come to the clinic today? 
Pap smear (Cervical cancer) Screening ..... 1 

Gynecological complaint .. ............... ......... .. 2 


















Clinical Examination: Colposcopy (Form 05) 
o 5 

Patient Name: ___________________ PATNO 3 
Month Year 
Date of clinical exam 	 7 
Clinician: 	 13 c 
1. 	 Are the results of the pap smear available (when this exam is done)? 
Yes ............................................................................... . 
No ................................................................................. 2 ....................... 14 c 
2. 	 Colposcopic exam: 
Satisfactory .................................................................. . 1 
Unsatisfactory .............................................................. . 2 ...................... 15 
3. Are there cervicallesion(s)? 
Yes ............................................................................... 1 

No ................................................................................. 2 ......................... 16 
 c 
3a. IF YES, score the most severe lesion using the following criteria: 
Margin 0 Condylomatous I micropapillary 1 Regular lesions with 2 Rolled, 
peeling edges cIndistinct borders 	 th outlines 
Jagged, angular lesions 
Color 0 Shiny snow white 1 Shiny, off-white 2 Dull, oyster 
grey 
Indistinct acetowhitening Intermediate white 
Semi-transparent 
Vessels 0 Uniform, fine caliber 	 1 Absence of surface vessels 2 Definite 
punctation or 
Randomly arranged with poorly formed mosaicism. Individual 




Iodine 0 Positive iodine uptake 	 1 Partial iodine uptake 2 Negative 
staining of 
Staining (mahogany brown) Variegated, tortoise shell lesion high 
grade 
Negative iodine uptake in appearance (>3/8) 
low grade lesion (<2/8) Mustard 
yellow 
Total Reid 










4. IF REID ~ 3, was LLETZ "'<>1'"1'1'"\,.,....<>£1 
Yes ................................................................................ 1 





4a. IF NO, reason why not: 
refused local anesthetic ............. ........ ..... 1 

Other infections ................................................ 2 






4b. IF 	 did patient complain of: 




teelltnl!: faint) .... 1 No 2 
................................... 25 
Other _____________________________________ 
IF YES, was there 
Yes, ~ lOO ml ................................................... 1 

< l00ml .................................................... 2 





5. IF REID 5. 2, was punch biopsy done? 
Yes ................................................................................ 1 
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